Archives of Toxicology

, Volume 84, Issue 11, pp 825–889 | Cite as

Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples

  • Douglas B. KellEmail author
Open Access
Review Article


Exposure to a variety of toxins and/or infectious agents leads to disease, degeneration and death, often characterised by circumstances in which cells or tissues do not merely die and cease to function but may be more or less entirely obliterated. It is then legitimate to ask the question as to whether, despite the many kinds of agent involved, there may be at least some unifying mechanisms of such cell death and destruction. I summarise the evidence that in a great many cases, one underlying mechanism, providing major stresses of this type, entails continuing and autocatalytic production (based on positive feedback mechanisms) of hydroxyl radicals via Fenton chemistry involving poorly liganded iron, leading to cell death via apoptosis (probably including via pathways induced by changes in the NF-κB system). While every pathway is in some sense connected to every other one, I highlight the literature evidence suggesting that the degenerative effects of many diseases and toxicological insults converge on iron dysregulation. This highlights specifically the role of iron metabolism, and the detailed speciation of iron, in chemical and other toxicology, and has significant implications for the use of iron chelating substances (probably in partnership with appropriate anti-oxidants) as nutritional or therapeutic agents in inhibiting both the progression of these mainly degenerative diseases and the sequelae of both chronic and acute toxin exposure. The complexity of biochemical networks, especially those involving autocatalytic behaviour and positive feedbacks, means that multiple interventions (e.g. of iron chelators plus antioxidants) are likely to prove most effective. A variety of systems biology approaches, that I summarise, can predict both the mechanisms involved in these cell death pathways and the optimal sites of action for nutritional or pharmacological interventions.


Antioxidants Apoptosis Atherosclerosis Cell death Chelation Chemical toxicology Iron Neurodegeneration Phlebotomy Polyphenols Sepsis SIRS Stroke Systems biology Toxicity 




Alzheimer’s disease


Amyotrophic lateral sclerosis (Lou Gehrig’s disease)


Bovine spongiform encephalopathy


Creutzfeldt-Jakob disease


Central nervous system


Experimental autoimmune encephalomyelitis




Huntington’s disease


Huntingtin protein


Markov chain Monte Carlo


Minimum information requested in the annotation of biochemical models




Multiple sclerosis


Parkinson’s disease


Reactive nitrogen species


Reactive oxygen species


Systems biology markup language


Systems biology results markup language


Systemic inflammatory response syndrome

TCDD, ‘dioxin’



Transmissible spongiform encephalopathies


2,4-dichlorophenoxyacetic acid


2,4,5-trichlorophenoxyacetic acid


As a transition metal that can exist in several valencies, and that can bind up to six ligands, iron is an important component of industrial catalysts in the chemical industry (Hagen 2006), especially for redox reactions. Its catalysis of specific reactions requires rather exact architectures at the catalytic centre, and indeed much of the art and science of catalyst production involves determining and synthesising them. Nearly half of all enzymes are metalloproteins (Waldron et al. 2009), and iron is also of considerable importance in biology as a component of all kinds of metalloproteins (Andreini et al. 2008, 2009) from haemoglobin to cytochromes, as well as in the directed evolution of novel enzyme activities (Pordea and Ward 2008; Que and Tolman 2008; Turner 2009). When serving in enzymes, the iron is normally safely liganded, and any reactions catalysed are usually fairly specific. However, as is widely recognised, iron can also have a dark side (Kell 2009a), in that when it is not properly liganded (Graf et al. 1984), and in the ferrous form, it can react with hydrogen peroxide (produced by mitochondria (e.g. Brennan and Kantorow 2009; Fato et al. 2008; Orrenius et al. 2007) or (per)oxidases (Bedard and Krause 2007; Cave et al. 2006) via the Fenton reaction (Goldstein et al. 1993; Kruszewski 2003; Toyokuni 2002; Wardman and Candeias 1996; Winterbourn 1995), leading to the very reactive and damaging hydroxyl radical (OH)
Fig. 1

The Haber-Weiss and Fenton reactions combine using poorly liganded iron in a catalytic cycle to produce the very damaging hydroxyl radical. Poorly liganded iron can also be liberated via the destruction of haem and other iron-containing substances. Peroxynitrite anion (ONOO) is produced by the reaction of superoxide and nitric oxide (NO) which when protonated (pH ca 6.5–6.8) decomposes to OH and NO2

Fig. 2

Some small molecules that are derived from the oxidative attack of hydroxyl and other radicals on cellular macromolecules and that can act as biomarkers of oxidative stress, including that mediated by iron

Fig. 3

Very strong relationship between serum ferritin concentrations and urinary concentrations of the DNA damage/oxidative stress marker 8-hydroxy-2′-deoxyguanosine. Data are replotted from Fig. 1 of Hori et al. (2010)

Fig. 4

A mind map (Buzan 2002) setting out the structure of this review. To read this start at “1 o’clock” and move outwards and clockwise

Fig. 5

Some of the interactions between the prion protein in its two main conformations, reactive oxygen species and iron dysregulation. This diagram is based on Fig. 12 of (Singh et al. 2010b), and illustrates in particular the autocatalytic nature of the ROS- and iron-dependent conversion of PrPC to PrPSc and the neurotoxicity of the latter

Fig. 6

Iron catalyses the formation of the hydroxyl radical (and thence other kinds of ROS) that can react with proteins and lipids to denature them, leading to insoluble plaques and other fibrotic structures that can themselves bind/entrap the iron that caused their formation. This bound iron can cause further hydroxyl radical formation such that the process is autocatalytic. Eventually this overwhelms cellular defences, leading to cell death (with further release of iron)

Fig. 7

Large (17-fold) accumulation of EPR-detectable iron in atherosclerotic plaques relative to healthy non-atherosclerotic (‘intima’) controls. The difference is highly significant (P = 0.0001). Data are replotted from those in Fig. 1b of Stadler et al. (2004)

Fig. 8

The major events accompanying sepsis and the Systemic Inflammatory Response Syndrome. Note in particular the positive feedback by which the release of pro-inflammatory cytokines and ROSs leads to the release of poorly liganded iron (e.g. from ferritin and haem) that causes the release of further inflammatory cytokines and ROSs. In principle, iron chelators could interfere with this vicious cycle

Fig. 9

A diagram, based very loosely on the narrative in (Kohanski et al. 2007), illustrating how the autocatalytic activity of the reactions of superoxide, peroxide and the hydroxyl radical involving poorly liganded iron can exert a positive feedback leading to the death of cells

Fig. 10

‘Bow-tie’ models of cellular networks. There are many examples of cellular networks in which a large variety of possible initial events leads to complex sequelae, but these are mediated via a comparatively small number of ‘intermediate’ reactions. While in the present case it is suggested that these in part involve complex positive feedbacks, the general ‘bow-tie’ idea does allow one to recognise that despite the many different possible inputs, a broadly unitary kind of mechanism of action—here involving iron dysregulation—can reasonably be invoked to explain the multiple causes that can lead to cell death and destruction

Fig. 11

The three main iron chelators approved for clinical use

Fig. 12

The extent of cell damage caused by the unliganded iron-catalysed production of ROSs and RNSs is determined by many factors, some of which promote and some of which act against it. While the existence of hormesis (see text) means that the see-saw illustrated here is an imperfect metaphor, the diagram serves to illustrate the complexity of the problem and the need for a systems biology approach to its solution

Fig. 13

The steady-state concentrations of a molecule depend on the rates of production and removal of the molecule in question. Both lowering creation and increasing removal represents a particularly effective strategy relative to doing just one of these alone. Thus if C is the hydroxyl radical we can lower its concentration by decreasing A and/or B and by increasing the rates of the reaction to D and E. The latter (decrease of concentration of C) may sometimes better be effected by increasing the activities of enzymes yet further downstream

Fig. 14

The relationship between ‘forward’ and ‘inverse’ methods of systems biology. The comparison of two ‘inverse’ systems (one a control and one treated with a toxin) in terms of the estimation of which parameters have changed most allows one to infer the sites or modes of action of that toxin [In a related manner we also discriminate forward and reverse genetics, including chemical genetics (Kell 2006a, b)].

$$ \hbox{Fe}(\hbox{II})+\hbox{H}_2\hbox{O}_2 \rightarrow \hbox{Fe}(\hbox{III})+\hbox{OH}^{-}+\hbox{OH}^{\bullet} $$
Superoxide (also produced by mitochondria) can react with ferric iron in the Haber-Weiss reaction (Kehrer 2000) to produce Fe(II) again, thereby effecting redox cycling of the iron (Fig. 1):
$$ \hbox{O}_2^{\bullet -}+\hbox{Fe}(\hbox{III})\rightarrow \hbox{O}_2+\hbox{Fe}(\hbox{II}) $$

Ascorbate (vitamin C) can also replace \( \hbox{O}_2^{\bullet -} \) for reducing the Fe(III) to Fe(II) (Hershko and Weatherall 1988), as can other reducing agents, and indeed too low a redox poise leads to DNA damage (e.g. Li and Marbán 2010; Seifried et al. 2007).

The hydroxyl radical is exceptionally reactive and damaging to cellular components, and, for instance, can liberate further Fe(II) from iron-sulphur centres and other iron-containing compounds such as ferritin (Arosio et al. 2009), thereby driving reaction (1) in an autocatalytic, runaway kind of reaction. This kind of phenomenon has the potential to overwhelm any kinds of attempts at repair, and inflammation and oxidative stress are the hallmarks of each of the conditions I summarise. Related reactions include peroxynitrite production (from the reaction of NO and superoxide) (Babior 2000; Beckman et al. 1990; Beckman and Koppenol 1996; Goldstein and Merényi 2008; Koppenol et al. 1992; Murphy et al. 1998; Pacher et al. 2007; Pavlovic and Santaniello 2007; Pryor and Squadrito 1995; Radi et al. 2001, 2002; Rubbo and O’Donnell 2005; Rubbo et al. 2009; Smith et al. 1997b; Squadrito and Pryor 1998; Szabo 1996; Szabó et al. 2007; Torreilles et al. 1999; White et al. 1994; Zimmet and Hare 2006). These can lead to nitrotyrosine (Beckman 1996; Goldstein and Merényi 2008; Herce-Pagliai et al. 1998) (a reaction catalysed by poorly liganded iron, Beckman et al. 1992), or nitro-fatty acid (Aslan et al. 2001; O’Donnell and Freeman 2001) production or protein cysteine nitrosylation (Lancaster 2008; Landino 2008; Vaz and Augusto 2008) that can provide a means of their detection downstream. Some of these are shown in Fig. 2. A key point here is that despite the widespread and uncritical use of the term ROS to describe any ‘Reactive Oxygen Species’, most such as superoxide and peroxide are not terribly reactive, in contrast to the hydroxyl radical (and peroxynitrite) which is, and unliganded iron is required for hydroxyl radical production in the Fenton reaction. Hence the focus on unliganded iron rather than the more nebulous ROSs, albeit that (su)peroxide is necessarily involved.

Clearly the occurrence of these activities leads to the (more or less irreversible) formation of a variety of substances that can act as biomarkers of these activities (Kell 2009a), and such oxidised compounds are represented by both small and macro-molecules. For instance, 8-hydroxy-2′-deoxyguanosine (8-OHdG) (ChEBI 40304) also referred to as its tautomer 8-oxo-7,8-dihydro-2’-deoxyguanosine (8-oxodG) (HMDB03333) is produced when the hydroxyl radical reacts with DNA and damages it (e.g. Bal and Kasprzak 2002; Burrows and Muller 1998; Cooke et al. 2003, 2008; Lloyd et al. 1998; Loft and Poulsen 1996; Orhan et al. 2004; Shi et al. 2003; Toyokuni and Sagripanti 1996; Valavanidis et al. 2009; Valko et al. 2005), and body-iron status correlates rather strongly with its production or urinary excretion (Agarwal et al. 2004; Broedbaek et al. 2009; Fujita et al. 2007a, 2009; Gackowski et al. 2002; Hori et al. 2010; Kang et al. 1998; Kuo et al. 2008; Maruyama et al. 2007; Nakano et al. 2003; Toyokuni and Sagripanti 1996; Tuomainen et al. 2007; Valavanidis et al. 2005). The data in (Hori et al. 2010) relating urinary 8-OHdG levels to serum ferritin concentrations are particularly striking, and I have digitised them (cf. Pettifer et al. 2009 for pointers to automated ways of doing this in the future) and replotted some of them in Fig. 3.

Ferritin levels (a common measure of body iron stores) are also widely associated with disease development/ severity/ poor outcomes (e.g. Alissa et al. 2007; Armand et al. 2007; Bartzokis et al. 2007; Braun et al. 2004; Bugianesi et al. 2004; Chen et al. 2006; Choi et al. 2005; Double et al. 2000; Fargion et al. 2001; Fernández-Real et al. 2002; Ford and Cogswell 1999; Forouhi et al. 2007; He et al. 2007; Hubel et al. 2004; Ishizaka et al. 2005; Jehn et al. 2004, 2007; Kaur et al. 2007; Kiechl et al. 1997; Lee et al. 2006f; Lim et al. 2001; Rayman et al. 2002; Rouault 2006; Salonen et al. 1992; Sheth and Brittenham 2000; Tuomainen et al. 1998; Valenti et al. 2007; Wilson et al. 2003; You et al. 2003; You and Wang 2005) (Adamkiewicz et al. 2009; Baune et al. 2010; Busca et al. 2010; DePalma et al. 2010; Ferrara et al. 2009; Ferrucci et al. 2010; Gamberini et al. 2008; Goodall et al. 2008; Inati et al. 2010; Kaysen 2009; Knovich et al. 2009; Kolberg et al. 2009; Lecube et al. 2008; Lim et al. 2010; Mateo-Gallego et al. 2010; McNeill et al. 2008; Menke et al. 2009; Qureshi et al. 2008; Rajpathak et al. 2009; Sharifi et al. 2008; Skinner et al. 2010; Song et al. 2009; Storey et al. 2009; Sun et al. 2008; Tsimikas et al. 2009; Valenti et al. 2010; Walker et al. 2010; Wang et al. 2010b; Yoneda et al. 2010; Zandman-Goddard and Shoenfeld 2008), though note that most assays are for the protein itself, and not for the full molecule including any iron that it may sequester effectively (Balla et al. 1992; Hintze and Theil 2006; Theil 2007) or otherwise.

Although iron is most commonly bivalent, Fe(II), or trivalent, Fe(III), this simple statement does not remotely cover the relevant chemistry and speciation that are necessary to recognise what forms of ‘iron’ may be safe and which are likely to catalyse damaging reactions. The first issue is that at neutral pH Fe(III) is more or less insoluble, and in aerobic environments it is necessary to chelate the otherwise ‘free’ Fe(III) with appropriate chelators or siderophores (especially for microbes, e.g. Andrews et al. 2003; Barry and Challis 2009; Cornelis and Andrews 2010; de Carvalho and Fernandes 2010; Haas et al. 2008; Johnson 2008; Miethke and Marahiel 2007; Raymond et al. 2003; Sandy and Butler 2009; Wandersman and Delepelaire 2004; Winkelmann 2002). These siderophores—secreted as are other bacterial pheromones (Kell et al. 1995)—typically have extremely tight binding constants (K f > 1030, e.g. Clifton et al. 2009; Loomis and Raymond 1991) and can solubilise and sequester iron such that it can be internalised via suitable transporter molecules within the plasma membrane (Stintzi et al. 2000).

Iron contains up to six individual chelation sites, arranged octahedrally, and ligands can typically satisfy them partially (i.e. some ligands are bidentate or tridentate and need three or two molecules for full liganding/activity) or fully i.e. are hexadentate. Since iron cannot be transmuted into any other substance, the only way to stop the damaging activity of free or partially liganded ‘iron’ is to ensure that all of its six possible liganding sites are satisfied , whether by endogenous chelators or those added from the diet or as pharmaceuticals. Put another way, it is not simply enough to know that ‘iron’ is present at an adequate level but that it is available in a suitably liganded form. Anaemia can be caused by poor liganding as well as by an actual shortage of ‘iron’ itself. Note too that partial chelation in the presence of an antioxidant agent such as ascorbate (vitamin C) can in fact make ascorbate (or other reducing agent) act as a pro-oxidant and thus actually promote the production of OH radicals in the presence of inappropriately or inadequately liganded Fe(II) (Allen and Cornforth 2009; Fábián and Csordás 2003; Halliwell 2009; Hininger et al. 2005; Lachili et al. 2001; Long et al. 2000; Miller et al. 1990; Reif 1992; Sugihara et al. 1999). This very likely explains the often and indeed surprisingly disappointing clinical results obtained when using antioxidants alone (Bjelakovic et al. 2008; Giustarini et al. 2009; Kell 2009a; Miller et al. 2005).

The above facts are well known (e.g. Halliwell and Gutteridge 2006; Weinberg 2004), and I discussed them at length in a recent and wide-ranging review (Kell 2009a). My purpose here is to look more closely at the evidence that they are part of the sequelae of a number of predispositions to cellular and organismal death (whether by necrosis or apoptosis) that follow from a large variety of initial ‘insults’ or distal causes, whether of genetic or environmental origin (or both). While, as a systems property, many other cellular processes contribute measurably to any specific activity, I suggest, in all the disparate cases I review, that it is the binding of poorly liganded iron (mainly bivalent) to inappropriate cellular structures that serves to generate this catalytic activity, albeit that the overall manifestations may differ at a physiological level, and I here review what evidence is available. This basic suggestion can be tested explicitly more or less easily. I suggest further that it is this ongoing, autocatalytic activity based on positive feedback that is responsible for the really large-scale damage, leading to organismal death, that can occur in affected cells, tissues, organs and organisms. This analysis also suggests an important role for iron chelation as part of combination approaches in the acute and chronic therapy of these conditions. An overview of this article is given as a Mind Map (Buzan 2002) in Fig. 4.

Note that I do recognise that other transition and polyvalent metal ions (Aln+, Crn+, Cun+, Mnn+, Sen+, Znn+ etc.) may also contribute to the kinds of process I describe. However, for reasons of simplicity, focus, and because of the natural abundance of this metal in biological systems, it is ‘iron’ on which I shall concentrate. As previously (Kell 2009a), I use the term ‘iron’ to include iron of any valencies or speciation, unless specified otherwise.

Since the role of iron is obvious in cases of primary diseases of iron overload, such as hereditary haemochromatosis (e.g. Camaschella and Merlini 2005; Ellervik et al. 2007; Gan et al. 2010; Limdi and Crampton 2004; Mair and Weiss 2009; Marx 2002; McLaren and Gordeuk 2009; Pantopoulos 2008; Papanikolaou and Pantopoulos 2005; Pietrangelo 2006; Weiss 2010), thalassaemias (e.g. Borgna-Pignatti et al. 2005; Camaschella and Merlini 2005; Cao and Galanello 2010; Cohen et al. 2004; Gattermann 2009; Lam et al. 2008; Li et al. 2010; Mohkam et al. 2008; Peng et al. 2008; Taher et al. 2010; Vichinsky et al. 2005) and myelodysplastic syndrome (e.g. Cazzola et al. 2008; Cuijpers et al. 2010; Dreyfus 2008; Gattermann 2008; Greenberg 2006; Greenberg et al. 2008; Jabbour et al. 2009; Jädersten and Hellström-Lindberg 2010; Leitch 2007; Mahesh et al. 2008; Malcovati 2009; Porter et al. 2008; Wimazal et al. 2009), I largely ignore this literature. However, I recognise that the sequelae of iron overload, especially various kinds of organ failure, share many similarities to those I describe below, consistent with the role of iron in these other cases where its involvement has been less widely recognised. Clearly the commonality of any specific effect with those of known iron overload (Dever et al. 2010) might give strong hints for the involvement of iron in specific toxicological processes.

The literature survey at the time of initial submission for review extended to 14 June, 2010.

To start our survey, we look at the consequences of an acute cerebral infarction or stroke.


Stroke is a term used to describe the destruction of brain cells, typically following a temporary blockage in blood flow (ischaemia-reperfusion injury) or an intra-cranial haemorrhage. The extent of damage varies considerably, and can be exacerbated because affected cells can release inflammatory cytokines that activate other cells in a similar way, providing a positive autocatalytic effect and leading to spreading of the damage. It is this secondary spreading that is especially damaging, but because it is slower (4–7days), it also affords the opportunity for therapeutic intervention (Qureshi et al. 2009). It is now clear that iron is intimately involved (Armengou and Davalos 2002; Bailey et al. 2006; Bishop and Robinson 2001; Chang et al. 2005; Dávalos, et al. 1994; Demougeot et al. 2004; Ferro and Dávalos 2006; Garoufi et al. 2006; Gillum et al. 1996; Lee et al. 2006e; Marniemi et al. 2005; Mascitelli and Pezzetta 2006; Mehta et al. 2004; Mu et al. 2005; Nakamura et al. 2006; Saxena et al. 2005; Selim and Ratan 2004; Switzer et al. 2006; Wagner et al. 2003; Wu et al. 2003; Zuliani et al. 2006; Adams 2007; Altamura et al. 2009; Assenza et al. 2009; Basak et al. 2008; Bosomtwi et al. 2008; Carbonell and Rama 2007; Cho et al. 2007; Ekblom et al. 2007; Hanson et al. 2009; Heckl 2007; Helal 2008; Jolkkonen et al. 2007; Justicia et al. 2008; Kaushal and Schlichter 2008; Kim et al. 2008a; Kobayashi et al. 2008; Lou et al. 2009; Maguire et al. 2007; Mazumdar et al. 2007; Mehdiratta et al. 2008; Millan et al. 2007, 2008; Millerot-Serrurot et al. 2008; Nighoghossian et al. 2008; O’Rourke et al. 2008; Ratan et al. 2008; Ross and Meschia 2009; Saleh et al. 2007; Santhosh et al. 2009; Verduzco and Nathan 2009; Walters and Rye 2009; Weng et al. 2008), whether by release from (ferritin in) cells or from the haem of haemoglobin. Iron chelators have thus shown promise in decreasing the sequelae of an initial stroke-inducing event (Demougeot et al. 2004; Ferro and Dávalos 2006; Hurn et al. 1995; Kompala et al. 1986; Mu et al. 2005; Patt et al. 1990; Prass et al. 2002; Selim and Ratan 2004; Soloniuk et al. 1992; White et al. 1988; Chen-Roetling et al. 2009; Gu et al. 2009; Hanson et al. 2009; Hua et al. 2008; Mazumdar et al. 2007; Méthy et al. 2008; Millerot-Serrurot et al. 2008; Mirre et al. 2010; Okauchi et al. 2009, 2010; Ratan et al. 2008; Robinson et al. 2009; Selim 2009; Verduzco and Nathan 2009), providing further evidence for the primary importance of iron in causing injury.

While stroke is a sudden occurrence, albeit with secondary consequences, a number of neurodegenerative diseases are rather more long term in their development, and we now look at several, each of which is seen to involve iron intimately.

Huntington’s disease

The pathology of HD reveals striking neurodegeneration in the corpus striatum and shrinkage of the brain, leading to its most prominent manifestation, viz. movement disorders or chorea (Bhidayasiri and Truong 2004). Huntington’s disease occurs via the addition of trinucleotide CAG repeats within exon 1 of the relevant gene, encoding (poly)glutamine (polyQ) repeats in the huntingtin protein (htt) and leading to a gain of (toxic) function (Bauer and Nukina 2009; Gusella and MacDonald 2000; Imarisio et al. 2008; Quintanilla and Johnson 2009). The number of these repeats determines both the time of onset of observable disease (more repeats meaning earlier onset) (Perutz and Windle 2001; Ross 1995; Walters and Murphy 2009), accounting for 70% of the variance (Imarisio et al. 2008), and the disease severity, implying that it is indeed the polyglutamines themselves that are the chief culprits. Some of the polyQ-containing huntingtin proteins can also aggregate to form inclusion bodies, and aggregation and neurodegeneration can in part be related (Chopra et al. 2007; Cowan et al. 2003; Michalik and Van Broeckhoven 2003; Nagai et al. 2003; Wang et al. 2005, 2009; Zhang et al. 2005a). Now the evidence for the involvement of poorly liganded iron in a wide variety of neurodegenerative diseases is overwhelming (e.g. Benarroch 2009; Bishop et al. 2010a; Brown 2009a; Friedman et al. 2007; Jellinger 1999; Ke and Qian 2003; Kell 2009a; Lee et al. 2006a; Perez and Franz 2010; Thompson et al. 2001; Youdim et al. 2004b; Zecca et al. 2004), and the question arises as to whether huntingtin (or, more likely, its degradation fragments), containing these polyQ tracts, can catalyse oxidative stress and/or hydroxyl formation directly. In an important paper, Firdaus et al. (Firdaus et al. 2006) show that that huntingtin inclusion bodies act as centres of oxidative stress and that partially purified inclusion bodies contain large amounts of oxidised proteins. Iron metabolism is deranged in gene knockdown models of Huntington’s (Henshall et al. 2009; Lumsden et al. 2007), and experiments with the iron chelator deferroxamine revealed that the oxidation, localisation and structural organisation of the inclusion bodies formed by mutant htt were indeed irondependent. They did not demonstrate the ability of these inclusion bodies to catalyse hydroxyl formation, but this could easily be shown using specific assays, such as the hydroxylation of suitable aromatics (e.g. Grootveld and Halliwell 1986; Halliwell and Gutteridge 2006; Thomas et al. 2009a). The iron chelator clioquinol is also protective (Nguyen et al. 2005).

Parkinson’s disease

Parkinson’s disease (PD) results primarily from the death of dopaminergic neurons in the substantia nigra part of the brain and is characterised in particular by the presence of intracytoplasmic inclusions from protein aggregates called Lewy bodies (LB) and at the physiological level by a variety of movement disorders (e.g. Singh et al. 2007). It is strongly linked with oxidative stress (e.g. Alam et al. 1997; Büeler 2009; Jenner 2003; Jenner and Olanow 1996; Kidd 2000; Mandel et al. 2003; Olivares et al. 2009; Seet et al. 2010; Van Laar and Berman 2009; Zhang et al. 1999). Again (e.g. Berg et al. 2001; Bharath et al. 2002; Buchanan et al. 2002; Bush 2000; Castellani et al. 2002; Double et al. 2000; Good et al. 1998; Gotz et al. 2004; Hirsch and Faucheux 1998; Jellinger 1999; Johnson 2000; Olanow and Arendash 1994; Ostrerova-Golts et al. 2000; Sofic et al. 1991; Wolozin and Golts 2002; Altamura and Muckenthaler 2009; Andersen 2004; Barapatre et al. 2010; Baudrexel et al. 2010; Becker 2010; Becker et al. 2010a, b; Berg 2006, 2007; Berg and Hochstrasser 2006; Berg et al. 2006, 2008; Brar et al. 2009; Brown 2009b; Crichton and Ward 2006; Fasano et al. 2006; Friedman et al. 2007, 2009; Ghosh et al. 2010; Hirsch 2009; Jellinger 2009; Jimenez-Del-Rio et al. 2010; Kaur and Andersen 2004; Lee and Andersen 2010; Levenson 2003; Mandemakers et al. 2007; Matusch et al. 2010; Oakley et al. 2007; Salvador 2010; Shi et al. 2010; Wayne Martin 2009; Wypijewska et al. 2010; Yeager and Coleman 2010; Zecca et al. 2004; Zhang et al. 2005, 2010b)—there is overwhelming evidence for the involvement of iron in this neurodegeneration. Why these dopaminergic neurons are especially susceptible is not entirely clear, although dopamine is capable of reacting with iron directly to form a toxic complex (Arreguin et al. 2009; Paris et al. 2005) that probably itself catalyses hydroxyl formation. Iron chelators inhibit these inimical processes (Gal et al. 2006; Perez et al. 2008; Xu et al. 2008; Youdim et al. 2004a, b; Zheng et al. 2005), including (Kaur et al. 2003; Reznichenko et al. 2010; Youdim 2003) in the case of a Parkinson-like disease induced (Blum et al. 2001; Choi et al. 2009; Gal et al. 2009; Yokoyama et al. 2008) by 1-methyl-4-phenyl-1,2,3,6-tetrahydro-pyridine (MPTP) (ChEBI 17963). The Lewy bodies contain lipid and a variety of proteins, including ubiquitin, neurofilament, various proteasomal elements and α-synuclein, which may be oxidatively modified (Double et al. 2008). Ferric iron may itself catalyse the formation of α-synuclein oligomers (Brown 2009a; Hillmer et al. 2009; Peng et al. 2010), and copper may also be involved (Wang et al. 2010c).

Melanins are polymers of polyphenols, especially of L-dopamine, although neuromelanin, which also contains oxidatively polymerised dopamine or noradrenaline with the possible involvement of cysteinylderivatives (Fedorow et al. 2005), is of special interest here. The substantia nigra also contains a substantial amount of the dark, insoluble polymeric pigment neuromelanin, and this has been shown directly to bind (and release) iron in high amounts (Double et al. 2003a, b; Fasano et al. 2006; Faucheux et al. 2003; Gerlach et al. 2003, 2008; Shamoto-Nagai et al. 2006), and thereby to produce an iron-loaded form that seems to serve as a reservoir catalysing (hydroxyl) radical formation and whose amounts correlate with PD. In this case, the in vitro experiments have been done, and incubation of human neuromelanin with iron in vitro stimulates oxidative tissue damage (Ben-Shachar et al. 1991; Double et al. 2003a; Gerlach et al. 2008).

Another dark pigment commonly observed in PD patients (and other neurodegenerative diseases) is lipofuscin (Double et al. 2008; Jung et al. 2007; Terman and Brunk 2004). Lipofuscin too consists of lipids and oxidised proteins, often crosslinked by oxidised lipid derivatives such as (E)-4-hydroxy-non-2-enal (ChEBI 58968) and can adsorb high contents of metals (including iron) of up to 2% by weight (Jung et al. 2007). It is typically formed in lysosomes from degrading mitochondria (Terman et al. 2006a), themselves rich in metalloproteins, and the inability of cells to degrade it means that (purportedly) non-dividing cells (such as brain tissue) simply accumulate it as cells age (Terman and Brunk 2004, 2006). This arguably explains why non- or rarely-dividing tissues such as brain tissues are particularly susceptible, though note the important and increasing evidence (e.g. Abrous et al. 2005; Christie and Cameron 2006; Demir et al. 2009; Fuchs and Gould 2000; Götz and Huttner 2005; Gould 2007; Imayoshi et al. 2009; Leuner et al. 2007; Lledo et al. 2006; Ohnuma and Harris 2003; Taupin 2007; Zhao et al. 2008) for considerable turnover—neurogenesis—in at least some regions of the brain. The autocatalytic nature of the process—lipofuscin loaded with iron catalyses more lipofuscin production—is especially dangerous and can (as one would predict) be inhibited using appropriate iron chelators (Persson et al. 2003). Iron chelation also assists neurogenesis (Nowicki et al. 2009).

Thus, as with Huntington’s, Parkinson’s disease is clearly characterised by all the hallmarks of hyperactive hydroxyl radical generation, leading to cell death and destruction, in this case mainly, it would seem (Chen et al. 2007; Chiueh et al. 2000; Ekshyyan and Aw 2004; Jellinger 2002; Jenner 2003; Jenner and Olanow 1996; Kermer et al. 2004; Levenson 2005; Loh et al. 2006; Mandel et al. 2005; Mattson 2006; Okouchi et al. 2007; Xu et al. 2008a; Yasuda and Mochizuki 2010), by apoptosis.

Gaucher’s disease

Gaucher’s disease is an autosomally recessive inborn error of metabolism due to deficiency of a lysosomal enzyme, glucocerebrosidase (GBA), resulting in the accumulation of glucocerebroside in large macrophages throughout the reticuloendothelial system, leading to various neuronopathies. Given that the lysosome is the site of most labile iron in the cell (Fakih et al. 2008; Gorria et al. 2008; Kurz et al. 2004, 2008a, b; Persson 2005; Tenopoulou et al. 2007; Terman et al. 2006b; Yu et al. 2003), it is also of interest that there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009). Iron dysregulation is also well established in Gaucher’s disease (Finch et al. 1986; Lee et al. 1967, 1977; Lorber 1960, 1970; Morgan et al. 1983; Schiano et al. 1993; Weisberger et al. 2004). This recognition of the role of iron dysregulation in Gaucher’s disease may offer novel therapeutic approaches.

Alzheimer’s disease

Alzheimer’s disease (AD), the commonest of the neurodegenerative disease of ageing, shares many similarities with Huntington’s and Parkinson’s diseases, not least the extensive evidence for the role of oxidative stress (e.g. Butterfield et al. 2007; Christen 2000; DiMauro and Schon 2008; Good et al. 1996; Milton 2004; Miranda et al. 2000; Moreira et al. 2009; Nunomura et al. 2001, 2006; Reddy and Beal 2008; Reddy et al. 2009; Rottkamp et al. 2000; Smith et al. 1996, 2000; Zhu et al. 2007) and of iron (e.g. Adlard and Bush 2006; Avramovich-Tirosh et al. 2007a; Becker et al. 2010b; Bishop et al. 2002; Blázquez et al. 2007; Bolognin et al. 2009b; Brar et al. 2009; Bush 2000, 2003, 2008; Casadesus et al. 2004; Castellani et al. 2007; Collingwood and Dobson 2006; Collingwood et al. 2008; Connor and Lee 2006; Ding et al. 2009; Doraiswamy and Finefrock 2004; Gerlach et al. 1994; Good et al. 1996; Hegde et al. 2009; Honda et al. 2004; Jellinger et al. 1990; Jellinger 2009; Kala et al. 1996; Lehmann et al. 2006; LeVine 1997; Lovell et al. 1998; Malecki and Connor 2002; Mandel et al. 2007; Markesbery 1997; Markesbery and Lovell 1998; Mascitelli et al. 2009; Olanow and Arendash 1994; Ong and Farooqui 2005; Quintana et al. 2006; Rival et al. 2009; Robson et al. 2004; Silvestri and Camaschella 2008; Smith et al. 1997a, 2010; Tabner et al. 2005; Thomas and Jankovic 2004; Thompson et al. 2001; Valko et al. 2005; Zatta et al. 2009; Zecca et al. 2004; Zheng et al. 2005). It is especially noteworthy that iron correlates with disease severity as measured by cognitive ability (Ding et al. 2009; Gómez Ravetti et al. 2010; Grossi et al. 2009; Lavados et al. 2008; Perez et al. 2010; Smith et al. 2010). AD is characterized by the loss of neurons in the cognitive centres of the brain and by the presence of two separate pathological lesions, extracellular β-amyloid (Aβ) plaques (e.g. Dong et al. 2003; Scott and Orvig 2009) and neurofibrillary tangles within neurons (Shcherbatykh and Carpenter 2007).

Again, there is evidence that insoluble polymers (fibrillary tangles) of proteins such as the β-amyloid can bind iron (Castellani et al. 2007; Dickens and Franz 2010; Exley 2006; Good et al. 1992; Jiang et al. 2009; Mancino et al. 2009; Rival et al. 2009; Sayre et al. 2000b; Smith et al. 2007) and thereby act in an autocatalytic manner to promote further radical production and oxidative stress. There is a also relationship between the ability to bind haem and neurotoxicity (Atamna 2009; Atamna et al. 2009), and (HFE) mutations that cause haemochromatosis increase the susceptibility to AD (Bartzokis et al. 2010; Candore et al. 2003; Combarros et al. 2003; Connor and Lee 2006; Haacke et al. 2005; Kauwe et al. 2010; Lleó et al. 2002; Moalem et al. 2000; Pulliam et al. 2003; Robson et al. 2004; Sampietro et al. 2001), especially when in the presence of the APOE4 allele (Pulliam et al. 2003). (HFE mutations also increase susceptibility to PD (Biasiotto et al. 2008; Dekker et al. 2003)—but cf. (Aamodt et al. 2007)—and to ALS (Ellervik et al. 2007)).

Importantly, iron chelators have been shown to ameliorate the development of fibril formation/neurodegeneration/dementia/AD (Amit et al. 2008; Avramovich-Tirosh et al. 2007a; Bandyopadhyay et al. 2006; Barnham et al. 2004; Biran et al. 2009; Bolognin et al. 2009a; Crapper McLachlan et al. 1991; Cuajungco et al. 2000; Faux et al. 2010; Finefrock et al. 2003; Liu et al. 2009b, c, 2010; Mancino et al. 2009; Mandel 2007, 2008; Reznichenko et al. 2006; Scott and Orvig 2009; Weinreb et al. 2009a; Zheng et al. 2005). Although this fact rarely appears in papers setting out therapeutic options for preventing (or at least ameliorating the progress of) AD, this already considerable literature suggests that trials using modern iron chelators would be of worth.

Amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease)

ALS is another neurodegenerative disease in which iron has been strongly implicated (and thus the same kinds of mechanism as described previously) (Bush 2000; Carri et al. 2003; Cozzolino et al. 2008; Goodall et al. 2008; Jeong et al. 2009; Kasarskis et al. 1995; Mattson 2004; Migliore et al. 2005; Molfino et al. 2009; Qureshi et al. 2008; Reynolds et al. 2007; Sadrzadeh and Saffari 2004; Sayre et al. 2000a; Scott and Orvig 2009; Spasojević et al. 2010; Sutedja et al. 2007; Wang et al. 2004). Again, the clear benefits of iron chelators in mouse models (Jeong et al. 2009; Petri et al. 2007) and elsewhere (Avramovich-Tirosh et al. 2007b; Bolognin et al. 2009a) would seem to merit trials in humans known to be at risk. Long-standing associations of some forms of ALS with mutations in genes coding for superoxide dismutase 1 (e.g. Dalle-Donne 2007; Pasinelli and Brown 2006; Rosen et al. 1993; Vucic and Kiernan 2009; Wijesekera and Leigh 2009) are consistent with this, and recent genetic associations (e.g. Kwiatkowski Jr. et al. 2009; Valdmanis et al. 2009; Vance et al. 2009) include one with optineurin (Maruyama et al. 2010) that together with other evidence implies an interaction with NF-κB (see later) leading to the downstream effects of apoptotic neuronal cell death.

Friedreich’s ataxia

Friedreich’s ataxia is another neurodegenerative disease caused by the insertion of a trinucleotide repeat (or occasionally a missense mutation) in the gene encoding a protein called frataxin (Adibhatla and Hatcher 2010; Babady et al. 2007; Becker and Richardson 2001; Bencze et al. 2006; Chakravarty 2003; González-Cabo et al. 2009; Palau 2001; Pandolfo 2009; Patel and Isaya 2001; Puccio 2009; Rötig et al. 2002; Santos et al. 2010; Sheftel et al. 2010). Driven not least by studies in bacteria and lower eukaryotes (Ayala-Castro et al. 2008; Becker and Richardson 2001; Bulteau et al. 2007; Cavadini et al. 2000; Cook et al. 2006; De Freitas et al. 2003; Foury 1997; Foury and Cazzalini 1997; Foury and Talibi 2001; González-Cabo et al. 2005; Irazusta et al. 2006, 2008; Knight et al. 1999; Pastore et al. 2007; Vázquez-Manrique et al. 2006; Wang and Craig 2008; cf. Seguin, et al. 2010), it is now understood that frataxin is a mitochondrial iron chaperone protein (Atkinson and Winge 2009; Ba et al. 2009; Babady et al. 2007; Bencze et al. 2007; Cavadini et al. 2002; Correia et al. 2008; Gakh et al. 2006; Haugen et al. 2010; Huang et al. 2008a; Huang et al. 2009; Karlberg et al. 2006; Kondapalli et al. 2008; Lill 2009; Lill and Muhlenhoff 2008; Lu and Cortopassi 2007; MacKenzie et al. 2008; Mandemakers et al. 2007; Marmolino and Acquaviva 2009; Napier et al. 2005; Napoli et al. 2006; O’Neill et al. 2005; Pandolfo 2009; Pandolfo and Pastore 2009; Pastore et al. 2007; Reddy 2008; Schagerlöf et al. 2008; Sparaco et al. 2009; Wilson 2006; Zanella et al. 2008) involved in the safe insertion of Fe(II) during the production of Fe–S centres in the mitochondrial respiratory chain (Anderson et al. 2005). The defect thus leads to the liberation of mitochondrial iron (Huang et al. 2009; Popescu et al. 2007; Richardson et al. 2009a). Fenton chemistry is strongly implicated (Park et al. 2002; Sturm et al. 2005), as the attenuation of H2O2 production (but not of superoxide) (Anderson et al. 2005) ameliorates the disease (Anderson et al. 2008). As would be expected, appropriate iron chelation may have therapeutic benefits (Boddaert et al. 2007; Campanella et al. 2009; Goncalves et al. 2008; Kakhlon et al. 2010; Lim et al. 2008; Marmolino and Acquaviva 2009; Santos et al. 2010; Schulz et al. 2009; Sohn et al. 2008). This very clear molecular picture underlines strongly the problems of iron release leading to cell death and destruction.

Multiple sclerosis

MS is an inflammatory demyelinating autoimmune disease affecting the CNS. While its underlying causes remain uncertain, and do not seem to have a significant genetic component (Baranzini et al. 2010; Oksenberg et al. 2008; Ramagopalan et al. 2008), ROS are certainly implicated (Adibhatla and Hatcher 2010), and antioxidant therapies may be useful (Mirshafiey and Mohsenzadegan 2009). It is at least plausible that part of the demyelination is caused by ROS and in particular hydroxyl radicals, and it is thus of much interest that iron dysregulation and/or deposition have indeed been implicated directly (Adams 1988; Bakshi et al. 2000, 2001, 2002, 2008; Bermel et al. 2005; Brass et al. 2006a, b; Ceccarelli et al. 2009, 2010; Chard and Miller 2009; Craelius et al. 1982; Drayer et al. 1987; Eissa et al. 2009; Exley et al. 2006; Filippi and Agosta 2009; Ge et al. 2007; Grimaud et al. 1995; Haacke et al. 2005, 2009, 2010; Hammond et al. 2008; He and Yablonskiy 2009; Khalil et al. 2009; LeVine and Chakrabarty 2004; Neema et al. 2007a, b, 2009a, b; Pirko et al. 2009; Sayre et al. 2005; Schenck and Zimmerman 2004; Simka and Rybak 2008; Singh and Zamboni 2009; Stankiewicz et al. 2007; Tjoa et al. 2005; Walter et al. 2009; Zamboni 2006; Zivadinov and Bakshi 2004; Zivadinov and Minagar 2009). While the extent of causality of the iron dysregulation in MS is not yet established, it is highly pertinent that iron chelators have been shown to suppress disease progression in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (Bowern et al. 1984; Mitchell et al. 2007; Pedchenko and LeVine 1998). To say the least, the question of the involvement of iron in the human disease would seem to need pursuing with some urgency.

Age-related macular degeneration

While this review is intended to be much more circumscribed than the previous one (Kell 2009a), there are some pertinent diseases in which my understanding has improved significantly, and age-related macular degeneration is one such. Age-related macular degeneration (AMD) (Rattner and Nathans 2006) is recognised as the leading cause of blindness and visual disability in the elderly in developed countries (Fine 2005; Harvey 2003; Lotery and Trump 2007; Tielsch et al. 1995). Interestingly, despite the relatively modest impact of genome-wide association studies to date (Maher 2008; Moore et al. 2010), and notwithstanding their promise as their statistical power improves, 80% of the variation in susceptibility to AMD is said to be explainable (Collins 2010) (and see e.g. Chu et al. 2008) though cf. e.g. (Chen et al. 2010; Hadley et al. 2010; Katta et al. 2009; Neale et al. 2010; Patel et al. 2008; Sobrin et al. 2010) by just two genes concerned with inflammation combined with two environmental factors (smoking and obesity). The environmental factors can certainly be related to iron dysregulation. Indeed, as previously discussed, iron is significantly implicated in AMD (and other related diseases such as glaucoma) (Blasiak et al. 2009; Cai et al. 2000; Charkoudian et al. 2008; Chen et al. 2009; Chowers et al. 2006; Dentchev et al. 2005; Dunaief 2006; García-Castiñeiras 2010; Goralska et al. 2009a, b, c; Hahn et al. 2003, 2004; He et al. 2007; Loh et al. 2009; Richer et al. 2002; Wong et al. 2007), iron chelation may help to reverse the process (Voloboueva et al. 2007), and dietary and other antioxidants are also protective (see Tan et al. 2008; Wang et al. 2009).

Prion diseases: including transmissible spongiform encephalopathies and Creutzfeldt–Jakob disease

A particularly striking set of diseases, where the downstream events manifest as extreme cellular destruction leading to large areas of (brain) tissue disappearing completely, are represented by the prion diseases, in particular the TSEs including bovine spongiform encephalopathy (BSE) (e.g. Aguzzi et al. 2008a; Aguzzi and Heikenwälder 2006; Caughey and Baron 2006; Caughey and Lansbury 2003; Linden et al. 2008) and scrapie (e.g. Bulgin and Melson 2007; Hur et al. 2002; Roostaee et al. 2010; Wisniewski and Sigurdsson 2007), kuru (Gajdusek 2008; McLean 2008) and CJD (e.g. McLean 2008; Peden and Ironside 2004) (note too the co-location of amyloid plaques and spongiform degeneration in CJD, Ghoshal et al. 2009).

Now it is well known that prion diseases are caused in part (or at least accompanied by) the conversion of the prion protein PrP from its normal form PrPC to a conformationally distinct version PrPSc and that the latter can autocatalyse this conversion (Aguzzi and Heikenwälder 2006; Aguzzi et al. 2008b; Prusiner 1998, 2001; Tamgüney et al. 2008; Watts and Westaway 2007). However, PrPSc levels are in many cases poorly correlated with prion disease progression, suggesting that it is necessary but not sufficient; ‘something else’ is required (Caughey and Baron 2006). Equally, it is far from clear how a simple conformational change of a protein leads to the vacuolation or spongiosis (e.g. Aguzzi 2006; Aguzzi et al. 2007; Armstrong et al. 2001; Chung et al. 1999; Crozet et al. 2008; Diedrich et al. 1991; Foster et al. 2001; Julius et al. 2008; Kourie 2002; Mallucci et al. 2003; Mallucci et al. 2007; Miele et al. 2001; Sakudo and Ikuta 2009a, b; Westaway et al. 1994; Williams et al. 1997) (formation of holes) in brain tissue characteristic of late-stage prion disease (and indeed of Alzheimer’s (Erkinjuntti et al. 1996; Sakudo and Ikuta 2009a). The question then arises as to whether it is possible that PrPSc modifies iron metabolism in an unfavourable way (and/or vice versa), not least since prion proteins bear phylogenetic relationships to the ZIP family of metal ion transporters (Schmitt-Ulms et al. 2009). Building on earlier work relating prion biology with (especially) iron-induced oxidative stress (e.g. Bareggi et al. 2009; Barnham et al. 2006; Basu et al. 2007; Choi et al. 2006; Fernaeus et al. 2005a, b; Fernaeus and Land 2005; Iwamaru et al. 2008; Kim et al. 2000, 2001, 2007; Lee et al. 2007; Lehmann 2002; Milhavet and Lehmann 2002; Pamplona et al. 2008; Park et al. 2008; Petersen et al. 2005; Pollera et al. 2005; Rana et al. 2009; Stegmann and Grohmann 2003; Westergard et al. 2007; Wong et al. 2001), this is exactly what Singh and colleagues (Singh et al. 2009a, b, c, 2010a, b) have now demonstrated, which is that the ‘something else’ (Kell 2009a, b) is (as so often) an imbalance in iron metabolism. They start by showing (Singh et al. 2009c) that even normal PrPC mediates cellular iron uptake and transport and that mutant PrP forms alter cellular iron levels differentially.

PrPC binds iron tightly, and this helps effect its conversion to PrPSc (Singh et al. 2010a, b). Singh et al. (2009a) showed that PrPSc can sequester cellular iron in insoluble PrPSc–ferritin complexes, making it bio-unavailable, and that this leads to an upregulation of iron uptake via transferrin and its receptor, leading to an overall iron excess in brain tissue. This was true for both scrapie and sporadic Creutzfeldt–Jakob disease, and stresses that it is not only the total amount of Fe(II) and Fe(III) that matter but their speciation. Mice knocked out for PrP also show derangement in iron metabolism (Singh et al. 2009b), and given what we know already (Kell 2009a) this leads to many obvious predictions of other diseases (Altamura and Muckenthaler 2009; Granic et al. 2009; Reddy et al. 2009; Serra et al. 2009) to which they might be susceptible. It has not yet been shown that PrPSc–ferritin complexes catalyse OH production directly, but if this is increased in diseased brains this continuous, autocatalytic spewing out of toxic OH radicals would clearly be able to account for the massive damage observed. A systems biology approach by Hwang et al. (Hwang et al. 2009) also found many genes of iron metabolism modified in prion disease. There is little doubt that all these new findings about the role of iron (and other metals, e.g. Brown et al. 1997) open up many new inroads into understanding the important role of iron in prion diseases, and thereby novel therapeutic options involving both anti-oxidants and cell-permeable iron chelators. Some of these new ideas and findings are illustrated in Fig. 5.

Finally, here, it is worth pointing up the evidence for the role of iron and its metabolic dysregulation in the oxidative stress-mediated aetiology of scrapie (Choi et al. 2006; Fernaeus et al. 2005a; Fernaeus and Land 2005; Gudmundsdóttir et al. 2006; Kim et al. 2000, 2007; Pamplona et al. 2008; Singh et al. 2009a, 2010a, b; Wong et al. 2001a, b; Yun et al. 2006), a prion disease of sheep and goats (Bulgin and Melson 2007; Hur et al. 2002) and of CJD (Choi et al. 2006; Freixes et al. 2006; Petersen et al. 2005; Singh et al. 2009a, 2010a, b). As such, the use of geostatistics relating the variation of metals present in soils to prion disease prevalence is also a powerful tool here (e.g. Gudmundsdóttir et al. 2006; Imrie et al. 2009; Purdey 2000; Stevens et al. 2009).

Iron deposition and disease: cause or effect? The case of atherosclerosis

I have implied that the role of unliganded iron is causative of a variety of sequelae, but sometimes this is hard to infer as the networks in which iron is involved are multiple and complex (hence the need for a systems approach—see later), and often simple one-time snapshots of covariates do not permit the inference of causality. However, one effect of the reaction of hydroxyl radicals (their formation catalysed by unliganded iron) with proteins (or lipids) is to tend to make those proteins (or lipids) insoluble or fibrotic (Davies 2005; Fig. 6), and if one believes that this is causative, the presence of insoluble plaques should correlate with the presence of the iron that is seen to have caused their formation and thereby became entrapped (and may yet be further reactive). Because of its biomedical importance, considerable work has been performed on atherosclerotic lesions, which provide a very clear example.

Atherosclerosis is a progressive (and inflammatory) disease (Altman 2003; Binder et al. 2002; Blake and Ridker 2001; Duewell et al. 2010; Dwyer et al. 2004; Forrester 2002, 2004; Gieseg et al. 2009; Grainger 2007; Hansson 2001, 2005; Himmelfarb et al. 2002; Kibel et al. 2008; Kunsch and Medford 1999; Libby 2002; Libby et al. 2002; Madamanchi et al. 2005a, b; Mullenix et al. 2005; Nigro et al. 2006; Packard and Libby 2008; Paoletti et al. 2004; Popa et al. 2007; Rader and Daugherty 2008; Ridker et al. 2004; Ross 1999; Schleicher and Friess 2007; Subramanian and Ferrante 2009; Sullivan 2009; Tan and Lip 2008; Tang et al. 2009; Taqueti et al. 2006; Tedgui and Mallat 2006; van Leuven et al. 2008; van Oostrom et al. 2004; Willerson and Ridker 2004; Young et al. 2002) characterized by the accumulation of both oxidised lipids and various fibrous elements in arteries, often as plaques (Lusis 2000; Stocker and Keaney 2004). Several lines of evidence point to the involvement of iron in these processes:
  • Both iron and oxidised lipids (de Valk and Marx 1999; Smith et al. 1992) are found in atherosclerotic lesions (Altamura and Muckenthaler 2009; Brewer 2007; Chau 2000; Fernandes de Godoy et al. 2007; Gajda et al. 2008; Halliwell 2009; Horwitz et al. 1998; Kazi et al. 2008; Lee et al. 1998; McRae et al. 2009; Rajendran et al. 2007; Ramakrishna et al. 2003; Roijers et al. 2005; Smith et al. 1992; Stadler et al. 2004; Stanley et al. 2006; Stocker and Keaney 2005; Sullivan 2009; Watt et al. 2006; Wolff et al. 2004; Yuan and Li 2008)

  • Iron depletion by dietary or other means delays the formation of such lesions (Ferrara and Taylor 2005; Halliwell 2009; Lee et al. 1999; Matthews et al. 1997; Ponraj et al. 1999; Ren et al. 2005).

  • There is a correlation between iron status and atherosclerosis (Ahluwalia et al. 2010; Chau 2000; Day et al. 2003; de Valk and Marx 1999; DePalma et al. 2010; Gozzelino et al. 2010; Howes et al. 2000; Kallianpur 2005; Kartikasari et al. 2009; Kiechl et al. 1997; Lapenna et al. 2007; Marx et al. 2008; McRae et al. 2009; Minqin et al. 2003; Ramakrishna et al. 2003; Ren et al. 2003; Salonen et al. 1992; Shah and Alam 2003; Sullivan 2007, 2009; You et al. 2003; You and Wang 2005; Zacharski et al. 2000; Zacharski and Gerhard 2003) (and zinc is protective only against subsequent calcification, Stadler et al. 2008)

  • Exogenous ferric iron is deleterious to endothelial function (Rooyakkers et al. 2002)

  • Iron chelation improves endothelial function (Altamura and Muckenthaler 2009; Duffy et al. 2001; Halliwell 2009; Ishizaka et al. 2005; Saito et al. 2005; Thomas et al. 2006).

  • Iron levels in plaques correlate with the amount of oxidised proteins therein (Stanley et al. 2006); indeed in one study (Stadler et al. 2004), the EPR-detectable iron (essentially Fe(III)) in atherosclerotic tissue was seventeen times greater than that in the equivalent healthy tissue. I redraw these data in Fig. 7.

It seems clear that the application of similar studies to other diseases in which plaque formation occurs will be of benefit. Indeed, the location of iron in plaques has also been observed, for instance, for Alzheimer’s (e.g. Collingwood et al. 2008; Connor et al. 1992; El Tannir El Tayara et al. 2006; Ghribi et al. 2006; Haacke et al. 2005; Lovell et al. 1998; Morgan et al. 2004; Quintana 2007; Quintana et al. 2006; Sayre et al. 2000b; Schrag et al. 2009), ALS (Leveugle et al. 1997), MS (Haacke et al. 2009) and Parkinson’s (see above).

Sepsis, septic shock and the systemic inflammatory response syndrome

Although prions lack nucleic acids, they are seen as infectious agents. Bacteria are more conventional infective agents, and bacterial sepsis provides a very interesting example in which iron release is the key to cell death and the multiple organ failure that normally precedes organismal death. This said, the processes leading to septic shock and ultimately death (Fig. 8) are independent of the presence of viable/culturable bacteria (as defined in Kaprelyants et al. 1993; Kell et al. 1998), i.e. in the apparent absence of infection (Goris 1990; Suntharalingam et al. 2006). This is because it is the products of bacteria, especially lipopolysaccharide (LPS), that cause the cells themselves to initiate the progressive processes of self-destruction. The sequelae are typically referred to as a systemic inflammatory response syndrome (SIRS) (e.g. Baue et al. 1998; Beal and Cerra 1994; Bolton 1996; Bone 1996; Davies and Hagen 1997; Gutteridge and Mitchell 1999; Hotchkiss and Karl 2003; Johnson and Mayers 2001; Keel and Trentz 2005; Leithead et al. 2009; Lolis and Bucala 2003; Martin et al. 2003; Nguyen et al. 2006; Protti and Singer 2006; Rittirsch et al. 2008; Ulloa et al. 2009).

It is by now well established that—while a ‘cytokine storm’ (Huang et al. 2005; Sriskandan and Altmann 2008; Stacey et al. 2009; Suntharalingam et al. 2006; Wang and Ma 2008; Woo et al. 2010) is an important part of the aetiology of sepsis/septic shock—these phenomena are associated with the hyperproduction of ROSs (Abdelrahman et al. 2005; Andrades et al. 2005; Bulger and Maier 2001; Cadenas and Cadenas 2002; Closa and Folch-Puy 2004; Crimi et al. 2006a, b; Goode and Webster 1993; Gutteridge and Mitchell 1999; Horn 1998; Javadi et al. 2005; Lagan et al. 2008; Lemineur et al. 2006; Mishra 2007; Protti and Singer 2006; Quinlan et al. 2001; Redl et al. 1993; Victor et al. 2004, 2005; Vlessis et al. 1995), and (local and circulating) free iron is raised in sepsis and related conditions (Duvigneau et al. 2008; Galley et al. 1996, 1997; Galley and Webster 1996; Ghio et al. 2003; Lagan et al. 2008), as is the iron siderophore-binding protein lipocalin-2 (Hattori et al. 2009).

The natural iron-chelating antioxidant melatonin has been found to be particularly effective in preventing septic shock (Carrillo-Vico et al. 2005; Escames et al. 2006; Reynolds et al. 2003), and a variety of suitable antioxidants have shown promise (Bekyarova et al. 2009; Cuzzocrea et al. 2001, 2004; Di Paola et al. 2006; Galley et al. 1997; Mishra 2007; Nathens et al. 2002; Sebai et al. 2009; Streck et al. 2008; Zapelini et al. 2008). Most importantly, antioxidants are especially effective when given in combination with iron chelators (Barichello et al. 2007; Ritter et al. 2004, 2006) (see also Bulucu et al. 2009; Cassol et al. 2009; Petronilho et al. 2009; Pinho et al. 2005; Teixeira et al. 2008; Valvassori et al. 2008). Erythropoietin is also protective (Abdelrahman et al. 2004; Cuzzocrea et al. 2006), as is the iron-binder lactoferrin (Tian et al. 2010) and as are anti-inflammatory statins (Durant et al. 2004; Gao et al. 2008; Kopterides and Falagas 2009). All of these observations make it very clear indeed that iron is intimately involved in the death following SIRS and sepsis, and—while not even mentioned in the guidelines (Dellinger et al. 2008)—that its effective chelation should be considered for research leading towards its inclusion as an important part of any therapy.

Bactericidal antibiotics

The classical test for if a bacterium is (or was) ‘alive’ is to analyze its ability to multiply, i.e. viability = culturability (Kell et al. 1998; Postgate 1967, 1976). Accordingly, bacterial antibiotics have long been classified into those that are bacteriostatic, i.e. stop individual cells growing but allow culturability to recover if the antibiotic is removed, and those that are bactericidal, i.e. that actually kill cells and thereby decrease the numbers of those that are culturable (capable of multiplication) even if the antibiotic is removed. Since this clearly implies that causing growth to cease is not of itself bactericidal, and anyway different antibiotics have a variety of different modes of action, it has always been a slight mystery as to what it is that makes a particular antibiotic bactericidal rather than merely bacteriostatic.

A very important paper (Kohanski et al. 2007) provides much of the answer. As one may suppose from the subject matter of this review, iron is again involved, specifically via the Fenton reaction in which poorly liganded ferrous ions reduce the comparatively harmless hydrogen peroxide to the deadly hydroxyl radical.

Based on a previous paper from the same group (Dwyer et al. 2007), Kohanski et al. (2007) (see also Davies et al. 2009; Dwyer et al. 2007, 2009; Imlay 2008; Kohanski et al. 2008; Liu et al.2009a; Wang and Zhao, 2009) reported that the three major classes of bactericidal antibiotics (exemplified by norfloxacin, ampicillin and kanamycin), regardless of drug–target interaction, utilize internal iron liberated from iron–sulphur clusters to promote Fenton-mediated hydroxyl radical formation in bacteria, that such hydroxyl radical generation contributes to the killing efficiency of these lethal drugs (probably via their known ability to damage DNA), and that in contrast antibiotics that are merely bacteriostatic do not cause the production of such hydroxyl radicals. The availability of multiple genetically marked strains allowed several predictions (such as the resistance to be expected in mutants that could not make iron-sulphur centres so effectively) to be tested successfully. Nitric oxide is correspondingly protective (Gusarov et al. 2009). This suggests, much as above, that there is a common mechanism of iron/hydroxyl-mediated cellular death underlying the action of all classes of bactericidal antibiotics and opens up many new possibilities for combination therapies based on promoting this kind of activity selectively (see Fig. 9). This said, how synergistic a combination is does depend on the exact speciation of the liganded iron; surprisingly, the iron chelator deferasirox promoted the antibacterial activity of ciprofloxacin against V. vulnificus (Neupane and Kim 2010), as did deferiprone with various azoles against Aspergillus fumigatus, while deferoxamine was antagonistic to azoles (Zarember et al. 2009). As with any complex system, the interactions can be highly dosedependent (Hegreness et al. 2008; Kohanski et al. 2010; Yeh et al. 2009).


A typical viral infection involves the biding of virus to the cell surface followed by internalisation and other effects. Some viruses are especially virulent, and as well as inflammation cause the death of cells that they have invaded. It is obviously of interest to establish whether iron is involved in this kind of cell death (and if so whether iron chelation might contribute to a suitable therapy during the acute phase of an infection).

The above suggestions are certainly true of infections caused by influenza A (Visseren et al. 2002) (see also Akaike et al. 1996; Beck et al. 2004), herpes simplex virus (Gennero et al. 2010; Lamey and Biagioni 1995; Romeo et al. 2001), hepatitis C (Alavian and Tabatabaei 2009; Alla and Bonkovsky 2005; Ameli et al. 2008; Bassett 2007; Batts 2007; Bonkovsky 2002; Bonkovsky et al. 2006; Desai et al. 2008; Di Marco et al. 2008; Drakesmith and Prentice 2008; Fargion et al. 2002; Ferrara et al. 2009; Franchini et al. 2008; Fujita et al. 2007a, b; Fujita and Takei 2007; Girelli et al. 2009; Gürkan et al. 2005; Guyader et al. 2007; Hayashi and Yano 2002; Heathcote 2004; Kaito 2007; Kaito et al. 2006; Kato et al. 2001, 2007; Ko et al. 2007; Mahmoud et al. 2008; Mueller et al. 2006; Nahon et al. 2008; Nishina et al. 2008; Otogawa et al. 2008; Price and Kowdley 2009; Rigamonti et al. 2005; Sebastiani and Walker 2007; Sikorska et al. 2010; Sugimoto et al. 2009; Tanaka et al. 2007; Tanaka and Kiyosawa 2004; Trinder et al. 2008; Tung et al. 2003; Valenti et al. 2008; Venturini et al. 2010; Won et al. 2009) and HIV (Boelaert et al. 1996; Butensky James et al. 2009; de Monyé et al. 1999; Debebe et al. 2007; Drakesmith and Prentice 2008; Georgiou et al. 2000; Gordeuk et al. 2001, 2006; Kagu et al. 2007; Ketonen et al. 1996; McDermid et al. 2007; McDermid and Prentice 2006; McDermid et al. 2009; Meyer 2006; Northrop-Clewes 2008; Rawat et al. 2008; Savarino et al. 1999; Schreck et al. 1992; Szajerka and Jablecki 2007; Traoré and Meyer 2004, 2007; van Asbeck et al. 2001; Weinberg 2006; Ziegler et al. 2001).

Microbial, plant and animal toxins

Before considering chemical toxicants, it is worth noting that the natural world contains a very great many molecules that are toxic to cells and hence organisms. Although the mechanisms of cell death are rather rarely pursued, there is evidence for the involvement of iron in the sequelae of exposure to toxic doses of gentamicin (Petronilho et al. 2009), ochratoxin (Hasinoff et al. 1990; Omar et al. 1990; Størmer and Hoiby 1996) and ricin (Hassoun and Wang 1999; Kumar et al. 2003; Muldoon et al. 1996), as well as to certain snake venoms (Gutierrez et al. 2010).

Chemical toxicants: aniline, asbestos, dioxins, hydrazines, methyl mercury and paraquat

The most dangerous kinds of man-made toxic chemical agents, those that kill cells or organisms, exhibit a rich diversity of chemical structures and can bind to multiple cellular targets, to the extent that a unitary mode of action is not considered likely. (This said, the same was thought to be true for the mode of action of general anaesthetics or narcotics, and they turn out to have a comparatively small number of rather specific protein targets (Dobson et al. 2009; Dobson and Kell 2008; Franks 2006, 2008; Grasshoff et al. 2006)). However, this does not mean that multiple initial events do not at some point converge to a comparatively small number of crucial events of cell death (whether through necrosis or apoptosis, Vanden Berghe et al. 2009), equivalent to the ‘bow-tie’ model of cellular networks (see e.g. Csete and Doyle 2004; Ma’ayan 2009; Ma et al. 2004, 2007; Ma and Zeng 2003; Oda and Kitano 2006; Rodríguez-Caso et al. 2009; Wang and Chen 2010; Zhao et al. 2006, 2010) and (Fig. 10), and my purpose here is to highlight the evidence that iron-based mechanisms, largely based on Fenton chemistry, are involved in a number of these cases. A recent special issue on toxicants and neurodegeneration is also of interest here (Gupta and Milatovic 2009).


Acetaminophen (paracetamol in the United Kingdom) (ChEBI 46195) is a well-known analgesic that is nevertheless highly toxic at concentrations in excess of the therapeutic dose, as it is converted to the electrophilic N-acetyl-p-benzoquinone imine (NAPQI). If glutathione is in insufficient supply, the NAPQI cannot be conjugated harmlessly by glutathione and so it reacts covalently with proteins, especially mitochondrial proteins (Hinson et al. 2004; Jaeschke and Bajt 2006; Kon et al. 2004; Masubuchi et al. 2005; Reid et al. 2005), resulting in apoptotic cell death and organismal death via liver damage (e.g. Barker et al. 1977; Beckett et al. 1989; James et al. 2003; Martin-Murphy et al. 2010; Olaleye and Rocha 2008). One of the effects of mitochondrial damage is iron release, and it has long been known that iron chelators help prevent this toxicity (Sakaida et al. 1995; Schnellmann et al. 1999). Appropriate hydroxyl radical scavengers are also partly protective (Chandrasekaran et al. 2009), while lactoferrin is also protective, although not apparently only via its iron-binding capacity (Yin et al. 2010).


As is well known, the adulteration with aniline of cooking oil in Spain showed that aniline so administered can be exceedingly toxic to humans (the ‘toxic oil syndrome’, Hill et al. 1987; Vázquez Roncero et al. 1983), especially in the lungs and spleen. It is now clear (Bomhard and Herbold 2005; Khan et al. 1995, 1999; Ma et al. 2008; Mellert et al. 2004; Wang et al. 2005, 2008, 2010) that iron is heavily involved in this via Fenton chemistry.


Many mutagens are carcinogens, typically by intercalating into DNA, so it was not a priori obvious why asbestos fibres—enormously larger than the diameter of DNA—should be so toxic. The mystery was solved when it was realised that asbestos does in fact contain and bind iron, that the sharp surface of the iron-loaded fibres can catalyse hydroxyl radical formation and that it is this that provides the toxic mechanism (Aljandali et al. 2001; Burrows and Muller 1998; Chao et al. 1996; Chen et al. 1996; Dai and Churg 2001; Fubini and Arean 1999; Gilmour et al. 1997; Governa et al. 1999; Gulumian and van Wyk 1987; Hardy and Aust 1995a, b; Hippeli and Elstner 1999; Jaurand 1997; Kamp et al. 1992; Kamp and Weitzman 1997, 1999; Kelleher et al. 2000; Levresse et al. 2000; Lund and Aust 1991, 1992; Mossman and Churg 1998; Mossman et al. 1987; Park and Aust 1998; Quinlan et al. 1994; Shatos et al. 1987; Shen et al. 1995; Weinberg 1989; Weitzman and Graceffa 1984; Xu et al. 1999; Azad et al. 2008; Bhattacharya et al. 2005; Daghino et al. 2006; Fantauzzi et al. 2010; Fattman et al. 2006; Gazzano et al. 2007; Ghio et al. 2004, 2009; Heintz et al. 2010; Kamp 2009; Knaapen et al. 2004; Liu et al. 2010; Nymark et al. 2008; Panduri et al. 2006; Poser et al. 2004; Quinlan et al. 2002; Shannahan et al.; Shukla et al. 2003a, b; Sørensen et al. 2007; Toyokuni 2009a, b; Upadhyay and Kamp 2003; Valavanidis et al. 2009).


Dioxins are formed typically via the thermal combustion of halogen-containing compounds, and a chief product, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD, often referred to simply as ‘dioxin’ (ChEBI 28119), notoriously produced during the 1976 Seveso chemical plant explosion and as an impurity in Agent Orange (a roughly 1:1 mixture of the plant hormone (auxin—ChEBI 22676) analogues) 2,4-dichlorophenoxyacetic acid (2,4-D; ChEBI 28854) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T; ChEBI 27903), is both a cause of chloracne and is a hepato-carcinogen. It was found that mice low in iron are resistant to this hepatotoxicity however (Poland and Knutson 1982; Sweeny et al. 1979), strongly implicating iron. In addition, iron enhances the toxicity of dioxin (Al-Turk et al. 1988; Smith et al. 1998) while iron chelators reduce it (Al-Bayati and Stohs 1987; Wahba et al. 1990). While the exact details have still not been worked out, there is little doubt that iron is important in the toxicity of a wide variety of polyhalogenated aromatics (Smith and Chernova 2009; Smith and Elder 2010), including hexachlorobenzene (ChEBI 5692) (Franklin et al. 2005).


Phenylhydrazine (ChEBI 27924) (like other hydrazines) is a reactive substance that is commonly used in toxicity studies. It is known (Agrawal et al. 2001; Atanasova et al. 2004; Ferrali et al. 1997a, b; Fraenkel et al. 2009; Karbownik et al. 2000; Kim et al. 2009; Latunde-Dada et al. 2004; Rokushima et al.2007a, b; Sharma and Haldar 2009; Yamamoto and Kawanishi 1992) to induce haemolytic anaemia and iron release and thence cytotoxicity. Melatonin can be protective (Sharma and Haldar 2009).

Methyl mercury

Originally highlighted via ‘Minamata disease’ (a prominent symptom of which, as with many neurological disease, is ataxia), methylmercury (ChEBI 30785) is a well-known neurotoxicant (Clarkson et al. 2003). Like most if not all other xenobiotics (Dobson et al. 2009a; Dobson and Kell 2008; Dobson et al. 2009b; Kell and Dobson 2009), it requires one or more carriers for cellular uptake—in this case, when complexed to L-cysteine, the ‘large amino acid’ transporter (Kanai and Endou 2003; Simmons-Willis et al. 2002; Yin et al. 2008). There is certainly evidence that exposure to this agent causes oxidative stress (Ali et al. 1992; Aschner et al. 2007; Atchison and Hare 1994; Franco et al. 2009; Johansson et al. 2007; Sanfeliu et al. 2003; Sarafian et al. 1994; Yee and Choi 1994, 1996; Yin et al. 2007) and raises cellular iron levels (Ilbäck et al. 2000) and that anti-oxidants (Daré et al. 2000; Kaur et al. 2006; Sarafian and Verity 1991; Shanker and Aschner 2003; Usuki et al. 2001; Watanabe et al. 2009; Yamashita et al. 2004; Zurich and Monnet-Tschudi 2009), metallothioneins (West et al. 2008) and/or iron chelators (Castoldi et al. 2001; LeBel et al. 1992; Sarafian and Verity 1991; Stohs and Bagchi 1995) can be protective. Taken together, this does imply strongly a role for iron-mediated cytotoxicity of the type highlighted herein in the pathogenesis of methylmercury poisoning.


Paraquat (N,N′-dimethyl-4,4′-bipyridinium dichloride; ChEBI 34905) is a well-known herbicide and toxicant, whose mode of action relies on the generation of superoxide radicals. As such, its toxicity may be expected to be exacerbated by iron, and this is the case (Andersen 2003; Ayaki et al. 2005; Fernandez et al. 2000; Peng et al. 2007, 2009). In addition, again as expected from the above (and consistent with its structural similarity to the Parkinson-inducing agent MPTP-1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, ChEBI 17963), it can induce Parkinson-like symptoms (Kaur et al. 2009; Miller et al. 2009; Ossowska et al. 2006; Peng et al. 2007, 2009). The protection by molecules—such as ferritin (Kaur et al. 2009) and polyphenols (Jimenez-Del-Rio et al. 2010)—capable of chelating iron harmlessly is thus of considerable interest.

Other toxicants in which iron release has been implicated as part of the mechanisms of their toxicity

The list of known and potential toxicants is limitless, and part of the role of this review is to alert domain experts to the likelihood that iron, and dysregulation in iron metabolism, may mediate the toxicity of such molecules (and thus that its chelation may be important, under both acute and chronic conditions, in assisting resolution of the toxicity). To this end, I note the role of iron-induced oxidative stress in the toxicity of anthracyclines (including adriamycin/doxorubicin ChEBI 28748) (Ceyssens et al. 2004; Kaiserová et al. 2007; Kotamraju et al. 2002, 2004; Luft 2006; Othman et al. 2008; Šimůnek et al. 2009; Thougaard et al. 2010; Xu et al. 2008), arsenic (De Vizcaya-Ruiz et al. 2009; Fujihara et al. 2009), beer brewed in cast iron pots (Kew and Asare 2007), bleomycin (ChEBI 3139) (Wu et al. 2004; Yang et al. 2010), C60 fullerenes (Usenko et al. 2008), carbon nanotubes (Murray et al. 2009) (and see Guo et al. 2007; Jurkschat et al. 2007), carbon tetrachloride (Mansour 2000; Ogeturk et al. 2004), organophosphates (Goel et al. 2006), sulphur mustard agents (Korkmaz et al. 2008; Korkmaz et al. 2006; Naghii 2002) and talc nanoparticles (Akhtar et al. 2010). Welding fumes are toxic and contain both iron and manganese (Flynn and Susi 2010; Sriram et al. 2010), and the toxicity of nano-iron itself has also been studied (Li et al. 2009).

Apoptosis or necrosis?

As is well known, cells can die by both necrosis and by a more regulated form, apoptosis. While this—nor ‘normal’ ageing (summarised e.g. by Bishop et al. 2010b; Finkel 2005; Franco et al. 2007; Gems 2009; Kenyon 2010; Kirkwood 2008; Muller et al. 2007; Vaupel 2010), in which various degradative processes including iron dysregulation can be implicated (e.g. Brewer 2010; Cass et al. 2007; Cook and Yu 1998; Facchini 2002; Galaris et al. 2008; Kell 2009a; Kujoth et al. 2005; Kurz et al. 2008b; Massie et al. 1983; Napoli et al. 2006; Pfefferbaum et al. 2009; Terman et al. 2010; Xu et al. 2010)—is not the focus of this review, it is reasonable to enquire as to what kind of evidence exists for the mechanism(s) of cell death contingent upon iron dysregulation. As it turns out, while there is a little evidence that iron overload can cause necrosis (Babatasi et al. 1996; Traoré and Meyer 2007; Vanden Berghe et al. 2009; Vanlangenakker et al. 2008), there is abundant evidence for the ability of iron to cause apoptosis (Kotamraju et al. 2004a, b; Kurz et al. 2007, 2008b; Vanden Berghe et al. 2009), and—depending presumably on the exact liganding of the iron (Kell 2009a)—this can be effected when iron is ostensibly depleted (e.g. Bergman et al. 2005; Bidle and Bender 2008; Brard et al. 2006; Buss et al. 2003; Fukuchi et al. 1994; Greene et al. 2002; Haq et al. 1995; Hileti et al. 1995; Jiang et al. 2002; Jin et al. 2007; Koc et al. 2006; Kovář et al. 1997, 2001; Leardi et al. 1998; Lee et al. 2006b, c; Pan et al. 2004; Simonart et al. 2000; Sun et al. 2009; Truksa et al. 2003; Zhang et al. 2003; Zhao et al. 2004) or in excess (e.g. Aljandali et al. 2001; Cozzi et al. 2003, 2010; Devireddy et al. 2005; Franke et al. 2010; Jacob et al. 1997, 2000; Javadi et al. 2004; Jímenez Del Río and Vélez-Pardo 2004; Kamp et al. 2002; Kawabata et al. 1997; Kermer et al. 2004; Kooncumchoo et al. 2006; Kruman et al. 1997; Kummer et al. 2008; Kurz et al. 2007, 2008b; Lakshmi Devi and Anuradha 2009; Lee et al. 2006d; Levenson 2005; Lu et al. 2008; Ma et al. 2009; Messer et al. 2009; Murakami et al. 2006; Natoli et al. 2009; Persson 2005; Polla et al. 2003; Schlawe et al. 2004; Shin and Kim 2009; Shukla et al. 2003; Tenopoulou et al. 2005; Upadhyay and Kamp 2003; Vélez-Pardo et al. 1997; Zhao et al. 1997).

Inflammation and NF-κB

As reviewed in the previous survey (Kell 2009a) and elsewhere (e.g. Shoelson and Goldfine 2009; Shoelson et al. 2007), inflammation lies at the heart of many of these processes, and pathways involving NF-κB (see e.g. are especially core here (e.g. Ali and Mann 2004; Circu and Aw 2010; Granic et al. 2009; Karin 2008; Karin and Greten 2005; Li et al. 2005; Maeda and Omata 2008; Simmonds and Foxwell 2008; Zhang and Rigas 2006). Of particular relevance in ROS/iron metabolism are the facts that NF-κB is redox-sensitive (e.g. Aggarwal and Sung 2009; Baeuerle and Henkel 1994; Chandrasekaran and Taylor 2008; Cho et al. 1998; Dröge 2002; Fulda et al. 2010; Galaris et al. 2008; Gloire et al. 2006; Gloire and Piette 2009; Ha et al. 2010; Haddad et al. 2000; Hayashi et al. 1993; Janssen-Heininger et al. 2008; Lagan et al. 2008; Lukosz et al. 2010; Nishi et al. 2002; Phillips et al. 2010; Schreck et al. 1991, 1992; Schreck and Baeuerle 1994; Sen and Packer 1996; She et al. 2002; Surh et al. 2005; Surh and Na 2008; Thannickal and Fanburg 2000; Trachootham et al. 2008, 2009; Valko et al. 2007; Weinberg and Chandel 2009; Wondrak 2009; Xiong et al. 2003) and that there are links between NF-κB and NGAL/lcn2 (Bu et al. 2006; Cowland et al. 2003, 2006, 2008; Karlsen et al. 2010) and/or hepcidin (Sow et al. 2009; Tacchini et al. 2008). Specificity is likely to come, in part, via the frequency encoding of NF-κB activity (Ashall et al. 2009; Nelson et al. 2004).

Catalytic behaviour of polypeptides and proteins

I have mentioned several times the idea that different proteins can bind unliganded iron to catalyse the production of hydroxyl radical, and it is certainly the case that the degree of liganding can affect these kinds of activities (Kell 2009a). Here it is appropriate to highlight the abilities of polypeptides and even poly(aminoacids)—whether binding metals (or not)—to exhibit catalytic activities, e.g. poly(leucine) (Carrea et al. 2005; Porter et al. 1999), and how adding metals to polypeptides to make metalloenzymes can have huge effects on their catalytic activities (Pierron et al. 2008; Pordea and Ward 2008; Turner 2009). The recent development of orthogonal ribosomes capable of incorporating novel amino acids into polypeptides (Neumann et al. 2010) opens up considerable possibilities here.

Dietary and/or pharmacological treatment of iron-mediated toxicity


Developing novel pharmaceutical agents is a costly enterprise, and many candidate drugs fall by the wayside during the development process (see e.g. Dobson et al. 2009b; Kola and Landis 2004; Leeson and Springthorpe 2007). As most recently reviewed (Agarwal 2010; Berdoukas et al. 2009; Bolognin et al. 2009a; Cappellini and Pattoneri 2009; Cappellini et al. 2010; Clifton et al. 2009; Hider et al. 2008; Kell 2009a; Kontoghiorghes et al. 2010; Kwiatkowski 2010; Mladĕnka et al. 2009; Pennell et al. 2010; Perez and Franz 2010; Richardson et al. 2009b and references therein), a number of (pharmacological drug) approved iron chelators do exist and thus clearly have the potential to prove beneficial in treating diseases and the sequelae of toxin exposure whose aetiology involves poorly liganded iron via the Fenton reaction. The benefits of administration of desferrioxamine in Alzheimer’s, for instance, have been known for nearly 20 years (Crapper McLachlan et al. 1991), benefits since observed with other iron chelators (e.g. Amit et al. 2008; Bolognin et al. 2009a; Bush 2008; Liu et al. 2009b, 2010b; Perez and Franz 2010; Smith et al. 2010; Zhang et al. 2009). The implications for this and other neurodegenerative diseases—and potentially for the more acute and even chronic effects of other toxins—are obvious. Those approved clinically include Deferoxamine (Desferal; ChEBI 31460), Deferiprone (Ferriprox; PubChem CID 2972) and Deferasirox (Exjade; ChEBI 49005) (Fig. 11). Note that—unlike the other two—Deferoxamine is not orally active and must be injected, and even then may fail to cross cellular membranes to exert its action appropriately (Warkentin et al. 2010).

Dietary or nutritional/nutraceutical

In addition, many organisms make so-called ‘secondary’ or natural products, whose functions are often unclear but that clearly have evolutionary benefits for the host (Hadacek et al. 2010; Kell et al. 1995). As I also reviewed (Kell 2009a), many iron-chelating natural products exist in (or may be added to, Pócsi et al. 2008) foodstuffs for which no full pharmaceutical regulatory controls are required and which are classed as nutritional substances. Many are polyphenols (ChEBI 26195) (Amic et al. 2007; Arts and Hollman 2005; Auclair et al. 2009; Cemeli et al. 2009; Cheynier 2005; Geronikaki and Gavalas 2006; Halliwell 2007; Jovanovic and Simic 2000; Kandaswami and Middleton 1994; Kiokias et al. 2008; Korkina and Afanas’ev 1997; Linseisen and Rohrmann 2008; Loke et al. 2009; Manach et al. 2004, 2005a, b; Pérez-Jiménez et al. 2010; Perron and Brumaghim 2009; Perron et al. 2008; Petti and Scully 2009; Pietta 2000; Rice-Evans and Packer 2003; Scalbert et al. 2005; Scalbert and Williamson 2000; Seifried et al. 2007; Slemmer et al. 2008; Spencer et al. 2008; Yadav and Bhatnagar 2007a, b, 2010), including the anthocyanins that proved chemoprotective (Butelli et al. 2008) in a mouse p53 cancer model. Since the previous review (Kell 2009a), I would draw particular attention to a comprehensive overview of the subject (Perron and Brumaghim 2009), as well as new reviews and papers on the chief polyphenol in green tea, (−)epigallocatechin-3-gallate (ChEBI 4806) (Adhami et al. 2009; Butt and Sultan 2009; Hsieh et al. 2009; Jimenez-Del-Rio et al. 2010; Johnson et al. 2010; Pandey and Gupta 2009; Paterniti et al. 2009; Ramesh et al. 2009; Reznichenko et al. 2010; Suh et al. 2009; Weinreb et al. 2009a), on curcumin (ChEBI 3962) (a constituent of turmeric) (Aggarwal and Harikumar 2009; Aggarwal and Sung 2009; Anand et al. 2010; Basile et al. 2009; Epstein et al. 2009; Hegde et al. 2009; Iqbal et al. 2009; Jiao et al. 2009; Jurenka 2009; Kalpravidh et al. 2010; Majumdar et al. 2009; Messner et al. 2009; Patil et al. 2009; Ravindran et al. 2009; Rivera-Espinoza and Muriel 2009; Thephinlap et al. 2009; Thomas et al. 2009; Tuntipopipat et al. 2009; Wang et al. 2009a), on eugenol (ChEBI 4917) (Nagababu et al. 2010) (and cf. Allen and Cornforth 2009), on nepetoidin caffeic acid esters (Maioli et al. 2010), on quercetin (ChEBI 16243) (Chobot 2010; Kitagawa et al. 2009; Krukoski et al. 2009; Lorrain et al. 2010; Park et al. 2010; Pavlica and Gebhardt 2010; Smirnova et al. 2009; Terao 2009; Vlachodimitropoulou et al. 2010) and on melatonin (CHEBI 16796) (Borah and Mohanakumar 2009; Korkmaz et al. 2008, 2009; Reiter et al. 2009; Sener et al. 2009; Sharma and Haldar 2009; Signorini et al. 2009). Many of the protective effects observed are likely due to the iron chelating, as well as directly antioxidative (redox) properties of these molecules (e.g. Ferrali et al. 1997a; Hague et al. 2006; Halliwell 2009; Halliwell et al. 2005; Hider et al. 2001; Končić et al. 2010; Lopes et al. 1999; Mandel et al. 2004; Mandel and Youdim 2004; Morel et al. 1994; Nijveldt et al. 2001; Rice-Evans et al. 1997; Rice-Evans and Packer 2003; Weinreb et al. 2007, 2009a; Yoshino and Murakami 1998). Other molecules that are not themselves directly antioxidant, but have iron-binding characteristics, may also be of benefit. This is certainly true of phytic acid (phytate; myo-inositol-1,2,3,4,5,6-hexakis phosphate; CHEBI 17401) (Aljandali et al. 2001; Allen and Cornforth 2009; Brune et al. 1989; Davidsson et al. 1994; Doria et al. 2009; Glahn et al. 2002; Graf and Eaton 1990, 1993; Graf et al. 1987; Grases et al. 2001; Hallberg et al. 1989; Han et al. 1994; Hanson et al. 2006; Hawkins et al. 1993; Kamp et al. 1995a, b, 2002; Kim et al. 2008; Kumar et al. 2010; Minihane and Rimbach 2002; Miyamoto et al. 2000; Panduri et al. 2006; Poser et al. 2004; Rao et al. 1991; Rimbach et al. 2008; Sandberg et al. 1999; Schlemmer et al. 2009; Shamsuddin 1995; Vucenik and Shamsuddin 2006; Xu et al. 2008).


In addition, as follows implicitly from Sullivan’s ‘iron hypothesis’ (Sullivan 1981, 2001, 2003, 2004) (and see Kell 2009a), one way to decrease the amount of iron in the body is to remove it by blood-letting or phlebotomy. While phlebotomy is a very traditional nostrum, often assumed or considered to have rather dubious or at best modest scientific support, there is in fact increasing literature implying its benefits in a variety of conditions (e.g. Aigner et al. 2008; Beutler 2007; Broedbaek et al. 2009; Brudevold et al. 2008; Busca et al. 2010; DePalma et al. 2007, 2010; Dereure et al. 2008; Desai et al. 2008; Dwyer et al. 2009; Equitani et al. 2008; Facchini et al. 2002; Fargion et al. 2002; Fernández-Real et al. 2002; Fujita et al. 2009; Fujita and Takei 2007; Hayashi et al. 2006; Hayashi and Yano 2002; Heathcote 2004; Horwitz and Rosenthal 1999; Hua et al. 2001; Kaito 2007; Kaito et al. 2006; Kato et al. 2001, 2007; Kom et al. 2006; Rajpathak et al. 2009; Sullivan 2009; Sumida et al. 2009; Tanaka et al. 2007, 2009; Toyokuni 2009b; Zacharski et al. 2008). Plausibly such benefits are due to its role in decreasing iron stores.

Discussion: toxicology as systems biology

“When sorrows come, they come not single spies but in battalions.” (Shakespeare, Hamlet.)

It is certainly the case that reasons for the co-occurrence of two or more observables are that one causes the other or they have the same, separate cause. Since I have argued strongly here for the essentiality of iron dysregulation in a variety of syndromes (and have omitted many others, such as non-alcoholic (Baptista-Gonzalez et al. 2008; Kirsch et al. 2006; Kowdley 2010) or alcoholic liver disease (Breitkopf et al. 2009; Lecube et al. 2009)), and indeed cancers of various kinds (see Kell 2009a), the implication is that iron dysregulation can manifest in multiple different ways and that these might co-occur. There is considerable and increasing evidence for that (see e.g. Adibhatla and Hatcher 2010; Baker et al. 2009; Beeri et al. 2008; Cole et al. 2007; Franco et al. 2009; Janson et al. 2004; Kell 2009a; Li and Hölscher 2007; Mascitelli et al. 2009; Neumann et al. 2008; Pandolfo 2009; Roriz-Filho et al. 2009; Schnaider Beeri et al. 2004; Starley et al. 2010; Utzschneider and Kowdley 2010; Verduzco and Nathan 2009; Xu et al. 2009), with the exact outcomes being determined by different levels of expression (see for instance of different proteins in different tissues.

In a similar vein, it is not news (Attwood et al. 2009; Evans 2008; Hull et al. 2008; Kostoff 2002) that the large floods of literature have led to something of a ‘balkanisation’ of the literature into increasingly specialised segments, and that this makes it hard to seek to bring together such disparate parts of the literature so as to draw out general truths (Dobson and Kell 2008; Kell 2009a), via the methods of inductive reasoning (Kell and Oliver 2004; King et al. 2004, 2009). As previously discussed, it is well established on theoretical grounds alone that the activity of any step in a biochemical network can influence the concentration of any variable (such as—fleetingly—the amount of hydroxyl radicals produced). Thus, while it is better to derive quantitative models (e.g. Coveney and Fowler 2005; Csikasz-Nágy 2009; Kell 2006a, b; Kell and Knowles 2006; Kell and Westerhoff 1986a, b; Milo et al. 2010; Mogilner et al. 2006; Noble 2002, 2006, 2010; Oates et al. 2009; Phillips and Milo 2009; Tomlin and Axelrod 2007), at the very minimum one should be looking qualitatively at those factors that should be increased or decreased in order to improve the organism’s ability to resist oxidative stress (Fig. 12).

Indeed, it is the very act of doing this that leads one to recognise these kinds of complex problems as problems of systems or network biology (Alon 2006; Klipp et al. 2005; Palsson 2006). What do I mean by this?

A systems biology view of toxicology: toxicology as systems biology

In the present case, I have adduced evidence that a range of distinct aetologies, which manifest as a variety of different syndromes or diseases, converge at some point on an autocatalytic series of reactions, involving imperfectly liganded iron, in the production of the very damaging hydroxyl radical, that by causing the destruction of appropriate cellular structures and proteins liberates further ‘free’ iron and other reactive oxygen species, thereby effecting positive feedback (also known as ‘vicious cycles’, Lin and Beal 2006; Proctor and Gray 2010; Proctor et al. 2007) that leads to the production of yet further damage. The implication of this is that to be more specific we need suitable network models of the biological systems of interest (Kell 2007), and of how toxicants of any kind can interact with their components.

Of course in the steady state, the amount of a substance is governed both by the processes that create it and those that decompose it (Fig. 13), and individual effects of particular substances can vary qualitatively depending on concentrations, as in hormesis (e.g. Calabrese 2008a, b, c; Calabrese and Baldwin 1997, 2001, 2003; Calabrese and Blain 2005, 2009; Cook and Calabrese 2006; Cox 2009; Gems and Partridge 2008; Gómez-Pinilla 2008; Hadacek et al. 2010; Hayes 2009; Hoffmann 2009; Mattson 2008a, b; Radak et al. 2008; Rattan 2004, 2008; Rattan and Demirovic 2009; Ristow and Zarse 2010; Sørensen et al. 2009), so any analysis should be a systems analysis. The simple fact that, for instance, iron chelators improve prospects in Alzheimer’s implies that there is a background level of natural repair (otherwise chelators would only slow the neurodegeneration and not reverse it) and that is not necessarily apparent from measuring only net effects. Hence, the need for accurate systems biology models.

The very fact that multiple reactions typically lead to the creation (and destruction) of a given metabolite (such as the hydroxyl radical) means that to minimise its concentration it is best to modify many reactions simultaneously. This exceptionally important point from systems biology should underpin any scientific and therapeutic programs.

Systems biology methods

Systems biology methods are typically classified into ‘forward’ and inverse’ (Fig. 14). For the purposes of this discussion, I shall concentrate on metabolic networks (in contrast to signalling networks they transfer both matter and information, Kell 2004). Metabolic and other networks are ‘graphs’ in that they consist of entities (‘nodes’, such as metabolites) that interact with each other via ‘edges’ (enzymatic reactions). There may of course be other interactions such those that do not involve substrates or products but are mediated via molecules (effectors) that modify the rates of reactions. The distinction between forward and inverse models is based on whether one starts with the parameters or variables of the system. In metabolic networks, the parameters are typically the starting concentrations of substances present and the kinetic constants (K m, K i, V max, etc.) of the enzymes. The variables are typically the concentrations of metabolic intermediates, and the metabolic fluxes that change over time until a steady state (if such exists) is attained. It is important to note that only the parameters control the system. In forward systems biology, we thus seek to create a model of the network based on its parameters, and this is done in four phases, the first two of which are qualitative and the second quantitative (Herrgård et al. 2008; Kell and Knowles 2006; Thiele and Palsson 2010).

Forward modelling

The first qualitative stage is one in which are listed all the reactions that are known to occur in the system or organism of interest; in the modern era, and especially for metabolic networks, these reaction lists are often derived in part from genomic annotations (Arakawa et al. 2006; Palsson 2006) with curation based on literature (‘bibliomic’) data (Duarte et al. 2007; Thiele and Palsson 2010). A second stage, again qualitative, adds known effectors (e.g. those involved in forming feedback loops), while the third and fourth stages—essentially amounting to molecular enzymology—include the known kinetic rate equations and the values of their parameters. Armed with such information, it is then possible to provide stochastic and ordinary differential equation models of the entire metabolic network of interest. In some cases, it is possible to make simplifying assumptions that require minimal knowledge of the kinetic parameters of the system and allow one to generate a time series of the system variables (Smallbone et al. 2007). An attractive feature of metabolism, for the purposes of modelling, is that, in contrast to signalling pathways, metabolism is subject to direct thermodynamic and (in particular) stoichiometric constraints (Palsson 2006). These constraints are extremely important in reducing the search space for the values of the kinetic parameters of the model, and indeed constrain significantly the states that the system can adopt (Kell 2004; Palsson 2006).

The modelling community has access to many tools, which are interoperable because they can be exchanged using community standards (Kell 2008) of which the most popular (Klipp et al. 2007) is SBML, the Systems Biology Markup Language (Hucka et al. 2003) ( Models are best made, and made available, in SBML. In addition, there is recognition that it is desirable to be clear about the meaning (semantics) of the elements in the model (Ananiadou et al. 2006; Attwood et al. 2009; Kell and Mendes 2008), since SBML puts no constraints on the names given to entities, and we have pioneered (Herrgård et al. 2008; Pettifer et al. 2009) the use of semantic annotation of all the entities, whether by reference to persistent databases or via database-independent means (e.g. the use of SMILES (Weininger 1988) and InChI (Coles et al. 2005; Stein et al. 2003) strings for small molecules). This is consistent with the MIRIAM proposals for describing the contents of a model accurately (Le Novère et al. 2005), and we have also used (Herrgård et al. 2008) the Systems Biology Ontology ( and the Gene Ontology ( as especially pertinent and useful ontologies. Tools also exist for creating such networks using CellDesigner ( and SBMLMerge (Schulz et al. 2006) for merging submodels, including visualising them (via the Systems Biology Graphical Notation (Le Novère et al. 2009) ( e.g. via Arcadia (Villéger et al. 2010) ( Armed with such networks, it is possible to analyse their dynamics and other properties using tools/ modelling environments such as COPASI (Hoops et al. 2006) ( and to compare model and experimental data, conveniently stored using SBRML (Dada et al. 2010). Models and attendant metadata are best stored directly in databases, such as that set down in the B-Net database model (see Li et al. 2003; Mehrotra et al. 2010) as used in our yeast model (Herrgård et al. 2008) (

Interrogating the model

Sensitivity analysis

Armed with a model, there are a number of important studies that are usefully performed. The first is the study of the contribution of individual steps to the control of the variables of interest. This is the domain of local and global sensitivity analysis (Saltelli et al. 2004, 2008), to which we have made significant contributions (e.g. Lüdtke et al. 2008; Sahle et al. 2008; Yue et al. 2006, 2007, 2008). Sensitivity analysis studies the quantitative contribution of individual steps to the overall control of a process. The ‘local’ version has been popularised in biochemistry as ‘metabolic control analysis’ (e.g. Fell 1996; Heinrich and Schuster 1996; Kell and Westerhoff 1986a), and, for instance COPASI (Hoops et al. 2006) calculates the control or sensitivity coefficients directly from a model. The results of these kinds of analyses are represented by a rank order of the most important reactions or parameters, which provides an important starting point for the combinatorial analysis of these complex networks. Formalisms such as Metabolic Control Analysis also explain why the modulation of individual steps singly rarely has much of an effect on an overall pathway (see e.g. Pérez et al. 2009a, b), reviewed by Gems (Gems and Doonan 2009), for a typical example.

Combinatorial analysis of parameter sensitivity

As indicated above, it is commonly the case in complex biochemical networks that while changes in individual parameters have little effect on the behaviour of biochemical pathways—indeed evolution is thought to have selected for robustness to individual parameter changes (Bornholdt and Sneppen 2000; Kitano 2007; Lehár et al. 2008; Morohashi et al. 2002; Stelling et al. 2004; Wagner 2005)—combinations of parameter changes can and do have major effects. A straightforward corollary of this is that in order to cause or inhibit the progression of diseases—including inflammatory diseases such as asthma (Biswas and Rahman 2009; Bowler 2004; Bowler and Crapo 2002; Boyer and Liu 2004; Chodaczek et al. 2007; Ciencewicki et al. 2008; Comhair and Erzurum 2010; Galli et al. 2008; Greene 1995; Han et al. 2001; Horváth et al. 1998; Jarvis et al. 2005; Kocyigit et al. 2004; Muñoz et al. 2009; Narula et al. 2007; Nemery 1990; Pae et al. 2008; Riedl and Nel 2008; Shore 2008; Vlašić et al. 2009)—it is necessary to affect multiple steps simultaneously. The problem is to find which ones, and that is a combinatorial problem that scales poorly. It is exactly here where the ability to interrogate a suitable model of the pathway comes to the fore, since computations to determine which combinations of parameters to affect can be done enormously more rapidly than can ‘wet’ experiments. To be explicit, if manipulating (let us say knocking out) just three genes out of 1,000 is necessary to secure a desired effect (as is often the case) and the question is to choose which three, the answer involves recognizing that this is a combinatorial optimization problem involving ca 100 million combinations—a trivial number computationally given a model and an easy number (i.e. 3) to work with post hoc, but an implausible number to interrogate with present experimental methods. See (Park et al. 2007, 2008) for a nice example of the approach.

At all events, the results of running a systems biology model in the forward direction are the time-varying concentrations of variables that result from the network topology and parameters of the system, and these can then be compared with measured variables to see how accurate the model is.

Of course it is typically the case (i) that the variables predicted by the model differ from those that one has measured, and (ii) one has only measurements of the variables and not the parameters anyway. Since it is the parameters that determine the system behaviour, it is then necessary to try and estimate or infer the parameters of the systems from measurements of the variables, the domain of inverse modelling (Liu and Wang 2008; Mendes and Kell 1996) or system identification (Bongard and Lipson 2005; Ljung 1987).

Inverse modelling

Finding the sets of parameters that can reflect a set (or sets) of variables is a much harder problem. If there are just 20 parameters, each of which can take just 10 values, there are at once 1020 combinations, although there may be multiple combinations that give a reasonable solution (the problem or system is then said to be under-determined). At all events, finding these combinations requires methods that can effectively search these combinatorial search spaces to find good solutions (they are not provably optimal solutions as these kinds of problems are NP-hard, Garey and Johnson 1979).

There are many kinds of approaches to attacking these kinds of combinatorial optimisation problems, and I give two examples. The first uses evolutionary methods to modify the search for these parameters, while the second is Bayesian in character.

Evolutionary computing methods (e.g. Bäck et al. 1997; Goldberg 1989, 2002) use ideas from Darwinian evolution to select and modify parameters to achieve a desired objective (or objectives—this is known as multi-objective optimisation, Handl et al. 2007). In an evolutionary algorithm, one selects a population of models encoding a different candidate set of parameters, assesses their performance, rejects those that perform poorly and modifies the parameters of the better-performing models using methods akin to recombination and mutation to create a second generation population and so on. Finally, one finds a candidate set of solutions that perform well and can indeed interrogate these solutions to determine the parameters that differ most frequently in the selected solutions from those in the starting pathway. These kinds of methods are recognised as highly effective (Banga 2008; Banga and Balsa-Canto 2008), and they have proved so for both modelling (Dada and Mendes 2009; Mendes and Kell 1998; Moles et al. 2003; Rodriguez-Fernandez et al. 2006) and other optimisation problems (e.g. Broadhurst et al. 1997; Kell et al. 2001; Knight et al. 2009; O’Hagan et al. 2005, 2007; Platt et al. 2009; Rowe et al. 2010). A related and novel approach that we have developed (Wilkinson et al. 2008) (and see Brown et al. 2010) also evolves estimates of parameters, but in a somewhat different way. Evolutionary computing methods are amenable to (‘coarse-grained’) parallelisation that allows them to run on many (hundreds or even thousands of) processors simultaneously, and we have used this approach with great effectiveness (Wedge and Kell 2008; Wedge et al. 2009). Overall, the result of this kind of approach is the effective determination of the multiple parameters that are required to explain the system variables.

A conceptually quite different approach, which may of course be expected to lead to the same result (and which in consequence strengthens further any conclusions from e.g. an evolutionary computing approach), is an approach based on Bayesian inference (Jayawardhana et al. 2008; Liebermeister and Klipp 2006; Vyshemirsky and Girolami 2008) and known as Markov Chain Monte Carlo or MCMC. In this approach (which we do not rehearse in detail as those details have recently been published by us, Jayawardhana et al. 2008), we have knowledge of the variables of interest and sample candidate models that can explain those variables using various estimates of their parameters from a distribution. The MCMC algorithm then slowly builds up the likeliest values of the parameters and their possible distribution given the demonstrable uncertainty.

Detecting the modes or sites of action of a toxin

Clearly, if we have measurements of the variables of a system before and after the addition of a toxin, we can estimate the parameters in the two cases and see which have most plausibly changed by applying these inferencing methods to the two cases. This automatically gives the mode(s) or site(s) of action of the intervention, whether of a toxic inhibitor or by any other means. In other words these methods can detect the modes or sites of action of anything that causes a system to change its state. Taking the Bayesian approach (see also e.g. Nidhi et al. 2006; O’Hagan 2006; Vyshemirsky and Girolami 2008; Wilkinson 2007), in the work described above (Jayawardhana et al. 2008) we ‘calibrated’ our approach using purely simulated data in which we knew exactly which parameters had been changed (and in which direction) and showed that we could detect this accurately. We then applied our approach to an experimental system of metabolic engineering in Lactococcus lactis (Hoefnagel et al. 2002) where the investigators had manipulated the activity of a specific enzyme to achieve a desired metabolic effect. Our approach detected both the enzyme whose activity had been modified and suggested the site of another significant pleiotropic effect (these always occur, Featherstone and Broadie 2002). Thus, the power of this general approach is that it is free of specific hypotheses and thus guides us to the hypotheses that can best explain the data. These are classic data mining methods (e.g. Breiman 2001; Kell and King 2000; Kell and Oliver 2004; Wu et al. 2008) that allow us to discover mechanisms of action that are unknown and/or have not previously been contemplated. Note, however, that such methods need careful handling from a statistical point of view (e.g. Altman and Royston 2000; Broadhurst and Kell 2006; Hastie et al. 2001; Ioannidis 2005, 2008). A variety of other network inferencing methods also exist (e.g. Lorenz et al. 2009; Managbanag et al. 2008; Stolovitzky and Califano 2006; Stolovitzky et al. 2009).

Why most toxins will have multiple sites of action

A variety of means are available for testing these mechanisms further, including the use of modulation of the expression of constituent parts of the proposed pathways by genetic means (e.g. Jones et al. 2007), and in particular the use of appropriate iron chelators and antioxidants, alone or (preferably) in combination. The combinatorial aspect is important, since there are theoretical grounds, as well as abundant evidence, to the effect that several steps in a network must be modulated simultaneously to exhibit substantial effects (see e.g. Ágoston et al. 2005; Ambesi-Impiombato and di Bernardo 2006; Bender et al. 2006; Borisy et al. 2003; Csermely et al. 2005; Dancey and Chen 2006; Fan et al. 2003, 2006; Haggarty et al. 2003; Hopkins et al. 2006; Kaelin 2005; Keith et al. 2005; Kostoff and Delafuente 2006; Millan 2006; Perlstein et al. 2006; Sharom et al. 2004; Shiomi et al. 1999; Wermuth 2004) (Brötz-Oesterhelt and Brunner 2008; Chong and Sullivan 2007; Costanzo et al. 2010; Gerber et al. 2007; Goltsov et al. 2009; Hegreness et al. 2008; Huang et al. 2008b; Jia et al. 2009; Koufaki et al. 2009; Kuhn et al. 2010; Lee et al. 2007; Lehár et al. 2007, 2008a, b; Li et al. 2007; Liby et al. 2007; Morphy and Rankovic 2007; Pachauri et al. 2009; Reznichenko et al. 2010; Sarkar and Li 2009; Sarkar et al. 2009; Sawyers 2007; Schrattenholz and Šoškić 2008; Silver et al. 2009; Silver 2007; Sporn et al. 2007; Stommel et al. 2007; Suchy et al. 2009; Ulrich-Merzenich et al. 2009; Watterson et al. 2008; Weinreb et al. 2009b; Whitehurst et al. 2007; Wong et al. 2008; Yeh et al. 2006, 2009; Ying et al. 2008; Zamin et al. 2009; Zhang 2006; Zhang et al. 2010; Zimmermann et al. 2007). The same holds true for biotechnology (Kell and Westerhoff 1986a), in which typically we seek to maximise fluxes (Park et al. 2007, 2008). Of course some molecules—both nutrients/ natural products and pharmaceutical agents—can act as both antioxidants and iron chelators; these are likely to be especially useful in minimising the damage from toxicants of many kinds.

Concluding remarks

Science consists of both analysis and synthesis, and thus a substantial amount of Science involves finding regularities (‘Laws’) that can be extracted from observables, even when some of those observables or their presumed causes seem to have little in common (Kell and Oliver 2004; Oldroyd 1986; Westerhoff and Kell 2007). Thus, there are many kinds of toxins that can cause death or injury, but it is not necessarily obvious what they share in terms of their modes of action. What I have therefore sought to do here is to bring together the evidence for the autocatalytic involvement of poorly liganded iron (leading, inter alia, to hydroxyl radical formation) in a considerable number of these. Certainly the exact molecular mechanisms, cascades and networks involved in each case depend on many other factors, and appropriate systems biology methods can tell us what they are, but I would argue that the extensive evidence for iron’s involvement that I cite here and elsewhere (Kell 2009a) is very hard to ignore. Hence, the view that iron is the nexus.



I thank a great many colleagues and correspondents for their contribution to the refinement of my thinking about these issues, and Julie Cowley for assistance with literature, etc. Previous work that has led to this review has been funded by the BBSRC, EPSRC and MRC.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.


  1. Aamodt AH, Stovner LJ, Thorstensen K, Lydersen S, White LR, Aasly JO (2007) Prevalence of haemochromatosis gene mutations in Parkinson’s disease. J Neurol Neurosurg Psychiatry 78(3):315–317PubMedCrossRefGoogle Scholar
  2. Abdelrahman M, Mazzon E, Bauer M, Bauer I, Delbosc S, Cristol JP et al (2005) Inhibitors of NADPH oxidase reduce the organ injury in hemorrhagic shock. Shock 23(2):107–114PubMedCrossRefGoogle Scholar
  3. Abdelrahman M, Sharples EJ, McDonald MC, Collin M, Patel NS, Yaqoob MM et al (2004) Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22(1):63–69PubMedCrossRefGoogle Scholar
  4. Abrous DN, Koehl M, Le Moal M (2005) Adult neurogenesis: from precursors to network and physiology. Physiol Rev 85(2):523–569PubMedCrossRefGoogle Scholar
  5. Adamkiewicz TV, Abboud MR, Paley C, Olivieri N, Kirby-Allen M, Vichinsky E et al (2009) Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood 114(21):4632–4638PubMedCrossRefGoogle Scholar
  6. Adams CWM (1988) Perivascular iron deposition and other vascular damage in multiple sclerosis. J Neurol Neurosurg Psychiatry 51(2):260–265PubMedCrossRefGoogle Scholar
  7. Adams RJ (2007) Big strokes in small persons. Arch Neurol 64(11):1567–1574PubMedCrossRefGoogle Scholar
  8. Adhami VM, Siddiqui IA, Sarfaraz S, Khwaja SI, Hafeez BB, Ahmad N et al (2009) Effective prostate cancer chemopreventive intervention with green tea polyphenols in the TRAMP model depends on the stage of the disease. Clin Cancer Res 15(6):1947–1953PubMedCrossRefGoogle Scholar
  9. Adibhatla RM, Hatcher JF (2010) Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 12:125–169PubMedCrossRefGoogle Scholar
  10. Adlard PA, Bush AI (2006) Metals and Alzheimer’s disease. J Alzheimers Dis 10(2–3):145–163PubMedGoogle Scholar
  11. Agarwal MB (2010) Deferasirox: oral, once daily iron chelator–an expert opinion. Indian J Pediatr 77(2):185–191PubMedCrossRefGoogle Scholar
  12. Agarwal R, Vasavada N, Sachs NG, Chase S (2004) Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 65(6):2279–2289PubMedCrossRefGoogle Scholar
  13. Aggarwal BB, Harikumar KB (2009) Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol 41(1):40–59PubMedCrossRefGoogle Scholar
  14. Aggarwal BB, Sung B (2009) Pharmacological basis for the role of curcumin in chronic diseases: an age-old spice with modern targets. Trends Pharmacol Sci 30(2):85–94PubMedCrossRefGoogle Scholar
  15. Ágoston V, Csermely P, Pongor S (2005) Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys Rev E 71(5):051909CrossRefGoogle Scholar
  16. Agrawal R, Sharma PK, Rao GS (2001) Release of iron from ferritin by metabolites of benzene and superoxide radical generating agents. Toxicology 168(3):223–230PubMedCrossRefGoogle Scholar
  17. Aguzzi A (2006) Prion diseases of humans and farm animals: epidemiology, genetics, and pathogenesis. J Neurochem 97(6):1726–1739PubMedCrossRefGoogle Scholar
  18. Aguzzi A, Heikenwälder M (2006) Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol 4(10):765–775PubMedCrossRefGoogle Scholar
  19. Aguzzi A, Heikenwalder M, Polymenidou M (2007) Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 8(7):552–561PubMedCrossRefGoogle Scholar
  20. Aguzzi A, Baumann F, Bremer J (2008a) The prion’s elusive reason for being. Annu Rev Neurosci 31:439–477PubMedCrossRefGoogle Scholar
  21. Aguzzi A, Sigurdson C, Heikenwaelder M (2008b) Molecular mechanisms of prion pathogenesis. Annu Rev Pathol 3:11–40PubMedCrossRefGoogle Scholar
  22. Aharon-Peretz J, Rosenbaum H, Gershoni-Baruch R (2004) Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews. N Engl J Med 351(19):1972–1977PubMedCrossRefGoogle Scholar
  23. Ahluwalia N, Genoux A, Ferrieres J, Perret B, Carayol M, Drouet L et al (2010) Iron status is associated with carotid atherosclerotic plaques in middle-aged adults. J Nutr 140(4):812–816PubMedCrossRefGoogle Scholar
  24. Aigner E, Theurl I, Theurl M, Lederer D, Haufe H, Dietze O et al (2008) Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am J Clin Nutr 87(5):1374–1383PubMedGoogle Scholar
  25. Akaike T, Noguchi Y, Ijiri S, Setoguchi K, Suga M, Zheng YM et al (1996) Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc Natl Acad Sci USA 93(6):2448–2453PubMedCrossRefGoogle Scholar
  26. Akhtar MJ, Kumar S, Murthy RC, Ashquin M, Khan MI, Patil G et al. (2010) The primary role of iron-mediated lipid peroxidation in the differential cytotoxicity caused by two varieties of talc nanoparticles on A(549) cells and lipid peroxidation inhibitory effect exerted by ascorbic acid. Toxicol In VitroGoogle Scholar
  27. Al-Bayati ZA, Stohs SJ (1987) The role of iron in 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced lipid peroxidation by rat liver microsomes. Toxicol Lett 38(1–2):115–121PubMedCrossRefGoogle Scholar
  28. Al-Turk WA, Shara MA, Mohammadpour H, Stohs SJ (1988) Dietary iron and 2,3,7,8-tetrachlorodibenzo-p-dioxin induced alterations in hepatic lipid peroxidation, glutathione content and body weight. Drug Chem Toxicol 11(1):55–70PubMedCrossRefGoogle Scholar
  29. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD et al (1997) Oxidative DNA damage in the parkinsonian brain: An apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69(3):1196–1203PubMedCrossRefGoogle Scholar
  30. Alavian SM, Tabatabaei SV (2009) Therapy of hepatitis C in thalassemia: the influence of iron on achieving sustained viral response. Ann HematolGoogle Scholar
  31. Ali S, Mann DA (2004) Signal transduction via the NF-kappaB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem Funct 22(2):67–79PubMedCrossRefGoogle Scholar
  32. Ali SF, LeBel CP, Bondy SC (1992) Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 13:637–648PubMedGoogle Scholar
  33. Alissa EM, Ahmed WH, Al-Ama N, Ferns GA (2007) Relationship between indices of iron status and coronary risk factors including diabetes and the metabolic syndrome in Saudi subjects without overt coronary disease. J Trace Elem Med Biol 21(4):242–254PubMedCrossRefGoogle Scholar
  34. Aljandali A, Pollack H, Yeldandi A, Li Y, Weitzman SA, Kamp DW (2001) Asbestos causes apoptosis in alveolar epithelial cells: role of iron-induced free radicals. J Lab Clin Med 137(5):330–339PubMedCrossRefGoogle Scholar
  35. Alla V, Bonkovsky HL (2005) Iron in nonhemochromatotic liver disorders. Semin Liver Dis 25(4):461–472PubMedCrossRefGoogle Scholar
  36. Allen K, Cornforth D (2009) Effect of chelating agents and spice-derived antioxidants on myoglobin oxidation in a lipid-free model system. J Food Sci 74(5):C375–379PubMedCrossRefGoogle Scholar
  37. Alon U (2006) An introduction to systems biology: design principles of biological circuits. Chapman and Hall/CRC, LondonGoogle Scholar
  38. Altamura C, Squitti R, Pasqualetti P, Gaudino C, Palazzo P, Tibuzzi F et al (2009) Ceruloplasmin/Transferrin system is related to clinical status in acute stroke. Stroke 40(4):1282–1288PubMedCrossRefGoogle Scholar
  39. Altamura S, Muckenthaler MU (2009) Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. J Alzheimers Dis 16(4):879–895PubMedGoogle Scholar
  40. Altman DG, Royston P (2000) What do we mean by validating a prognostic model? Stat Med 19(4):453–473PubMedCrossRefGoogle Scholar
  41. Altman R (2003) Risk factors in coronary atherosclerosis athero-inflammation: the meeting point. Thromb J 1(1):4PubMedCrossRefGoogle Scholar
  42. Ambesi-Impiombato A, di Bernardo D (2006) Computational biology and drug discovery: from single-target to network drugs. Curr Bioinform 1(1):3–13CrossRefGoogle Scholar
  43. Ameli M, Besharati S, Nemati K, Zamani F (2008) Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. Saudi Med J 29(11):1611–1615PubMedGoogle Scholar
  44. Amic D, Davidovic-Amic D, Beslo D, Rastija V, Lucic B, Trinajstic N (2007) SAR and QSAR of the antioxidant activity of flavonoids. Curr Med Chem 14(7):827–845PubMedCrossRefGoogle Scholar
  45. Amit T, Avramovich-Tirosh Y, Youdim MB, Mandel S (2008) Targeting multiple Alzheimer’s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 22(5):1296–1305PubMedCrossRefGoogle Scholar
  46. Anand P, Nair HB, Sung B, Kunnumakkara AB, Yadav VR, Tekmal RR et al (2010) Design of curcumin-loaded PLGA nanoparticles formulation with enhanced cellular uptake, and increased bioactivity in vitro and superior bioavailability in vivo. Biochem Pharmacol 79(3):330–338PubMedCrossRefGoogle Scholar
  47. Ananiadou S, Kell DB, Tsujii J-i (2006) Text mining and its potential applications in systems biology. Trends Biotechnol 24:571–579PubMedCrossRefGoogle Scholar
  48. Andersen JK (2003) Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson’s disease. Neurotox Res 5(5):307–313PubMedCrossRefGoogle Scholar
  49. Andersen JK (2004) Iron dysregulation and Parkinson’s disease. J Alzheimers Dis 6(6 Suppl):S47–S52PubMedGoogle Scholar
  50. Anderson PR, Kirby K, Hilliker AJ, Phillips JP (2005) RNAi-mediated suppression of the mitochondrial iron chaperone, frataxin, in Drosophila. Hum Mol Genet 14(22):3397–3405PubMedCrossRefGoogle Scholar
  51. Anderson PR, Kirby K, Orr WC, Hilliker AJ, Phillips JP (2008) Hydrogen peroxide scavenging rescues frataxin deficiency in a Drosophila model of Friedreich’s ataxia. Proc Natl Acad Sci USA 105(2):611–616PubMedCrossRefGoogle Scholar
  52. Andrades M, Ritter C, Moreira JC, Dal-Pizzol F (2005) Oxidative parameters differences during non-lethal and lethal sepsis development. J Surg Res 125(1):68–72PubMedCrossRefGoogle Scholar
  53. Andreini C, Bertini I, Cavallaro G, Holliday GL, Thornton JM (2008) Metal ions in biological catalysis: from enzyme databases to general principles. J Biol Inorg Chem 13(8):1205–1218PubMedCrossRefGoogle Scholar
  54. Andreini C, Bertini I, Cavallaro G, Najmanovich RJ, Thornton JM (2009) Structural analysis of metal sites in proteins: non-heme iron sites as a case study. J Mol Biol 388(2):356–380PubMedCrossRefGoogle Scholar
  55. Andrews SC, Robinson AK, Rodriguez-Quinones F (2003) Bacterial iron homeostasis. FEMS Microbiol Rev 27(2–3):215–237PubMedCrossRefGoogle Scholar
  56. Arakawa K, Yamada Y, Shinoda K, Nakayama Y, Tomita M (2006) GEM System: automatic prototyping of cell-wide metabolic pathway models from genomes. BMC Bioinform 7:168CrossRefGoogle Scholar
  57. Armand P, Kim HT, Cutler CS, Ho VT, Koreth J, Alyea EP et al (2007) Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 109(10):4586–4588PubMedCrossRefGoogle Scholar
  58. Armengou A, Davalos A (2002) A review of the state of research into the role of iron in stroke. J Nutr Health Aging 6(3):207–208PubMedGoogle Scholar
  59. Armstrong RA, Lantos PL, Cairns NJ (2001) Spatial correlations between the vacuolation, prion protein deposits, and surviving neurons in the cerebral cortex in sporadic Creutzfeldt-Jakob disease. Neuropathology 21(4):266–271PubMedCrossRefGoogle Scholar
  60. Arosio P, Ingrassia R, Cavadini P (2009) Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790:589–599PubMedGoogle Scholar
  61. Arreguin S, Nelson P, Padway S, Shirazi M, Pierpont C (2009) Dopamine complexes of iron in the etiology and pathogenesis of Parkinson’s disease. J Inorg Biochem 103(1):87–93PubMedCrossRefGoogle Scholar
  62. Arts ICW, Hollman PCH (2005) Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 81(1):317S–325SPubMedGoogle Scholar
  63. Aschner M, Syversen T, Souza DO, Rocha JB, Farina M (2007) Involvement of glutamate and reactive oxygen species in methylmercury neurotoxicity. Braz J Med Biol Res 40(3):285–291PubMedCrossRefGoogle Scholar
  64. Ashall L, Horton CA, Nelson DE, Paszek P, Ryan S, Sillitoe K et al (2009) Pulsatile stimulation determines timing and specificity of NFkappa-B-dependent transcription. Science 324:242–246PubMedCrossRefGoogle Scholar
  65. Aslan M, Ryan TM, Adler B, Townes TM, Parks DA, Thompson JA et al (2001) Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci 98(26):15215–15220PubMedCrossRefGoogle Scholar
  66. Assenza G, Zappasodi F, Squitti R, Altamura C, Ventriglia M, Ercolani M et al (2009) Neuronal functionality assessed by magnetoencephalography is related to oxidative stress system in acute ischemic stroke. Neuroimage 44(4):1267–1273PubMedCrossRefGoogle Scholar
  67. Atamna H (2009) Amino acids variations in amyloid-beta peptides, mitochondrial dysfunction, and new therapies for Alzheimer’s disease. J Bioenerg Biomembr 41:457–464Google Scholar
  68. Atamna H, Frey W H 2nd, Ko N (2009) Human and rodent amyloid-beta peptides differentially bind heme: relevance to the human susceptibility to Alzheimer’s disease. Arch Biochem Biophys 487(1):59–65PubMedCrossRefGoogle Scholar
  69. Atanasova B, Mudway IS, Laftah AH, Latunde-Dada GO, McKie AT, Peters TJ et al (2004) Duodenal ascorbate levels are changed in mice with altered iron metabolism. J Nutr 134(3):501–505PubMedGoogle Scholar
  70. Atchison WD, Hare MF (1994) Mechanisms of methylmercury-induced neurotoxicity. FASEB J 8(9):622–629PubMedGoogle Scholar
  71. Atkinson A, Winge DR (2009) Metal acquisition and availability in the mitochondria. Chem Rev 109(10):4708–4721PubMedCrossRefGoogle Scholar
  72. Attwood TK, Kell DB, McDermott P, Marsh J, Pettifer SR, Thorne D (2009) Calling international rescue: knowledge lost in literature and data landslide!. Biochem J 424:317–333PubMedCrossRefGoogle Scholar
  73. Auclair S, Milenkovic D, Besson C, Chauvet S, Gueux E, Morand C et al (2009) Catechin reduces atherosclerotic lesion development in apo E-deficient mice: a transcriptomic study. Atherosclerosis 204(2):e21–e27PubMedCrossRefGoogle Scholar
  74. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng HL, Fridkin M, Youdim MBH (2007a) Therapeutic targets and potential of the novel brain- permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer’s disease. J Neurochem 100(2):490–502PubMedCrossRefGoogle Scholar
  75. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O et al (2007b) Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4(4):403–411PubMedCrossRefGoogle Scholar
  76. Ayaki H, Lee MJ, Sumino K, Nishio H (2005) Different cytoprotective effect of antioxidants and change in the iron regulatory system in rodent cells exposed to paraquat or formaldehyde. Toxicology 208(1):73–79PubMedCrossRefGoogle Scholar
  77. Ayala-Castro C, Saini A, Outten FW (2008) Fe-S cluster assembly pathways in bacteria. Microbiol Mol Biol Rev 72(1): 110–125. Table of contentsGoogle Scholar
  78. Azad N, Rojanasakul Y, Vallyathan V (2008) Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ Health B Crit Rev 11(1):1–15PubMedGoogle Scholar
  79. Ba LA, Doering M, Burkholz T, Jacob C (2009) Metal trafficking: from maintaining the metal homeostasis to future drug design. Metallomics 1(4):292–311CrossRefGoogle Scholar
  80. Babady NE, Carelle N, Wells RD, Rouault TA, Hirano M, Lynch DR et al (2007) Advancements in the pathophysiology of Friedreich’s Ataxia and new prospects for treatments. Mol Genet Metab 92(1–2):23–35PubMedCrossRefGoogle Scholar
  81. Babatasi G, Massetti M, Galateau F, Mosquet B, Khayat A, Evrard C (1996) Bronchial necrosis induced by inhalation of an iron tablet. J Thorac Cardiovasc Surg 112(5):1397–1399PubMedCrossRefGoogle Scholar
  82. Babior BM (2000) Phagocytes and oxidative stress. Am J Med 109(1):33–44PubMedCrossRefGoogle Scholar
  83. Bäck T, Fogel DB, Michalewicz Z (eds) (1997) Handbook of evolutionary computation. IOP Publishing/Oxford University Press, OxfordGoogle Scholar
  84. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141–179PubMedGoogle Scholar
  85. Bailey DM, Robach P, Thomsen JJ, Lundby C (2006) Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke? Stroke 37(10):2453PubMedCrossRefGoogle Scholar
  86. Baker ML, Wang JJ, Rogers S, Klein R, Kuller LH, Larsen EK et al (2009) Early age-related macular degeneration, cognitive function, and dementia: the cardiovascular health study. Arch Ophthalmol 127(5):667–673PubMedCrossRefGoogle Scholar
  87. Bakshi R, Benedict RH, Bermel RA, Caruthers SD, Puli SR, Tjoa CW et al (2002) T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study. Arch Neurol 59(1):62–68PubMedCrossRefGoogle Scholar
  88. Bakshi R, Dmochowski J, Shaikh ZA, Jacobs L (2001) Gray matter T2 hypointensity is related to plaques and atrophy in the brains of multiple sclerosis patients. J Neurol Sci 185(1):19–26PubMedCrossRefGoogle Scholar
  89. Bakshi R, Shaikh ZA, Janardhan V (2000) MRI T2 shortening (‘black T2’) in multiple sclerosis: frequency, location, and clinical correlation. Neuroreport 11(1):15–21PubMedCrossRefGoogle Scholar
  90. Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F et al (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7):615–625PubMedCrossRefGoogle Scholar
  91. Bal W, Kasprzak KS (2002) Induction of oxidative DNA damage by carcinogenic metals. Toxicol Lett 127(1–3):55–62PubMedCrossRefGoogle Scholar
  92. Balla G, Jacob HS, Balla J, Rosenberg M, Nath K, Apple F et al (1992) Ferritin: a cytoprotective antioxidant strategem of endothelium. J Biol Chem 267(25):18148–18153PubMedGoogle Scholar
  93. Bandyopadhyay S, Huang X, Cho H, Greig NH, Youdim MB, Rogers JT (2006) Metal specificity of an iron-responsive element in Alzheimer’s APP mRNA 5′ untranslated region, tolerance of SH-SY5Y and H4 neural cells to desferrioxamine, clioquinol, VK-28, and a piperazine chelator. J Neural Trans Suppl 71:237–247CrossRefGoogle Scholar
  94. Banga JR (2008) Optimization in computational systems biology. BMC Syst Biol 2(1):47PubMedCrossRefGoogle Scholar
  95. Banga JR, Balsa-Canto E (2008) Parameter estimation and optimal experimental design. Essays Biochem 45:195–209PubMedCrossRefGoogle Scholar
  96. Baptista-Gonzalez H, Chavez-Tapia NC, Zamora-Valdes D, Uribe M, Mendez-Sanchez N (2008) Importance of iron and iron metabolism in nonalcoholic fatty liver disease. Mini Rev Med Chem 8(2):171–174PubMedCrossRefGoogle Scholar
  97. Baranzini SE, Mudge J, van Velkinburgh JC, Khankhanian P, Khrebtukova I, Miller NA et al (2010) Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464(7293):1351–1356PubMedCrossRefGoogle Scholar
  98. Barapatre N, Morawski M, Butz T, Reinert T (2010) Trace element mapping in Parkinsonian brain by quantitative ion beam microscopy. Nucl Instrum Methods Phys Res B 268:2156–2159Google Scholar
  99. Bareggi SR, Braida D, Pollera C, Bondiolotti G, Formentin E, Puricelli M et al (2009) Effects of clioquinol on memory impairment and the neurochemical modifications induced by scrapie infection in golden hamsters. Brain Res 1280:195–200PubMedCrossRefGoogle Scholar
  100. Barichello T, Machado RA, Constantino L, Valvassori SS, Reus GZ, Martins MR et al (2007) Antioxidant treatment prevented late memory impairment in an animal model of sepsis. Crit Care Med 35(9):2186–2190PubMedCrossRefGoogle Scholar
  101. Barker JD Jr, de Carle DJ, Anuras S (1977) Chronic excessive acetaminophen use and liver damage. Ann Intern Med 87(3):299–301PubMedGoogle Scholar
  102. Barnham KJ, Cappai R, Beyreuther K, Masters CL, Hill AF (2006) Delineating common molecular mechanisms in Alzheimer’s and prion diseases. Trends Biochem Sci 31(8):465–472PubMedCrossRefGoogle Scholar
  103. Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3(3):205–214PubMedCrossRefGoogle Scholar
  104. Barry SM, Challis GL (2009) Recent advances in siderophore biosynthesis. Curr Opin Chem Biol 13(2):205–215PubMedCrossRefGoogle Scholar
  105. Bartzokis G, Lu PH, Tishler TA, Peters DG, Kosenko A, Barrall KA et al (2010) Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis 20(1):333–341PubMedGoogle Scholar
  106. Bartzokis G, Tishler TA, Lu PH, Villablanca P, Altshuler LL, Carter M et al (2007) Brain ferritin iron may influence age- and gender-related risks of neurodegeneration. Neurobiol Aging 28(3):414–423PubMedCrossRefGoogle Scholar
  107. Basak R, Chowdhury A, Fatmi L, Saha N, Mollah A, Yasmin S (2008) Stroke in the young: relationship with iron deficiency anemia and thrombocytosis. Mymensingh Med J 17(1):74–77PubMedGoogle Scholar
  108. Basile V, Ferrari E, Lazzari S, Belluti S, Pignedoli F, Imbriano C (2009) Curcumin derivatives: molecular basis of their anti-cancer activity. Biochem Pharmacol 78(10):1305–1315PubMedCrossRefGoogle Scholar
  109. Bassett ML (2007) Iron and hepatitis C: beginning to make sense. J Gastroenterol Hepatol 22(11):1703–1704PubMedCrossRefGoogle Scholar
  110. Basu S, Mohan ML, Luo X, Kundu B, Kong Q, Singh N (2007) Modulation of proteinase K-resistant prion protein in cells and infectious brain homogenate by redox iron: implications for prion replication and disease pathogenesis. Mol Biol Cell 18(9):3302–3312PubMedCrossRefGoogle Scholar
  111. Batts KP (2007) Iron overload syndromes and the liver. Mod Pathol 20(Suppl 1):S31–S39PubMedCrossRefGoogle Scholar
  112. Baudrexel S, Nurnberger L, Rub U, Seifried C, Klein JC, Deller T et al. (2010) Quantitative mapping of T1 and T2* discloses nigral and brainstem pathology in early Parkinson’s disease. NeuroimageGoogle Scholar
  113. Baue AE, Durham R, Faist E (1998) Systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), multiple organ failure (MOF): are we winning the battle? Shock 10(2):79–89PubMedCrossRefGoogle Scholar
  114. Bauer PO, Nukina N (2009) The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J Neurochem 110(6):1737–1765PubMedCrossRefGoogle Scholar
  115. Baune BT, Neuhauser H, Ellert U, Berger K (2010) The role of the inflammatory markers ferritin, transferrin and fibrinogen in the relationship between major depression and cardiovascular disorders—the German health interview and examination survey. Acta Psychiatr Scand 121(2):135–142PubMedCrossRefGoogle Scholar
  116. Beal AL, Cerra FB (1994) Multiple organ failure syndrome in the 1990s—systemic inflammatory response and organ dysfunction. JAMA 271(3):226–233PubMedCrossRefGoogle Scholar
  117. Beck MA, Handy J, Levander OA (2004) Host nutritional status: the neglected virulence factor. Trends Microbiol 12(9):417–423PubMedCrossRefGoogle Scholar
  118. Becker E, Richardson DR (2001) Frataxin: its role in iron metabolism and the pathogenesis of Friedreich’s ataxia. Int J Biochem Cell Biol 33(1):1–10PubMedCrossRefGoogle Scholar
  119. Becker JS (2010) Bioimaging of metals in brain tissue from micrometre to nanometre scale by laser ablation inductively coupled plasma mass spectrometry: state of the art and perspectives. Int J Mass Spectrom 289(2–3):65–75Google Scholar
  120. Becker JS, Matusch A, Palm C, Salber D, Morton KA, Becker S (2010a) Bioimaging of metals in brain tissue by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) and metallomics. Metallomics 2(2):104–111CrossRefPubMedGoogle Scholar
  121. Becker JS, Zoriy M, Matusch A, Wu B, Salber D, Palm C et al (2010b) Bioimaging of metals by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). Mass Spectrom Rev 29(1):156–175PubMedGoogle Scholar
  122. Beckett GJ, Foster GR, Hussey AJ, Oliveira DB, Donovan JW, Prescott LF et al (1989) Plasma glutathione S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen)-induced liver damage. Clin Chem 35(11):2186–2189PubMedGoogle Scholar
  123. Beckman JS (1996) Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res Toxicol 9(5):836–844PubMedCrossRefGoogle Scholar
  124. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 87(4):1620–1624PubMedCrossRefGoogle Scholar
  125. Beckman JS, Ischiropoulos H, Zhu L, van der Woerd M, Smith C, Chen J et al (1992) Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch Biochem Biophys 298(2):438–445PubMedCrossRefGoogle Scholar
  126. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271(5 Pt 1):C1424–C1437PubMedGoogle Scholar
  127. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87(1):245–313PubMedCrossRefGoogle Scholar
  128. Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM et al (2008) Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 71(10):750–757PubMedCrossRefGoogle Scholar
  129. Bekyarova G, Tancheva S, Hristova M (2009) Protective effect of melatonin against oxidative hepatic injury after experimental thermal trauma. Methods Find Exp Clin Pharmacol 31(1):11–14PubMedCrossRefGoogle Scholar
  130. Ben-Shachar D, Riederer P, Youdim MB (1991) Iron-melanin interaction and lipid peroxidation: implications for Parkinson’s disease. J Neurochem 57(5):1609–1614PubMedCrossRefGoogle Scholar
  131. Benarroch EE (2009) Brain iron homeostasis and neurodegenerative disease. Neurology 72(16):1436–1440PubMedCrossRefGoogle Scholar
  132. Bencze KZ, Kondapalli KC, Cook JD, McMahon S, Millán-Pacheco C, Pastor N et al (2006) The structure and function of frataxin. Crit Rev Biochem Mol Biol 41(5):269–291PubMedCrossRefGoogle Scholar
  133. Bencze KZ, Yoon T, Millán-Pacheco C, Bradley PB, Pastor N, Cowan JA et al (2007) Human frataxin: iron and ferrochelatase binding surface. Chem Commun (Camb) 18:1798–1800CrossRefGoogle Scholar
  134. Bender A, Jenkins JL, Glick M, Deng Z, Nettles JH, Davies JW (2006) “Bayes affinity fingerprints” improve retrieval rates in virtual screening and define orthogonal bioactivity space: when are multitarget drugs a feasible concept? J Chem Inf Model 46(6):2445–2456PubMedCrossRefGoogle Scholar
  135. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V (2009) The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 11(1):20PubMedCrossRefGoogle Scholar
  136. Berg D (2006) In vivo detection of iron and neuromelanin by transcranial sonography—a new approach for early detection of substantia nigra damage. J Neural Transm 113(6):775–780PubMedCrossRefGoogle Scholar
  137. Berg D (2007) Disturbance of iron metabolism as a contributing factor to SN hyperechogenicity in Parkinson’s disease: implications for idiopathic and monogenetic forms. Neurochem Res 32(10):1646–1654PubMedCrossRefGoogle Scholar
  138. Berg D, Gerlach M, Youdim MBH, Double KL, Zecca L, Riederer P et al (2001) Brain iron pathways and their relevance to Parkinson’s disease. J Neurochem 79(2):225–236PubMedCrossRefGoogle Scholar
  139. Berg D, Hochstrasser H (2006) Iron metabolism in parkinsonian syndromes. Mov Disord 21(9):1299–1310PubMedCrossRefGoogle Scholar
  140. Berg D, Hochstrasser H, Schweitzer KJ, Riess O (2006) Disturbance of iron metabolism in Parkinson’s disease ultrasonography as a biomarker. Neurotox Res 9(1):1–13PubMedCrossRefGoogle Scholar
  141. Berg D, Riederer P, Gerlach M (2008) Contribution of disturbed iron metabolism to the pathogenesis of Parkinson’s disease. Future Med 3(4):447–461Google Scholar
  142. Bergman M, Salman H, Pinchasi R, Straussberg R, Djaldetti M, Bessler H (2005) Phagocytic capacity and apoptosis of peripheral blood cells from patients with iron deficiency anemia. Biomed Pharmacother 59(6):307–311PubMedCrossRefGoogle Scholar
  143. Bermel RA, Puli SR, Rudick RA, Weinstock-Guttman B, Fisher E, Munschauer F E 3rd et al (2005) Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol 62(9):1371–1376PubMedCrossRefGoogle Scholar
  144. Beutler E (2007) Iron storage disease: facts, fiction and progress. Blood Cells Mol Dis 39(2):140–147PubMedCrossRefGoogle Scholar
  145. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2002) Glutathione, iron and Parkinson’s disease. Biochem Pharmacol 64(5–6):1037–1048PubMedCrossRefGoogle Scholar
  146. Bhattacharya K, Dopp E, Kakkar P, Jaffery FN, Schiffmann D, Jaurand MC et al (2005) Biomarkers in risk assessment of asbestos exposure. Mutat Res 579(1–2):6–21PubMedGoogle Scholar
  147. Bhidayasiri R, Truong DD (2004) Chorea and related disorders. Postgrad Med J 80(947):527–534PubMedCrossRefGoogle Scholar
  148. Biasiotto G, Goldwurm S, Finazzi D, Tunesi S, Zecchinelli A, Sironi F et al (2008) HFE gene mutations in a population of Italian Parkinson’s disease patients. Parkinsonism Relat Disord 14(5):426–430PubMedCrossRefGoogle Scholar
  149. Bidle KD, Bender SJ (2008) Iron starvation and culture age activate metacaspases and programmed cell death in the marine diatom Thalassiosira pseudonana. Eukaryot Cell 7(2):223–236PubMedCrossRefGoogle Scholar
  150. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A et al (2002) Innate and acquired immunity in atherogenesis. Nat Med 8(11):1218–1226PubMedCrossRefGoogle Scholar
  151. Biran Y, Masters CL, Barnham KJ, Bush AI, Adlard PA (2009) Pharmacotherapeutic targets in Alzheimer’s disease. J Cell Mol Med 13(1):61–86PubMedCrossRefGoogle Scholar
  152. Bishop GM, Robinson SR (2001) Quantitative analysis of cell death and ferritin expression in response to cortical iron: implications for hypoxia-ischemia and stroke. Brain Res 907(1–2):175–187PubMedCrossRefGoogle Scholar
  153. Bishop GM, Robinson SR, Liu Q, Perry G, Atwood CS, Smith MA (2002) Iron: a pathological mediator of Alzheimer disease? Dev Neurosci 24(2–3):184–187PubMedCrossRefGoogle Scholar
  154. Bishop GM, Dang TN, Dringen R, Robinson SR (2010a) Accumulation of non-transferrin-bound iron by neurons, astrocytes, and microglia. Neurotox Res (in press)Google Scholar
  155. Bishop NA, Lu T, Yankner BA (2010b) Neural mechanisms of ageing and cognitive decline. Nature 464(7288):529–535PubMedCrossRefGoogle Scholar
  156. Biswas SK, Rahman I (2009) Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. Mol Aspects Med 30(1–2):60–76PubMedCrossRefGoogle Scholar
  157. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C (2008) Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database of Systematic Reviews 2008, CD007176.Google Scholar
  158. Blake GJ, Ridker PM (2001) Novel clinical markers of vascular wall inflammation. Circ Res 89(9):763–771PubMedCrossRefGoogle Scholar
  159. Blasiak J, Sklodowska A, Ulinska M, Szaflik JP (2009) Iron and age-related macular degeneration. Klin Oczna 111(4–6):174–177PubMedGoogle Scholar
  160. Blázquez L, De Juan D, Ruiz-Martinez J, Emparanza JI, Saenz A, Otaegui D et al (2007) Genes related to iron metabolism and susceptibility to Alzheimer’s disease in Basque population. Neurobiol Aging 28(12):1941–1943PubMedCrossRefGoogle Scholar
  161. Blum D, Torch S, Lambeng N, Nissou MF, Benabid AL, Sadoul R et al (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson’s disease. Prog Neurobiol 65(2):135–172PubMedCrossRefGoogle Scholar
  162. Boddaert N, Le Quan Sang KH, Rotig A, Leroy-Willig A, Gallet S, Brunelle F et al (2007) Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110(1):401–408PubMedCrossRefGoogle Scholar
  163. Boelaert JR, Weinberg GA, Weinberg ED (1996) Altered iron metabolism in HIV infection: mechanisms, possible consequences, and proposals for management. Infect Agents Dis 5(1):36–46PubMedGoogle Scholar
  164. Bolognin S, Drago D, Messori L, Zatta P (2009a) Chelation therapy for neurodegenerative diseases. Med Res Rev 29(4):547–570PubMedCrossRefGoogle Scholar
  165. Bolognin S, Messori L, Zatta P (2009b) Metal ion physiopathology in neurodegenerative disorders. Neuromol Med 11(4):223–238CrossRefGoogle Scholar
  166. Bolton CF (1996) Sepsis and the systemic inflammatory response syndrome: neuromuscular manifestations. Crit Care Med 24(8):1408–1416PubMedCrossRefGoogle Scholar
  167. Bomhard EM, Herbold BA (2005) Genotoxic activities of aniline and its metabolites and their relationship to the carcinogenicity of aniline in the spleen of rats. Crit Rev Toxicol 35(10):783–835PubMedCrossRefGoogle Scholar
  168. Bone RC (1996) Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 24(1):163–172PubMedCrossRefGoogle Scholar
  169. Bongard JC, Lipson H (2005) Nonlinear system identification using coevolution of models and tests. IEEE Trans Evol Comput 9(4):361–384CrossRefGoogle Scholar
  170. Bonkovsky HL (2002) Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 97(1):1–4PubMedCrossRefGoogle Scholar
  171. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR et al (2006) Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 131(5):1440–1451PubMedCrossRefGoogle Scholar
  172. Borah A, Mohanakumar KP (2009) Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents. J Pineal Res 47(4):293–300PubMedCrossRefGoogle Scholar
  173. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR et al (2005) Survival and complications in thalassemia. Ann NY Acad Sci 1054:40–47PubMedCrossRefGoogle Scholar
  174. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER et al (2003) Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 100(13):7977–7982PubMedCrossRefGoogle Scholar
  175. Bornholdt S, Sneppen K (2000) Robustness as an evolutionary principle. Proc R Soc B Biol Sci 267(1459):2281–2286CrossRefGoogle Scholar
  176. Bosomtwi A, Jiang Q, Ding GL, Zhang L, Zhang ZG, Lu M et al (2008) Quantitative evaluation of microvascular density after stroke in rats using MRI. J Cereb Blood Flow Metab 28(12):1978–1987PubMedCrossRefGoogle Scholar
  177. Bowern N, Ramshaw IA, Clark IA, Doherty PC (1984) Inhibition of autoimmune neuropathological process by treatment with an iron-chelating agent. J Exp Med 160(5):1532–1543PubMedCrossRefGoogle Scholar
  178. Bowler RP (2004) Oxidative stress in the pathogenesis of asthma. Curr Allergy Asthma Rep 4(2):116–122PubMedCrossRefGoogle Scholar
  179. Bowler RP, Crapo JD (2002) Oxidative stress in allergic respiratory diseases. J Allergy Clin Immunol 110(3):349–356PubMedCrossRefGoogle Scholar
  180. Boyer J, Liu RH (2004) Apple phytochemicals and their health benefits. Nutr J 3:5PubMedCrossRefGoogle Scholar
  181. Brar S, Henderson D, Schenck J, Zimmerman EA (2009) Iron accumulation in the substantia nigra of patients with Alzheimer disease and parkinsonism. Arch Neurol 66(3):371–374PubMedCrossRefGoogle Scholar
  182. Brard L, Granai CO, Swamy N (2006) Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol Oncol 100(1):116–127PubMedCrossRefGoogle Scholar
  183. Brass SD, Benedict RH, Weinstock-Guttman B, Munschauer F, Bakshi R (2006a) Cognitive impairment is associated with subcortical magnetic resonance imaging grey matter T2 hypointensity in multiple sclerosis. Mult Scler 12(4):437–444PubMedCrossRefGoogle Scholar
  184. Brass SD, Chen NK, Mulkern RV, Bakshi R (2006b) Magnetic resonance imaging of iron deposition in neurological disorders. Top Magn Reson Imaging 17(1):31–40PubMedCrossRefGoogle Scholar
  185. Braun S, Ndrepepa G, von Beckerath N, Vogt W, Schomig A, Kastrati A (2004) Value of serum ferritin and soluble transferrin receptor for prediction of coronary artery disease and its clinical presentations. Atherosclerosis 174(1):105–110PubMedCrossRefGoogle Scholar
  186. Breiman L (2001) Statistical modeling: the two cultures. Stat Sci 16(3):199–215CrossRefGoogle Scholar
  187. Breitkopf K, Nagy LE, Beier JI, Mueller S, Weng H, Dooley S (2009) Current experimental perspectives on the clinical progression of alcoholic liver disease. Alcohol Clin Exp Res 33(10):1647–1655PubMedCrossRefGoogle Scholar
  188. Brennan LA, Kantorow M (2009) Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. Exp Eye Res 88(2):195–203PubMedCrossRefGoogle Scholar
  189. Brewer GJ (2007) Iron and copper toxicity in diseases of aging, particularly atherosclerosis and Alzheimer’s disease. Exp Biol Med 232(2):323–335Google Scholar
  190. Brewer GJ (2010) Risks of copper and iron toxicity during aging in humans. Chem Res Toxicol 23(2):319–326PubMedCrossRefGoogle Scholar
  191. Broadhurst D, Goodacre R, Jones A, Rowland JJ, Kell DB (1997) Genetic algorithms as a method for variable selection in multiple linear regression and partial least squares regression, with applications to pyrolysis mass spectrometry. Anal Chim Acta 348(1–3):71–86CrossRefGoogle Scholar
  192. Broadhurst D, Kell DB (2006) Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2(4):171–196. doi: 10.1007/s11306-006-0037-z CrossRefGoogle Scholar
  193. Broedbaek K, Poulsen HE, Weimann A, Kom GD, Schwedhelm E, Nielsen P et al (2009) Urinary excretion of biomarkers of oxidatively damaged DNA and RNA in hereditary hemochromatosis. Free Radic Biol Med 47:1230–1233PubMedCrossRefGoogle Scholar
  194. Brötz-Oesterhelt H, Brunner NA (2008) How many modes of action should an antibiotic have? Curr Opin Pharmacol 8:567–573Google Scholar
  195. Brown DR (2009a) Brain proteins that mind metals: a neurodegenerative perspective. Dalton Trans 21:4069–4076PubMedCrossRefGoogle Scholar
  196. Brown DR (2009b) Role of microglia in age-related changes to the nervous system. ScientificWorldJournal 9:1061–1071PubMedGoogle Scholar
  197. Brown DR, Qin K, Herms JW, Madlung A, Manson J, Strome R et al (1997) The cellular prion protein binds copper in vivo. Nature 390(6661):684–687PubMedCrossRefGoogle Scholar
  198. Brown M, He F, Wilkinson SJ (2010) Properties of the proximate parameter tuning regularization algorithm. Bull Math Biol 72(3):697–718PubMedCrossRefGoogle Scholar
  199. Brudevold R, Hole T, Hammerstrøm J (2008) Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS One 3(10):e3547PubMedCrossRefGoogle Scholar
  200. Brune M, Rossander L, Hallberg L (1989) Iron absorption and phenolic compounds: importance of different phenolic structures. Eur J Clin Nutr 43(8):547–557PubMedGoogle Scholar
  201. Bu DX, Hemdahl AL, Gabrielsen A, Fuxe J, Zhu C, Eriksson P et al (2006) Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol 169(6):2245–2253PubMedCrossRefGoogle Scholar
  202. Buchanan DD, Silburn PA, Chalk JB, Le Couteur DG, Mellick GD (2002) The Cys282Tyr polymorphism in the HFE gene in Australian Parkinson’s disease patients. Neurosci Lett 327(2):91–94PubMedCrossRefGoogle Scholar
  203. Büeler H (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Exp Neurol 218(2):235–246PubMedCrossRefGoogle Scholar
  204. Bugianesi E, Manzini P, D’Antico S, Vanni E, Longo F, Leone N et al (2004) Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39(1):179–187PubMedCrossRefGoogle Scholar
  205. Bulger EM, Maier RV (2001) Antioxidants in critical illness. Arch Surg 136(10):1201–1207PubMedCrossRefGoogle Scholar
  206. Bulgin MS, Melson SS (2007) What veterinary practitioners should know about scrapie. J Am Vet Med Assoc 230(8):1158–1164, 1120.Google Scholar
  207. Bulteau AL, Dancis A, Gareil M, Montagne JJ, Camadro JM, Lesuisse E (2007) Oxidative stress and protease dysfunction in the yeast model of Friedreich ataxia. Free Radic Biol Med 42(10):1561–1570PubMedCrossRefGoogle Scholar
  208. Bulucu F, Ocal R, Karadurmus N, Sahin M, Kenar L, Aydin A et al (2009) Effects of N-acetylcysteine, deferoxamine and selenium on doxorubicin-induced hepatotoxicity. Biol Trace Elem Res 132:184–196CrossRefGoogle Scholar
  209. Burrows CJ, Muller JG (1998) Oxidative nucleobase modifications leading to strand scission. Chem Rev 98(3):1109–1152PubMedCrossRefGoogle Scholar
  210. Busca A, Falda M, Manzini P, D’Antico S, Valfre A, Locatelli F et al (2010) Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transpl 16(1):115–122CrossRefGoogle Scholar
  211. Bush AI (2000) Metals and neuroscience. Curr Opin Chem Biol 4(2):184–191PubMedCrossRefGoogle Scholar
  212. Bush AI (2003) The metallobiology of Alzheimer’s disease. Trends Neurosci 26(4):207–214PubMedCrossRefGoogle Scholar
  213. Bush AI (2008) Drug development based on the metals hypothesis of Alzheimer’s disease. J Alzheimers Dis 15(2):223–240PubMedGoogle Scholar
  214. Buss JL, Neuzil J, Gellert N, Weber C, Ponka P (2003) Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties. Biochem Pharmacol 65(2):161–172PubMedCrossRefGoogle Scholar
  215. Butelli E, Titta L, Giorgio M, Mock HP, Matros A, Peterek S et al (2008) Enrichment of tomato fruit with health-promoting anthocyanins by expression of select transcription factors. Nat Biotechnol 26(11):1301–1308PubMedCrossRefGoogle Scholar
  216. Butensky James E, Harmatz P, Lee M, Kennedy C, Petru A, Wara D et al (2009) Altered iron metabolism in children with human immunodeficiency virus disease. Pediatr Hematol Oncol 26(2):69–84PubMedCrossRefGoogle Scholar
  217. Butt MS, Sultan MT (2009) Green tea: nature’s defense against malignancies. Crit Rev Food Sci Nutr 49(5):463–473PubMedCrossRefGoogle Scholar
  218. Butterfield DA, Reed T, Newman SF, Sultana R (2007) Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic Biol Med 43(5):658–677PubMedCrossRefGoogle Scholar
  219. Buzan T (2002) How to mind map. Thorsons, LondonGoogle Scholar
  220. Cadenas S, Cadenas AM (2002) Fighting the stranger-antioxidant protection against endotoxin toxicity. Toxicology 180(1):45–63PubMedCrossRefGoogle Scholar
  221. Cai J, Nelson KC, Wu M, Sternberg P Jr, Jones DP (2000) Oxidative damage and protection of the RPE. Prog Retin Eye Res 19(2):205–221PubMedCrossRefGoogle Scholar
  222. Calabrese E (2008a) Hormesis: why it is important to toxicology and toxicologists. Environ Toxicol Chem 27:1451–1474Google Scholar
  223. Calabrese EJ (2008b) Converging concepts: adaptive response, preconditioning, and the Yerkes-Dodson Law are manifestations of hormesis. Ageing Res Rev 7(1):8–20PubMedCrossRefGoogle Scholar
  224. Calabrese EJ (2008c) Hormesis and medicine. Br J Clin PharmacolGoogle Scholar
  225. Calabrese EJ, Baldwin LA (1997) The dose determines the stimulation (and poison): development of a chemical hormesis database. Int J Toxicol 16(6):545–559CrossRefGoogle Scholar
  226. Calabrese EJ, Baldwin LA (2001) Hormesis: U-shaped dose responses and their centrality in toxicology. Trends Pharmacol Sci 22(6):285–291PubMedCrossRefGoogle Scholar
  227. Calabrese EJ, Baldwin LA (2003) Hormesis: the dose-response revolution. Annu Rev Pharmacol Toxicol 43:175–197PubMedCrossRefGoogle Scholar
  228. Calabrese EJ, Blain R (2005) The occurrence of hormetic dose responses in the toxicological literature, the hormesis database: an overview. Toxicol Appl Pharmacol 202(3):289–301PubMedCrossRefGoogle Scholar
  229. Calabrese EJ, Blain RB (2009) Hormesis and plant biology. Environ Pollut 157(1):42–48PubMedCrossRefGoogle Scholar
  230. Camaschella C, Merlini R (2005) Inherited hemochromatosis: from genetics to clinics. Minerva Med 96(3):207–222PubMedGoogle Scholar
  231. Campanella A, Rovelli E, Santambrogio P, Cozzi A, Taroni F, Levi S (2009) Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in Friedreich ataxia. Hum Mol Genet 18(1):1–11PubMedCrossRefGoogle Scholar
  232. Candore G, Licastro F, Chiappelli M, Franceschi C, Lio D, Rita Balistreri C et al (2003) Association between the HFE mutations and unsuccessful ageing: a study in Alzheimer’s disease patients from Northern Italy. Mech Ageing Dev 124(4):525–528PubMedCrossRefGoogle Scholar
  233. Cao A, Galanello R (2010) Beta-thalassemia. Genet Med 12(2):61–76PubMedCrossRefGoogle Scholar
  234. Cappellini MD, Pattoneri P (2009) Oral iron chelators. Annu Rev Med 60:25–38PubMedCrossRefGoogle Scholar
  235. Cappellini MD, Porter J, El-Beshlawy A, Li CK, Seymour JF, Elalfy M et al (2010) Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 95(4):557–566PubMedCrossRefGoogle Scholar
  236. Carbonell T, Rama R (2007) Iron, oxidative stress and early neurological deterioration in ischemic stroke. Curr Med Chem 14(8):857–874PubMedCrossRefGoogle Scholar
  237. Carrea G, Colonna S, Kelly DR, Lazcano A, Ottolina G, Roberts SM (2005) Polyamino acids as synthetic enzymes: mechanism, applications and relevance to prebiotic catalysis. Trends Biotechnol 23(10):507–513PubMedCrossRefGoogle Scholar
  238. Carri MT, Ferri A, Cozzolino M, Calabrese L, Rotilio G (2003) Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 61(4):365–374PubMedCrossRefGoogle Scholar
  239. Carrillo-Vico A, Lardone PJ, Naji L, Fernández-Santos JM, Martín-Lacave I, Guerrero JM et al (2005) Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and anti-apoptotic effects. J Pineal Res 39(4):400–408PubMedCrossRefGoogle Scholar
  240. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K et al (2004) Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. J Alzheimers Dis 6(2):165–169PubMedGoogle Scholar
  241. Cass WA, Grondin R, Andersen AH, Zhang Z, Hardy PA, Hussey-Andersen LK et al (2007) Iron accumulation in the striatum predicts aging-related decline in motor function in rhesus monkeys. Neurobiol Aging 28(2):258–271PubMedCrossRefGoogle Scholar
  242. Cassol OJ Jr, Rezin GT, Petronilho FC, Scaini G, Goncalves CL, Ferreira GK et al. (2009) Effects of N-acetylcysteine/deferoxamine, taurine and RC-3095 on respiratory chain complexes and creatine kinase activities in rat brain after sepsis. Neurochem ResGoogle Scholar
  243. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA et al (2007) Iron: the redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 32(10):1640–1645PubMedCrossRefGoogle Scholar
  244. Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, Zhang J et al (2002) Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem lewy bodies in humans. Neurosci Lett 319(1):25–28PubMedCrossRefGoogle Scholar
  245. Castoldi AF, Coccini T, Ceccatelli S, Manzo L (2001) Neurotoxicity and molecular effects of methylmercury. Brain Res Bull 55(2):197–203PubMedCrossRefGoogle Scholar
  246. Caughey B, Baron GS (2006) Prions and their partners in crime. Nature 443(7113):803–810PubMedCrossRefGoogle Scholar
  247. Caughey B, Lansbury PT (2003) Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 26:267–298PubMedCrossRefGoogle Scholar
  248. Cavadini P, Gellera C, Patel PI, Isaya G (2000) Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet 9(17):2523–2530PubMedCrossRefGoogle Scholar
  249. Cavadini P, O’Neill HA, Benada O, Isaya G (2002) Assembly and iron-binding properties of human frataxin, the protein deficient in Friedreich ataxia. Hum Mol Genet 11(3):217–227PubMedCrossRefGoogle Scholar
  250. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S et al (2006) NADPH oxidases in cardiovascular health and disease. [Review]. Antioxid Redox Signal 8(5–6):691–728PubMedCrossRefGoogle Scholar
  251. Cazzola M, Della Porta MG, Malcovati L (2008) Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematol Am Soc Hematol Educ Program 2008:166–175Google Scholar
  252. Ceccarelli A, Filippi M, Neema M, Arora A, Valsasina P, Rocca MA et al (2009) T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis. Mult Scler 15(6):678–686PubMedCrossRefGoogle Scholar
  253. Ceccarelli A, Rocca MA, Neema M, Martinelli V, Arora A, Tauhid S et al (2010) Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 16(1):39–44PubMedCrossRefGoogle Scholar
  254. Cemeli E, Baumgartner A, Anderson D (2009) Antioxidants and the comet assay. Mutat Res 681(1):51–67PubMedCrossRefGoogle Scholar
  255. Ceyssens B, Pauwels M, Meulemans B, Verbeelen D, Van den Branden C (2004) Increased oxidative stress in the mouse adriamycin model of glomerulosclerosis is accompanied by deposition of ferric iron and altered GGT activity in renal cortex. Ren Fail 26(1):21–27PubMedCrossRefGoogle Scholar
  256. Chakravarty A (2003) Friedreich’s ataxia—yesterday, today and tomorrow. Neurol India 51(2):176–182PubMedGoogle Scholar
  257. Chandrasekaran V, Taylor EW (2008) Molecular modeling of the oxidized form of nuclear factor-kappa B suggests a mechanism for redox regulation of DNA binding and transcriptional activation. J Mol Graph Model 26(5):861–867PubMedCrossRefGoogle Scholar
  258. Chandrasekaran VR, Hsu DZ, Liu MY (2009) The protective effect of sesamol against mitochondrial oxidative stress and hepatic injury in acetaminophen-overdosed rats. Shock 32(1):89–93PubMedCrossRefGoogle Scholar
  259. Chang EF, Claus CP, Vreman HJ, Wong RJ, Noble-Haeusslein LJ (2005) Heme regulation in traumatic brain injury: relevance to the adult and developing brain. J Cereb Blood Flow Metab 25(11):1401–1417PubMedCrossRefGoogle Scholar
  260. Chao CC, Park SH, Aust AE (1996) Participation of nitric oxide and iron in the oxidation of DNA in asbestos-treated human lung epithelial cells. Arch Biochem Biophys 326(1):152–157PubMedCrossRefGoogle Scholar
  261. Chard DT, Miller DH (2009) What you see depends on how you look: gray matter lesions in multiple sclerosis. Neurology 73(12):918–919PubMedCrossRefGoogle Scholar
  262. Charkoudian LK, Dentchev T, Lukinova N, Wolkow N, Dunaief JL, Franz KJ (2008) Iron prochelator BSIH protects retinal pigment epithelial cells against cell death induced by hydrogen peroxide. J Inorg Biochem 102(12):2130–2135PubMedCrossRefGoogle Scholar
  263. Chau LY (2000) Iron and atherosclerosis. Proc Natl Sci Counc Repub China B 24(4):151–155PubMedGoogle Scholar
  264. Chen-Roetling J, Chen L, Regan RF (2009) Minocycline attenuates iron neurotoxicity in cortical cell cultures. Biochem Biophys Res CommunGoogle Scholar
  265. Chen H, Lukas TJ, Du N, Suyeoka G, Neufeld AH (2009) Dysfunction of the retinal pigment epithelium with age: increased iron decreases phagocytosis and lysosomal activity. Invest Ophthalmol Vis Sci 50(4):1895–1902PubMedCrossRefGoogle Scholar
  266. Chen LW, Wang YQ, Wei LC, Shi M, Chan YS (2007) Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson’s disease. CNS Neurol Disord Drug Targets 6(4):273–281PubMedCrossRefGoogle Scholar
  267. Chen Q, Marsh J, Ames B, Mossman B (1996) Detection of 8-oxo-2’-deoxyguanosine, a marker of oxidative DNA damage, in culture medium from human mesothelial cells exposed to crocidolite asbestos. Carcinogenesis 17(11):2525–2527PubMedCrossRefGoogle Scholar
  268. Chen W, Stambolian D, Edwards AO, Branham KE, Othman M, Jakobsdottir J et al (2010) Genetic variants near TIMP3 and high-density lipoprotein-associated loci influence susceptibility to age-related macular degeneration. Proc Natl Acad Sci USAGoogle Scholar
  269. Chen X, Scholl TO, Stein TP (2006) Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women: the Camden study. Diabetes Care 29(5):1077–1082PubMedCrossRefGoogle Scholar
  270. Cheynier V (2005) Polyphenols in foods are more complex than often thought. Am J Clin Nutr 81(1 Suppl):223S–229SPubMedGoogle Scholar
  271. Chiueh CC, Andoh T, Lai AR, Lai E, Krishna G (2000) Neuroprotective strategies in Parkinson’s disease: protection against progressive nigral damage induced by free radicals. Neurotox Res 2(2–3):293–310PubMedCrossRefGoogle Scholar
  272. Cho S, Urata Y, Iida T, Goto S, Yamaguchi M, Sumikawa K et al (1998) Glutathione downregulates the phosphorylation of I kappa B: autoloop regulation of the NF-kappa B-mediated expression of NF-kappa B subunits by TNF-alpha in mouse vascular endothelial cells. Biochem Biophys Res Commun 253(1):104–108PubMedCrossRefGoogle Scholar
  273. Cho TH, Nighoghossian N, Wiart M, Desestret V, Cakmak S, Berthezene Y et al (2007) USPIO-enhanced MRI of neuroinflammation at the sub-acute stage of ischemic stroke: preliminary data. Cerebrovasc Dis 24(6):544–546PubMedCrossRefGoogle Scholar
  274. Chobot V (2010) Simultaneous detection of pro- and antioxidative effects in the variants of the deoxyribose degradation assay. J Agric Food Chem 58(4):2088–2094PubMedCrossRefGoogle Scholar
  275. Chodaczek G, Saavedra-Molina A, Bacsi A, Kruzel ML, Sur S, Boldogh I (2007) Iron-mediated dismutation of superoxide anion augments antigen-induced allergic inflammation: effect of lactoferrin. Postepy Hig Med Dosw (Online) 61:268–276Google Scholar
  276. Choi CJ, Kanthasamy A, Anantharam V, Kanthasamy AG (2006) Interaction of metals with prion protein: possible role of divalent cations in the pathogenesis of prion diseases. Neurotoxicology 27(5):777–787PubMedCrossRefGoogle Scholar
  277. Choi KM, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH et al (2005) Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism 54(11):1510–1514PubMedCrossRefGoogle Scholar
  278. Choi YG, Park JH, Lim S (2009) Acupuncture inhibits ferric iron deposition and ferritin-heavy chain reduction in an MPTP-induced parkinsonism model. Neurosci Lett 450(2):92–96PubMedCrossRefGoogle Scholar
  279. Chong CR, Sullivan D J Jr (2007) New uses for old drugs. Nature 448(7154):645–646PubMedCrossRefGoogle Scholar
  280. Chopra V, Fox JH, Lieberman G, Dorsey K, Matson W, Waldmeier P et al (2007) A small-molecule therapeutic lead for Huntington’s disease: preclinical pharmacology and efficacy of C2–8 in the R6/2 transgenic mouse. Proc Natl Acad Sci USA 104(42):16685–16689PubMedCrossRefGoogle Scholar
  281. Chowers I, Wong R, Dentchev T, Farkas RH, Iacovelli J, Gunatilaka TL et al (2006) The iron carrier transferrin is upregulated in retinas from patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 47(5):2135–2140PubMedCrossRefGoogle Scholar
  282. Christen Y (2000) Oxidative stress and Alzheimer disease. Am J Clin Nutr 71(2):621S–629SPubMedGoogle Scholar
  283. Christie BR, Cameron HA (2006) Neurogenesis in the adult hippocampus. Hippocampus 16(3):199–207PubMedCrossRefGoogle Scholar
  284. Chu J, Zhou CC, Lu N, Zhang X, Dong FT (2008) Genetic variants in three genes and smoking show strong associations with susceptibility to exudative age-related macular degeneration in a Chinese population. Chin Med J (Engl) 121(24):2525–2533Google Scholar
  285. Chung YL, Williams A, Ritchie D, Williams SC, Changani KK, Hope J et al (1999) Conflicting MRI signals from gliosis and neuronal vacuolation in prion diseases. Neuroreport 10(17):3471–3477PubMedCrossRefGoogle Scholar
  286. Ciencewicki J, Trivedi S, Kleeberger SR (2008) Oxidants and the pathogenesis of lung diseases. J Allergy Clin Immunol 122(3):456–468 (quiz 469–470)Google Scholar
  287. Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48(6):749–762PubMedCrossRefGoogle Scholar
  288. Clark LN, Ross BM, Wang Y, Mejia-Santana H, Harris J, Louis ED et al (2007) Mutations in the glucocerebrosidase gene are associated with early-onset Parkinson disease. Neurology 69(12):1270–1277PubMedCrossRefGoogle Scholar
  289. Clarkson TW, Magos L, Myers GJ (2003) The toxicology of mercury—current exposures and clinical manifestations. N Engl J Med 349(18):1731–1737PubMedCrossRefGoogle Scholar
  290. Clifton MC, Corrent C, Strong RK (2009) Siderocalins: siderophore-binding proteins of the innate immune system. Biometals 22(4):557–564PubMedCrossRefGoogle Scholar
  291. Closa D, Folch-Puy E (2004) Oxygen free radicals and the systemic inflammatory response. IUBMB Life 56(4):185–191PubMedCrossRefGoogle Scholar
  292. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E (2004) Thalassemia. Hematology 14–34Google Scholar
  293. Cole AR, Astell A, Green C, Sutherland C (2007) Molecular connexions between dementia and diabetes. Neurosci Biobehav Rev 31(7):1046–1063PubMedCrossRefGoogle Scholar
  294. Coles SJ, Day NE, Murray-Rust P, Rzepa HS, Zhang Y (2005) Enhancement of the chemical semantic web through the use of InChI identifiers. Organic & Biomolecular Chemistry 3(10):1832–1834CrossRefGoogle Scholar
  295. Collingwood J, Dobson J (2006) Mapping and characterization of iron compounds in Alzheimer’s tissue. J Alzheimers Dis 10(2–3):215–222PubMedGoogle Scholar
  296. Collingwood JF, Chong RK, Kasama T, Cervera-Gontard L, Dunin-Borkowski RE, Perry G et al (2008) Three-dimensional tomographic imaging and characterization of iron compounds within Alzheimer’s plaque core material. J Alzheimers Dis 14(2):235–245PubMedGoogle Scholar
  297. Collins FS (2010) The langage of life. Profile Books, LondonGoogle Scholar
  298. Combarros O, Garcia-Roman M, Fontalba A, Fernandez-Luna JL, Llorca J, Infante J et al (2003) Interaction of the H63D mutation in the hemochromatosis gene with the apolipoprotein E epsilon 4 allele modulates age at onset of Alzheimer’s disease. Dement Geriatr Cogn Disord 15(3):151–154PubMedCrossRefGoogle Scholar
  299. Comhair SA, Erzurum SC (2010) Redox control of asthma: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 12(1):93–124PubMedCrossRefGoogle Scholar
  300. Connor JR, Lee SY (2006) HFE mutations and Alzheimer’s disease. J Alzheimers Dis 10(2–3):267–276PubMedGoogle Scholar
  301. Connor JR, Menzies SL, St Martin SM, Mufson EJ (1992) A histochemical study of iron, transferrin, and ferritin in Alzheimer’s diseased brains. J Neurosci Res 31(1):75–83PubMedCrossRefGoogle Scholar
  302. Cook CI, Yu BP (1998) Iron accumulation in aging: modulation by dietary restriction. Mech Ageing Devel 102(1):1–13CrossRefGoogle Scholar
  303. Cook JD, Bencze KZ, Jankovic AD, Crater AK, Busch CN, Bradley PB et al (2006) Monomeric yeast frataxin is an iron-binding protein. Biochemistry 45(25):7767–7777PubMedCrossRefGoogle Scholar
  304. Cook R, Calabrese EJ (2006) The importance of hormesis to public health. Environ Health Perspect 114(11):1631–1635PubMedGoogle Scholar
  305. Cooke MS, Evans MD, Dizdaroglu M, Lunec J (2003) Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J 17(10):1195–1214PubMedCrossRefGoogle Scholar
  306. Cooke MS, Olinski R, Loft S (2008) Measurement and meaning of oxidatively modified DNA lesions in urine. Cancer Epidemiol Biomarkers Prev 17(1):3–14PubMedCrossRefGoogle Scholar
  307. Cornelis P, Andrews SC (eds) (2010) Iron uptake and homeostasis in microorganisms. Horizon Press, New YorkGoogle Scholar
  308. Correia AR, Pastore C, Adinolfi S, Pastore A, Gomes CM (2008) Dynamics, stability and iron-binding activity of frataxin clinical mutants. FEBS J 275(14):3680–3690PubMedCrossRefGoogle Scholar
  309. Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS et al (2010) The genetic landscape of a cell. Science 327(5964):425–431PubMedCrossRefGoogle Scholar
  310. Coveney PV, Fowler PW (2005) Modelling biological complexity: a physical scientist’s perspective. J R Soc Interface 2(4):267–280PubMedCrossRefGoogle Scholar
  311. Cowan KJ, Diamond MI, Welch WJ (2003) Polyglutamine protein aggregation and toxicity are linked to the cellular stress response. Hum Mol Genet 12(12):1377–1391PubMedCrossRefGoogle Scholar
  312. Cowland JB, Muta T, Borregaard N (2006) IL-1beta-specific up-regulation of neutrophil gelatinase-associated lipocalin is controlled by IkappaB-zeta. J Immunol 176(9):5559–5566PubMedGoogle Scholar
  313. Cowland JB, Sorensen OE, Sehested M, Borregaard N (2003) Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1 beta, but not by TNF-alpha. J Immunol 171(12):6630–6639PubMedGoogle Scholar
  314. Cox LA Jr (2009) Hormesis without cell killing. Risk Anal 29(3):393–400PubMedCrossRefGoogle Scholar
  315. Cozzi A, Levi S, Corsi B, Santambrogio P, Campanella A, Gerardi G et al (2003) Role of iron and ferritin in TNFalpha-induced apoptosis in HeLa cells. FEBS Lett 537(1–3):187–192PubMedCrossRefGoogle Scholar
  316. Cozzi A, Rovelli E, Frizzale G, Campanella A, Amendola M, Arosio P et al (2010) Oxidative stress and cell death in cells expressing L-ferritin variants causing neuroferritinopathy. Neurobiol Dis 37(1):77–85PubMedCrossRefGoogle Scholar
  317. Cozzolino M, Ferri A, Carri MT (2008) Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal 10(3):405–443PubMedCrossRefGoogle Scholar
  318. Craelius W, Migdal MW, Luessenhop CP, Sugar A, Mihalakis I (1982) Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 106(8):397–399PubMedGoogle Scholar
  319. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W et al (1991) Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet 337(8753):1304–1308PubMedCrossRefGoogle Scholar
  320. Crichton RR, Ward RJ (2006) Metal-based neurodegeneration. Wiley/Blackwell, ChichesterGoogle Scholar
  321. Crimi E, Sica V, Slutsky AS, Zhang HB, Williams-Ignarro S, Ignarro LJ et al (2006a) Role of oxidative stress in experimental sepsis and multisystem organ dysfunction. Free Radic Res 40(7):665–672PubMedCrossRefGoogle Scholar
  322. Crimi E, Sica V, Williams-Ignarro S, Zhang H, Slutsky AS, Ignarro LJ et al (2006b) The role of oxidative stress in adult critical care. Free Radic Biol Med 40(3):398–406PubMedCrossRefGoogle Scholar
  323. Crozet C, Beranger F, Lehmann S (2008) Cellular pathogenesis in prion diseases. Vet Res 39(4):44PubMedCrossRefGoogle Scholar
  324. Csermely P, Agoston V, Pongor S (2005) The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 26(4):178–182PubMedCrossRefGoogle Scholar
  325. Csete M, Doyle J (2004) Bow ties, metabolism and disease. Trends Biotechnol 22(9):446–450PubMedCrossRefGoogle Scholar
  326. Csikasz-Nágy A (2009) Computational systems biology of the cell cycle. Brief Bioinform 10(4):424–434PubMedCrossRefGoogle Scholar
  327. Cuajungco MP, Fagét KY, Huang X, Tanzi RE, Bush AI (2000) Metal chelation as a potential therapy for Alzheimer’s disease. Ann NY Acad Sci 920:292–304PubMedCrossRefGoogle Scholar
  328. Cuijpers ML, Raymakers RA, Mackenzie MA, de Witte TJ, Swinkels DW (2010) Recent advances in the understanding of iron overload in sideroblastic myelodysplastic syndrome. Br J Haematol 149:322–333Google Scholar
  329. Cuzzocrea S, Di Paola R, Mazzon E, Patel NS, Genovese T, Muia C et al (2006) Erythropoietin reduces the development of nonseptic shock induced by zymosan in mice. Crit Care Med 34(4):1168–1177PubMedCrossRefGoogle Scholar
  330. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D (2001) Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury. Pharmacol Rev 53(1):135–159PubMedGoogle Scholar
  331. Cuzzocrea S, Thiemermann C, Salvemini D (2004) Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr Med Chem 11(9):1147–1162PubMedGoogle Scholar
  332. Dada JO, Mendes P (2009) Design and architecture of web services for simulation of biochemical systems. Data Integr Life Sci Proc 5647:182–195CrossRefGoogle Scholar
  333. Dada JO, Spasic I, Paton NW, Mendes P (2010) SBRML: a markup language for associating systems biology data with models. BioinformaticsGoogle Scholar
  334. Daghino S, Turci F, Tomatis M, Favier A, Perotto S, Douki T et al (2006) Soil fungi reduce the iron content and the DNA damaging effects of asbestos fibers. Environ Sci Technol 40(18):5793–5798PubMedCrossRefGoogle Scholar
  335. Dai J, Churg A (2001) Relationship of fiber surface iron and active oxygen species to expression of procollagen, PDGF-A, and TGF-beta(1) in tracheal explants exposed to amosite asbestos. Am J Respir Cell Mol Biol 24(4):427–435PubMedGoogle Scholar
  336. Dalle-Donne I (2007) Familial amyotrophic lateral sclerosis (FALS): emerging hints from redox proteomics. Highlight commentary on: “Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis”. Free Radic Biol Med 43(2):157–159PubMedCrossRefGoogle Scholar
  337. Dancey JE, Chen HX (2006) Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 5(8):649–659PubMedCrossRefGoogle Scholar
  338. Daré E, Götz ME, Zhivotovsky B, Manzo L, Ceccatelli S (2000) Antioxidants J811 and 17beta-estradiol protect cerebellar granule cells from methylmercury-induced apoptotic cell death. J Neurosci Res 62(4):557–565PubMedCrossRefGoogle Scholar
  339. Dávalos A, Fernandezreal JM, Ricart W, Soler S, Molins A, Planas E et al (1994) Iron-related damage in acute ischemic stroke. Stroke 25(8):1543–1546PubMedGoogle Scholar
  340. Davidsson L, Galan P, Kastenmayer P, Cherouvrier F, Juillerat MA, Hercberg S et al (1994) Iron bioavailability studied in infants: the influence of phytic acid and ascorbic acid in infant formulas based on soy isolate. Pediatr Res 36(6):816–822PubMedCrossRefGoogle Scholar
  341. Davies BW, Kohanski MA, Simmons LA, Winkler JA, Collins JJ, Walker GC (2009) Hydroxyurea induces hydroxyl radical-mediated cell death in Escherichia coli. Mol Cell 36(5):845–860PubMedCrossRefGoogle Scholar
  342. Davies MG, Hagen PO (1997) Systemic inflammatory response syndrome. Br J Surg 84(7):920–935PubMedCrossRefGoogle Scholar
  343. Davies MJ (2005) The oxidative environment and protein damage. Biochim Biophys Acta 1703(2):93–109PubMedGoogle Scholar
  344. Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S et al (2003) Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation 107(20):2601–2606PubMedGoogle Scholar
  345. de Carvalho CC, Fernandes P (2010) Production of metabolites as bacterial responses to the marine environment. Mar Drugs 8(3):705–727PubMedCrossRefGoogle Scholar
  346. De Freitas J, Wintz H, Kim JH, Poynton H, Fox T, Vulpe C (2003) Yeast, a model organism for iron and copper metabolism studies. Biometals 16(1):185–197PubMedCrossRefGoogle Scholar
  347. de Monyé C, Karcher DS, Boelaert JR, Gordeuk VR (1999) Bone marrow macrophage iron grade and survival of HIV-seropositive patients. Aids 13(3):375–380PubMedCrossRefGoogle Scholar
  348. de Valk B, Marx JJM (1999) Iron, atherosclerosis, and ischemic heart disease. Arch Internal Med 159(14):1542–1548CrossRefGoogle Scholar
  349. De Vizcaya-Ruiz A, Barbier O, Ruiz-Ramos R, Cebrian ME (2009) Biomarkers of oxidative stress and damage in human populations exposed to arsenic. Mutat Res 674(1–2):85–92PubMedGoogle Scholar
  350. Debebe Z, Ammosova T, Jerebtsova M, Kurantsin-Mills J, Niu X, Charles S et al (2007) Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology 367(2):324–333PubMedCrossRefGoogle Scholar
  351. Dekker MC, Giesbergen PC, Njajou OT, van Swieten JC, Hofman A, Breteler MM et al (2003) Mutations in the hemochromatosis gene (HFE), Parkinson’s disease and parkinsonism. Neurosci Lett 348(2):117–119PubMedCrossRefGoogle Scholar
  352. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36(1):296–327PubMedCrossRefGoogle Scholar
  353. Demir O, Singh S, Klimaschewski L, Kurnaz IA (2009) From birth till death: neurogenesis, cell cycle, and neurodegeneration. Anat Rec (Hoboken) 292(12):1953–1961Google Scholar
  354. Demougeot C, Van Hoecke M, Bertrand N, Prigent-Tessier A, Mossiat C, Beley A et al (2004) Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2, 2 ‘-dipyridyl in the rat photothrombotic ischemic stroke model. J Pharm Exp Therapeut 311(3):1080–1087CrossRefGoogle Scholar
  355. Dentchev T, Hahn P, Dunaief JL (2005) Strong labeling for iron and the iron-handling proteins ferritin and ferroportin in the photoreceptor layer in age-related macular degeneration. Arch Ophthalmol 123(12):1745–1746PubMedCrossRefGoogle Scholar
  356. DePalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR (2010) Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the iron (Fe) and atherosclerosis study (FeAST) Trial. J Vasc SurgGoogle Scholar
  357. DePalma RG, Hayes VW, Zacharski LR (2007) Bloodletting: past and present. J Am Coll Surg 205(1):132–144PubMedCrossRefGoogle Scholar
  358. Dereure O, Jumez N, Bessis D, Gallix B, Guillot B (2008) Measurement of liver iron content by magnetic resonance imaging in 20 patients with overt porphyria cutanea tarda before phlebotomy therapy: a prospective study. Acta Derm Venereol 88(4):341–345PubMedGoogle Scholar
  359. Desai TK, Jamil LH, Balasubramaniam M, Koff R, Bonkovsky HL (2008) Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 53(3):815–822PubMedCrossRefGoogle Scholar
  360. Dever JB, Mallory MA, Mallory JE, Wallace D, Kowdley KV (2010) Phenotypic characteristics and diagnoses of patients referred to an iron overload clinic. Dig Dis Sci 55:803–807PubMedCrossRefGoogle Scholar
  361. Devireddy LR, Gazin C, Zhu X, Green MR (2005) A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell 123(7):1293–1305PubMedCrossRefGoogle Scholar
  362. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F et al (2008) Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 93(8):1243–1246PubMedCrossRefGoogle Scholar
  363. Di Paola R, Mazzon E, Muia C, Crisafulli C, Genovese T, Di Bella P et al (2006) Green tea polyphenol extract attenuates zymosan-induced non-septic shock in mice. Shock 26(4):402–409PubMedCrossRefGoogle Scholar
  364. Dickens MG, Franz KJ (2010) A prochelator activated by hydrogen peroxide prevents metal-induced amyloid beta aggregation. Chembiochem 11(1):59–62PubMedCrossRefGoogle Scholar
  365. Diedrich JF, Bendheim PE, Kim YS, Carp RI, Haase AT (1991) Scrapie-associated prion protein accumulates in astrocytes during scrapie infection. Proc Natl Acad Sci USA 88(2):375–379PubMedCrossRefGoogle Scholar
  366. DiMauro S, Schon EA (2008) Mitochondrial disorders in the nervous system. Annu Rev Neurosci 31:91–123PubMedCrossRefGoogle Scholar
  367. Ding B, Chen KM, Ling HW, Sun F, Li X, Wan T et al (2009) Correlation of iron in the hippocampus with MMSE in patients with Alzheimer’s disease. J Magn Reson Imaging 29(4):793–798PubMedCrossRefGoogle Scholar
  368. Dobson P, Lanthaler K, Oliver SG, Kell DB (2009a) Implications of the dominant role of cellular transporters in drug uptake. Curr Top Med Chem 9:163–184PubMedCrossRefGoogle Scholar
  369. Dobson PD, Patel Y, Kell DB (2009b) “Metabolite-likeness” as a criterion in the design and selection of pharmaceutical drug libraries. Drug Disc Today 14:31–40CrossRefGoogle Scholar
  370. Dobson PD, Kell DB (2008) Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 7:205–220PubMedCrossRefGoogle Scholar
  371. Dong J, Atwood CS, Anderson VE, Siedlak SL, Smith MA, Perry G et al (2003) Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry 42(10):2768–2773PubMedCrossRefGoogle Scholar
  372. Doraiswamy PM, Finefrock AE (2004) Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol 3(7):431–434PubMedCrossRefGoogle Scholar
  373. Doria E, Galleschi L, Calucci L, Pinzino C, Pilu R, Cassani E et al (2009) Phytic acid prevents oxidative stress in seeds: evidence from a maize (Zea mays L.) low phytic acid mutant. J Exp Bot 60(3):967–978PubMedCrossRefGoogle Scholar
  374. Double KL, Dedov VN, Fedorow H, Kettle E, Halliday GM, Garner B et al (2008) The comparative biology of neuromelanin and lipofuscin in the human brain. Cell Mol Life Sci 65(11):1669–1682PubMedCrossRefGoogle Scholar
  375. Double KL, Gerlach M, Schunemann V, Trautwein AX, Zecca L, Gallorini M et al (2003a) Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 66(3):489–494PubMedCrossRefGoogle Scholar
  376. Double KL, Halliday GM, Henderson J, Griffiths FM, Heinemann T, Riederer P et al (2003b) The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration. Exp Neurol 184(1):530–535PubMedCrossRefGoogle Scholar
  377. Double KL, Gerlach M, Youdim MB, Riederer P (2000) Impaired iron homeostasis in Parkinson’s disease. J Neural Transm Suppl 60: 37–58Google Scholar
  378. Drakesmith H, Prentice A (2008) Viral infection and iron metabolism. Nat Rev Microbiol 6(7):541–552PubMedCrossRefGoogle Scholar
  379. Drayer B, Burger P, Hurwitz B, Dawson D, Cain J (1987) Reduced signal intensity on MR images of thalamus and putamen in multiple sclerosis—increased iron content. Am J Neuroradiol 8(3):413–419Google Scholar
  380. Dreyfus F (2008) The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev 22(Suppl 2):S29–S34PubMedCrossRefGoogle Scholar
  381. Dröge W (2002) Free radicals in the physiological control of cell function. Physiol Rev 82(1):47–95PubMedGoogle Scholar
  382. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Vo TD et al (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci 104(6):1777–1782PubMedCrossRefGoogle Scholar
  383. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG et al (2010) NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293):1357–1361PubMedCrossRefGoogle Scholar
  384. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney J F Jr et al (2001) Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 103(23):2799–2804PubMedGoogle Scholar
  385. Dunaief JL (2006) Iron induced oxidative damage as a potential factor in age-related macular degeneration: The Cogan Lecture. Invest Ophthalmol Vis Sci 47(11):4660–4664PubMedCrossRefGoogle Scholar
  386. Durant R, Klouche K, Delbosc S, Morena M, Amigues L, Beraud JJ et al (2004) Superoxide anion overproduction in sepsis: effects of vitamin E and simvastatin. Shock 22(1):34–39PubMedCrossRefGoogle Scholar
  387. Duvigneau JC, Piskernik C, Haindl S, Kloesch B, Hartl RT, Huttemann M et al (2008) A novel endotoxin-induced pathway: upregulation of heme oxygenase 1, accumulation of free iron, and free iron-mediated mitochondrial dysfunction. Lab Invest 88(1):70–77PubMedCrossRefGoogle Scholar
  388. Dwyer BE, Zacharski LR, Balestra DJ, Lerner AJ, Perry G, Zhu X et al (2009a) Getting the iron out: phlebotomy for Alzheimer’s disease? Med Hypotheses 72(5):504–509PubMedCrossRefGoogle Scholar
  389. Dwyer DJ, Kohanski MA, Collins JJ (2009b) Role of reactive oxygen species in antibiotic action and resistance. Curr Opin Microbiol 12(5):482–489PubMedCrossRefGoogle Scholar
  390. Dwyer DJ, Kohanski MA, Hayete B, Collins JJ (2007) Gyrase inhibitors induce an oxidative damage cellular death pathway in Escherichia coli. Mol Syst Biol 3:91PubMedCrossRefGoogle Scholar
  391. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R et al (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350(1):29–37PubMedCrossRefGoogle Scholar
  392. Eissa A, Lebel RM, Korzan JR, Zavodni AE, Warren KG, Catz I et al (2009) Detecting lesions in multiple sclerosis at 4.7 tesla using phase susceptibility-weighting and T2-weighting. J Magn Reson Imaging 30(4):737–742PubMedCrossRefGoogle Scholar
  393. Ekblom K, Hultdin J, Stegmayr B, Johansson I, Van Guelpen B, Hallmans G et al (2007) Iron stores and HFE genotypes are not related to increased risk of ischemic stroke. A prospective nested case-referent study. Cerebrovasc Dis 24(5):405–411PubMedCrossRefGoogle Scholar
  394. Ekshyyan O, Aw TY (2004) Apoptosis: a key in neurodegenerative disorders. Curr Neurovasc Res 1(4):355–371PubMedCrossRefGoogle Scholar
  395. El Tannir El Tayara N, Delatour B, Le Cudennec C, Guegan M, Volk A, Dhenain M (2006) Age-related evolution of amyloid burden, iron load, and MR relaxation times in a transgenic mouse model of Alzheimer’s disease. Neurobiol Dis 22(1):199–208PubMedCrossRefGoogle Scholar
  396. Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG (2007) Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66, 000 cases and 226, 000 controls. Hepatology 46(4):1071–1080PubMedCrossRefGoogle Scholar
  397. Epstein J, Sanderson IR, MacDonald TT (2009) Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. Br J Nutr. doi: 10.1017/S0007114509993667
  398. Equitani F, Fernandez-Real JM, Menichella G, Koch M, Calvani M, Nobili V et al (2008) Bloodletting ameliorates insulin sensitivity and secretion in parallel to reducing liver iron in carriers of HFE gene mutations. Diabetes Care 31(1):3–8PubMedCrossRefGoogle Scholar
  399. Erkinjuntti T, Benavente O, Eliasziw M, Munoz DG, Sulkava R, Haltia M et al (1996) Diffuse vacuolization (spongiosis) and arteriolosclerosis in the frontal white matter occurs in vascular dementia. Arch Neurol 53(4):325–332PubMedGoogle Scholar
  400. Escames G, Acuna-Castroviejo D, López LC, Tan DX, Maldonado MD, Sanchez-Hidalgo M et al (2006) Pharmacological utility of melatonin in the treatment of septic shock: experimental and clinical evidence. J Pharm Pharmacol 58(9):1153–1165PubMedCrossRefGoogle Scholar
  401. Evans JA (2008) Electronic publication and the narrowing of science and scholarship. Science 321(5887):395–399PubMedCrossRefGoogle Scholar
  402. Exley C (2006) Aluminium and iron, but neither copper nor zinc, are key to the precipitation of beta-sheets of Abeta_{42} in senile plaque cores in Alzheimer’s disease. J Alzheimers Dis 10(2–3):173–177PubMedGoogle Scholar
  403. Exley C, Mamutse G, Korchazhkina O, Pye E, Strekopytov S, Polwart A et al (2006) Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult Scler 12(5):533–540PubMedCrossRefGoogle Scholar
  404. Fábián I, Csordás V (2003) Metal ion catalyzed autoxidation reactions: Kinetics and mechanisms. Adv Inorg Chem 54:395–461CrossRefGoogle Scholar
  405. Facchini FS (2002) The iron factor of aging: why do Americans age faster?. Fenestra Books, Tucson, AZGoogle Scholar
  406. Facchini FS, Hua NW, Stoohs RA (2002) Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease. Gastroenterology 122(4):931–939PubMedCrossRefGoogle Scholar
  407. Fakih S, Podinovskaia M, Kong X, Collins HL, Schaible UE, Hider RC (2008) Targeting the lysosome: fluorescent iron(III) chelators to selectively monitor endosomal/lysosomal labile iron pools. J Med Chem 51(15):4539–4552PubMedCrossRefGoogle Scholar
  408. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5):341–349PubMedCrossRefGoogle Scholar
  409. Fan QW, Specht KM, Zhang C, Goldenberg DD, Shokat KM, Weiss WA (2003) Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. Cancer Res 63(24):8930–8938PubMedGoogle Scholar
  410. Fantauzzi M, Pacella A, Atzei D, Gianfagna A, Andreozzi GB, Rossi A (2010) Combined use of X-ray photoelectron and Mössbauer spectroscopic techniques in the analytical characterization of iron oxidation state in amphibole asbestos. Anal Bioanal Chem 396(8):2889–2898PubMedCrossRefGoogle Scholar
  411. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G et al (2002) Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol 97(5):1204–1210PubMedGoogle Scholar
  412. Fargion S, Mattioli M, Fracanzani AL, Sampietro M, Tavazzi D, Fociani P et al (2001) Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis. Am J Gastroenterol 96(8):2448–2455PubMedCrossRefGoogle Scholar
  413. Fasano M, Bergamasco B, Lopiano L (2006) Modifications of the iron-neuromelanin system in Parkinson’s disease. J Neurochem 96(4):909–916PubMedCrossRefGoogle Scholar
  414. Fato R, Bergamini C, Leoni S, Strocchi P, Lenaz G (2008) Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res 33(12):2487–2501PubMedCrossRefGoogle Scholar
  415. Fattman CL, Tan RJ, Tobolewski JM, Oury TD (2006) Increased sensitivity to asbestos-induced lung injury in mice lacking extracellular superoxide dismutase. Free Radic Biol Med 40(4):601–607PubMedCrossRefGoogle Scholar
  416. Faucheux BA, Martin ME, Beaumont C, Hauw JJ, Agid Y, Hirsch EC (2003) Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson’s disease. J Neurochem 86(5):1142–1148PubMedCrossRefGoogle Scholar
  417. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J et al (2010) PBT2 rapidly improves cognition in Alzheimer’s disease: additional phase II analyses. J Alzheimers DisGoogle Scholar
  418. Featherstone DE, Broadie K (2002) Wrestling with pleiotropy: genomic and topological analysis of the yeast gene expression network. Bioessays 24(3):267–274PubMedCrossRefGoogle Scholar
  419. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL (2005) Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson’s disease. Prog Neurobiol 75(2):109–124PubMedCrossRefGoogle Scholar
  420. Fell DA (1996) Understanding the control of metabolism. Portland Press, LondonGoogle Scholar
  421. Fernaeus S, Halldin J, Bedecs K, Land T (2005a) Changed iron regulation in scrapie-infected neuroblastoma cells. Brain Res Mol Brain Res 133(2):266–273PubMedCrossRefGoogle Scholar
  422. Fernaeus S, Land T (2005) Increased iron-induced oxidative stress and toxicity in scrapie-infected neuroblastoma cells. Neurosci Lett 382(3):217–220PubMedCrossRefGoogle Scholar
  423. Fernaeus S, Reis K, Bedecs K, Land T (2005b) Increased susceptibility to oxidative stress in scrapie-infected neuroblastoma cells is associated with intracellular iron status. Neurosci Lett 389(3):133–136PubMedCrossRefGoogle Scholar
  424. Fernandes de Godoy M, Takakura IT, Machado RD, Grassi LV, Nogueira PR (2007) Serum ferritin and obstructive coronary artery disease: angiographic correlation. Arquivos Brasileiros De Cardiologia 88(4):430–433Google Scholar
  425. Fernández-Real JM, Peñarroja G, Castro A, García-Bragado F, López-Bermejo A, Ricart W (2002) Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity. Diabetes Care 25(12):2249–2255PubMedCrossRefGoogle Scholar
  426. Fernandez Y, Anglade F, Mitjavila S (2000) Paraquat and iron-dependent lipid peroxidation. NADPH versus NADPH-generating systems. Biol Trace Elem Res 74(3):191–201PubMedCrossRefGoogle Scholar
  427. Ferrali M, Signorini C, Caciotti B, Sugherini L, Ciccoli L, Giachetti D et al (1997a) Protection against oxidative damage of erythrocyte membrane by the flavonoid quercetin and its relation to iron chelating activity. FEBS Lett 416(2):123–129PubMedCrossRefGoogle Scholar
  428. Ferrali M, Signorini C, Sugherini L, Pompella A, Lodovici M, Caciotti B et al (1997b) Release of free, redox-active iron in the liver and DNA oxidative damage following phenylhydrazine intoxication. Biochem Pharmacol 53(11):1743–1751PubMedCrossRefGoogle Scholar
  429. Ferrara DE, Taylor WR (2005) Iron chelation and vascular function: in search of the mechanisms. Arterioscler Thromb Vasc Biol 25(11):2235–2237PubMedCrossRefGoogle Scholar
  430. Ferrara F, Ventura P, Vegetti A, Guido M, Abbati G, Corradini E et al (2009) Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 104(3):605–616PubMedCrossRefGoogle Scholar
  431. Ferro JM, Dávalos A (2006) Other neuroprotective therapies on trial in acute stroke. Cerebrovasc Dis 21(Suppl 2):127–130Google Scholar
  432. Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV et al (2010) Proinflammatory state, hepcidin, and anemia in older persons. Blood 115(18):3810–3816PubMedCrossRefGoogle Scholar
  433. Filippi M, Agosta F (2009) Closing the clinical-imaging gap in multiple sclerosis? Imaging iron deposition in deep gray matter. J Neuroimaging 19(1):1–2PubMedCrossRefGoogle Scholar
  434. Finch CA, Bellotti V, Stray S, Lipschitz DA, Cook JD, Pippard MJ et al (1986) Plasma ferritin determination as a diagnostic tool. West J Med 145(5):657–663PubMedGoogle Scholar
  435. Fine SL (2005) Age-related macular degeneration 1969–2004: a 35-year personal perspective. Am J Ophthalmol 139(3):405–420PubMedCrossRefGoogle Scholar
  436. Finefrock AE, Bush AI, Doraiswamy PM (2003) Current status of metals as therapeutic targets in Alzheimer’s disease. J Am Geriatr Soc 51(8):1143–1148PubMedCrossRefGoogle Scholar
  437. Finkel T (2005) Radical medicine: treating ageing to cure disease. Nat Rev Mol Cell Biol 6(12):971–976PubMedCrossRefGoogle Scholar
  438. Firdaus WJ, Wyttenbach A, Giuliano P, Kretz-Remy C, Currie RW, Arrigo AP (2006) Huntingtin inclusion bodies are iron-dependent centers of oxidative events. FEBS J 273(23):5428–5441PubMedCrossRefGoogle Scholar
  439. Flynn MR, Susi P (2010) Manganese, iron, and total particulate exposures to welders. J Occup Environ Hyg 7(2):115–126PubMedCrossRefGoogle Scholar
  440. Ford ES, Cogswell ME (1999) Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 22(12):1978–1983PubMedCrossRefGoogle Scholar
  441. Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R et al (2007) Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50(5):949–956PubMedCrossRefGoogle Scholar
  442. Forrester JS (2002) Prevention of plaque rupture: a new paradigm of therapy. Ann Intern Med 137(10):823–833PubMedGoogle Scholar
  443. Forrester JS (2004) Common ancestors: chronic progressive diseases have the same pathogenesis. Clin Cardiol 27(4):186–190PubMedCrossRefGoogle Scholar
  444. Foster J, Goldmann W, Parnham D, Chong A, Hunter N (2001) Partial dissociation of PrP(Sc) deposition and vacuolation in the brains of scrapie and BSE experimentally affected goats. J Gen Virol 82(Pt 1):267–273PubMedGoogle Scholar
  445. Foury F (1997) Human genetic diseases: a cross-talk between man and yeast. Gene 195:1–10PubMedCrossRefGoogle Scholar
  446. Foury F, Cazzalini O (1997) Deletion of the yeast homologue of the human gene associated with Friedreich’s ataxia elicits iron accumulation in mitochondria. FEBS Lett 411:373–377PubMedCrossRefGoogle Scholar
  447. Foury F, Talibi D (2001) Mitochondrial control of iron homeostasis. A genome wide analysis of gene expression in a yeast frataxin-deficient strain. J Biol Chem 276(11):7762–7768PubMedCrossRefGoogle Scholar
  448. Fraenkel PG, Gibert Y, Holzheimer JL, Lattanzi VJ, Burnett SF, Dooley KA et al (2009) Transferrin-a modulates hepcidin expression in zebrafish embryos. Blood 113(12):2843–2850PubMedCrossRefGoogle Scholar
  449. Franchini M, Targher G, Capra F, Montagnana M, Lippi G (2008) The effect of iron depletion on chronic hepatitis C virus infection. Hepatol Internat 2(3):335–340CrossRefGoogle Scholar
  450. Franco JL, Posser T, Dunkley PR, Dickson PW, Mattos JJ, Martins R et al (2009a) Methylmercury neurotoxicity is associated with inhibition of the antioxidant enzyme glutathione peroxidase. Free Radic Biol Med 47(4):449–457PubMedCrossRefGoogle Scholar
  451. Franco R, Sánchez-Olea R, Reyes-Reyes EM, Panayiotidis MI (2009b) Environmental toxicity, oxidative stress and apoptosis: menage a trois. Mutat Res 674(1–2):3–22PubMedGoogle Scholar
  452. Franco OH, Kirkwood TB, Powell JR, Catt M, Goodwin J, Ordovas JM et al (2007) Ten commandments for the future of ageing research in the UK: a vision for action. BMC Geriatr 7:10PubMedCrossRefGoogle Scholar
  453. Franke JC, Plotz M, Prokop A, Geilen CC, Schmalz HG, Eberle J (2010) New caspase-independent but ROS-dependent apoptosis pathways are targeted in melanoma cells by an iron-containing cytosine analogue. Biochem Pharmacol 79(4):575–586PubMedCrossRefGoogle Scholar
  454. Franklin MR, Phillips JD, Kushner JP (2005) Attenuation of polychlorinated biphenyl induced uroporphyria by iron deprivation. Environ Toxicol Pharmacol 20(3):417–423CrossRefGoogle Scholar
  455. Franks NP (2006) Molecular targets underlying general anaesthesia. Br J Pharmacol 147(Suppl 1):S72–S81PubMedGoogle Scholar
  456. Franks NP (2008) General anaesthesia: from molecular targets to neuronal pathways of sleep and arousal. Nat Rev Neurosci 9(5):370–386PubMedCrossRefGoogle Scholar
  457. Freixes M, Rodríguez A, Dalfó E, Ferrer I (2006) Oxidation, glycoxidation, lipoxidation, nitration, and responses to oxidative stress in the cerebral cortex in Creutzfeldt-Jakob disease. Neurobiol Aging 27(12):1807–1815PubMedCrossRefGoogle Scholar
  458. Friedman A, Gałązka-Friedman J, Bauminger ER (2007) Iron as a trigger of neurodegeneration in Parkinson’s disease. Handb Clin Neurol 83:493–505PubMedCrossRefGoogle Scholar
  459. Friedman A, Galazka-Friedman J, Koziorowski D (2009) Iron as a cause of Parkinson disease—a myth or a well established hypothesis? Parkinsonism Rel Disord 15S3:S212–S214CrossRefGoogle Scholar
  460. Fubini B, Arean CO (1999) Chemical aspects of the toxicity of inhaled mineral dusts. Chem Soc Rev 28(6):373–381CrossRefGoogle Scholar
  461. Fuchs E, Gould E (2000) Mini-review: in vivo neurogenesis in the adult brain: regulation and functional implications. Eur J Neurosci 12(7):2211–2214PubMedCrossRefGoogle Scholar
  462. Fujihara J, Agusa T, Tanaka J, Fujii Y, Moritani T, Hasegawa M et al (2009) 8-Hydroxy-2’-deoxyguanosine (8-OHdG) as a possible marker of arsenic poisoning: a clinical case study on the relationship between concentrations of 8-OHdG and each arsenic compound in urine of an acute promyelocytic leukemia patient being treated with arsenic trioxide. Forensic Toxicol 27(1):41–44CrossRefGoogle Scholar
  463. Fujita N, Horiike S, Sugimoto R, Tanaka H, Iwasa M, Kobayashi Y et al (2007a) Hepatic oxidative DNA damage correlates with iron overload in chronic hepatitis C patients. Free Radic Biol Med 42(3):353–362PubMedCrossRefGoogle Scholar
  464. Fujita N, Sugimoto R, Takeo M, Urawa N, Mifuji R, Tanaka H et al (2007b) Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med 13(1–2):97–104PubMedGoogle Scholar
  465. Fujita N, Sugimoto R, Urawa N, Tanaka H, Konishi M, Kobayashi Y et al (2007c) Influence of phlebotomy on iron-related gene expression levels in the livers of patients with chronic hepatitis C. J Gastroenterol 42(4):326–327PubMedCrossRefGoogle Scholar
  466. Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y et al (2009) Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomarkers Prev 18(2):424–432PubMedCrossRefGoogle Scholar
  467. Fujita N, Takei Y (2007) Iron, hepatitis C virus, and hepatocellular carcinoma: iron reduction preaches the gospel for chronic hepatitis C. J Gastroenterol 42(11):923–926PubMedCrossRefGoogle Scholar
  468. Fukuchi K, Tomoyasu S, Tsuruoka N, Gomi K (1994) Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett 350(1):139–142PubMedCrossRefGoogle Scholar
  469. Fulda S, Gorman AM, Hori O, Samali A (2010) Cellular stress responses: cell survival and cell death. Int J Cell Biol 2010:214074PubMedGoogle Scholar
  470. Gackowski D, Kruszewski M, Bartlomiejczyk T, Jawien A, Ciecierski M, Olinski R (2002) The level of 8-oxo-7, 8-dihydro-2’-deoxyguanosine is positively correlated with the size of the labile iron pool in human lymphocytes. J Biol Inorg Chem 7(4–5):548–550PubMedGoogle Scholar
  471. Gajda M, Banas K, Banas A, Jawien J, Mateuszuk L, Chlopicki S et al (2008) Distribution of selected elements in atherosclerotic plaques of apoE/LDLR-double knockout mice assessed by synchrotron radiation-induced micro-XRF spectrometry. X-Ray Spectrom 37(5):495–502CrossRefGoogle Scholar
  472. Gajdusek DC (2008) Review. Kuru and its contribution to medicine. Philos Trans R Soc Lond B Biol Sci 363(1510):3697–3700PubMedCrossRefGoogle Scholar
  473. Gakh O, Park S, Liu G, Macomber L, Imlay JA, Ferreira GC et al (2006) Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity. Human Mol Genet 15(3):467–479CrossRefGoogle Scholar
  474. Gal S, Fridkin M, Amit T, Zheng H, Youdim MBH (2006) M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease. J Neural Transm Suppl 70:447–456PubMedCrossRefGoogle Scholar
  475. Gal S, Zheng H, Fridkin M, Youdim MB (2009) Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox ResGoogle Scholar
  476. Galaris D, Mantzaris M, Amorgianiotis C (2008a) Oxidative stress and aging: the potential role of iron. Hormones (Athens) 7(2):114–122Google Scholar
  477. Galaris D, Skiada V, Barbouti A (2008b) Redox signaling and cancer: the role of “labile” iron. Cancer Lett 266(1):21–29PubMedCrossRefGoogle Scholar
  478. Galley HF, Davies MJ, Webster NR (1996) Ascorbyl radical formation in patients with sepsis: effect of ascorbate loading. Free Radic Biol Med 20(1):139–143PubMedCrossRefGoogle Scholar
  479. Galley HF, Howdle PD, Walker BE, Webster NR (1997) The effects of intravenous antioxidants in patients with septic shock. Free Radic Biol Med 23(5):768–774PubMedCrossRefGoogle Scholar
  480. Galley HF, Webster NR (1996) Elevated serum bleomycin-detectable iron concentrations in patients with sepsis syndrome. Intensive Care Med 22(3):226–229PubMedCrossRefGoogle Scholar
  481. Galli SJ, Tsai M, Piliponsky AM (2008) The development of allergic inflammation. Nature 454(7203):445–454PubMedCrossRefGoogle Scholar
  482. Gamberini MR, De Sanctis V, Gilli G (2008) Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev 6(Suppl 1):158–169PubMedGoogle Scholar
  483. Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T et al (2008) Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology 70(24):2277–2283PubMedCrossRefGoogle Scholar
  484. Gan EK, Ayonrinde OT, Trinder D, Olynyk JK (2010) Phenotypic expression of hereditary hemochromatosis: what have we learned from the population studies? Curr Gastroenterol Rep 12(1):7–12PubMedCrossRefGoogle Scholar
  485. Gao F, Linhartova L, Johnston AM, Thickett DR (2008) Statins and sepsis. Br J Anaesth 100(3):288–298PubMedCrossRefGoogle Scholar
  486. García-Castiñeiras S (2010) Iron, the retina and the lens: A focused review. Exp Eye Res 90:664–678PubMedCrossRefGoogle Scholar
  487. Garey M, Johnson D (1979) Computers and intractability: a guide to the theory of NP-completeness. Freeman, San FranciscoGoogle Scholar
  488. Garoufi AJ, Prassouli AA, Attilakos AV, Voudris KA, Katsarou ES (2006) Homozygous MTHFR C677T gene mutation and recurrent stroke in an infant. Pediatr Neurol 35(1):49–51PubMedCrossRefGoogle Scholar
  489. Gattermann N (2008) Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 88(1):24–29PubMedCrossRefGoogle Scholar
  490. Gattermann N (2009) The treatment of secondary hemochromatosis. Dtsch Ärztebl Int 106(30): 499–504, IGoogle Scholar
  491. Gazzano E, Turci F, Foresti E, Putzu MG, Aldieri E, Silvagno F et al (2007) Iron-loaded synthetic chrysotile: a new model solid for studying the role of iron in asbestos toxicity. Chem Res Toxicol 20(3):380–387PubMedCrossRefGoogle Scholar
  492. Ge Y, Jensen JH, Lu H, Helpern JA, Miles L, Inglese M et al (2007) Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 28(9):1639–1644PubMedCrossRefGoogle Scholar
  493. Gems D (2009) Ageing and oxidants in the nematode Caenorhabditis elegans. SEB Exp Biol Ser 62:31–56PubMedGoogle Scholar
  494. Gems D, Doonan R (2009) Antioxidant defense and aging in C. elegans: is the oxidative damage theory of aging wrong? Cell Cycle 8(11):1681–1687PubMedGoogle Scholar
  495. Gems D, Partridge L (2008) Stress-response hormesis and aging: “that which does not kill us makes us stronger”. Cell Metab 7(3):200–203PubMedCrossRefGoogle Scholar
  496. Gennero L, Roos MA, D’Amelio P, Denysenko T, Morra E, Sperber K et al (2010) Iron metabolism markers and haptoglobin phenotypes in susceptibility to HSV-1 or/and HSV-2 lesion relapses. Cell Biochem Funct 28(2):142–148PubMedCrossRefGoogle Scholar
  497. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HH, Marx JJ, van Asbeck BS (2000) Combining iron chelators with the nucleoside analog didanosine in anti-HIV therapy. Transfus Sci 23(3):249–250PubMedCrossRefGoogle Scholar
  498. Gerber S, Assmus H, Bakker B, Klipp E (2007) Drug-efficacy depends on the inhibitor type and the target position in a metabolic network—a systematic study. J Theor Biol 255:442–455Google Scholar
  499. Gerlach M, Benshachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases. J Neurochem 63(3):793–807PubMedCrossRefGoogle Scholar
  500. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P (2003) Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res 5(1–2):35–44PubMedCrossRefGoogle Scholar
  501. Gerlach M, Riederer P, Double KL (2008) Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson’s disease. Parkinsonism Relat Disord 14(Suppl 2):S185–S188PubMedCrossRefGoogle Scholar
  502. Geronikaki AA, Gavalas AM (2006) Antioxidants and inflammatory disease: synthetic and natural antioxidants with anti-inflammatory activity. Comb Chem High Throughput Screen 9(6):425–442PubMedCrossRefGoogle Scholar
  503. Ghio A, Tan RJ, Ghio K, Fattman CL, Oury TD (2009) Iron accumulation and expression of iron-related proteins following murine exposure to crocidolite. J Environ Pathol Toxicol Oncol 28(2):153–162PubMedGoogle Scholar
  504. Ghio AJ, Carter JD, Richards JH, Richer LD, Grissom CK, Elstad MR (2003) Iron and iron-related proteins in the lower respiratory tract of patients with acute respiratory distress syndrome. Crit Care Med 31(2):395–400PubMedCrossRefGoogle Scholar
  505. Ghio AJ, Churg A, Roggli VL (2004) Ferruginous bodies: implications in the mechanism of fiber and particle toxicity. Toxicol Pathol 32(6):643–649PubMedCrossRefGoogle Scholar
  506. Ghosh B, Antonio T, Reith ME, Dutta AK (2010) Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl) piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson’s disease. J Med Chem 53(5):2114–2125PubMedCrossRefGoogle Scholar
  507. Ghoshal N, Cali I, Perrin RJ, Josephson SA, Sun N, Gambetti P et al (2009) Codistribution of amyloid beta plaques and spongiform degeneration in familial Creutzfeldt-Jakob disease with the E200K–129M haplotype. Arch Neurol 66(10):1240–1246PubMedCrossRefGoogle Scholar
  508. Ghribi O, Golovko MY, Larsen B, Schrag M, Murphy EJ (2006) Deposition of iron and beta-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J Neurochem 99(2):438–449PubMedCrossRefGoogle Scholar
  509. Gieseg SP, Leake DS, Flavall EM, Amit Z, Reid L, Yang YT (2009) Macrophage antioxidant protection within atherosclerotic plaques. Frontiers Biosci 14:1230–1246CrossRefGoogle Scholar
  510. Gillum RF, Sempos CT, Makuc DM, Looker AC, Chien CY, Ingram DD (1996) Serum transferrin saturation, stroke incidence, and mortality in women and men. The NHANES I epidemiologic followup study. National health and nutrition examination survey. Am J Epidemiol 144(1):59–68PubMedGoogle Scholar
  511. Gilmour PS, Brown DM, Beswick PH, MacNee W, Rahman I, Donaldson K (1997) Free radical activity of industrial fibers: role of iron in oxidative stress and activation of transcription factors. Environ Health Perspect 105(Suppl 5):1313–1317PubMedCrossRefGoogle Scholar
  512. Girelli D, Pasino M, Goodnough JB, Nemeth E, Guido M, Castagna A et al (2009) Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 51(5):845–852PubMedCrossRefGoogle Scholar
  513. Giustarini D, Dalle-Donne I, Tsikas D, Rossi R (2009) Oxidative stress and human diseases: origin, link, measurement, mechanisms, and biomarkers. Crit Rev Clin Lab Sci 46(5–6):241–281PubMedCrossRefGoogle Scholar
  514. Glahn RP, Wortley GM, South PK, Miller DD (2002) Inhibition of iron uptake by phytic acid, tannic acid, and ZnCl2: studies using an in vitro digestion/Caco-2 cell model. J Agric Food Chem 50(2):390–395PubMedCrossRefGoogle Scholar
  515. Gloire G, Legrand-Poels S, Piette J (2006) NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72(11):1493–1505PubMedCrossRefGoogle Scholar
  516. Gloire G, Piette J (2009) Redox regulation of nuclear post-translational modifications during NF-kappaB activation. Antioxid Redox Signal 11(9):2209–2222PubMedCrossRefGoogle Scholar
  517. Goel A, Dani V, Dhawan DK (2006) Role of zinc in mitigating the toxic effects of chlorpyrifos on hematological alterations and electron microscopic observations in rat blood. Biometals 19(5):483–492PubMedCrossRefGoogle Scholar
  518. Goldberg DE (1989) Genetic algorithms in search, optimization and machine learning. Addison-Wesley, Reading, MAGoogle Scholar
  519. Goldberg DE (2002) The design of innovation: lessons from and for competent genetic algorithms. Kluwer, BostonGoogle Scholar
  520. Goldstein S, Merényi G (2008) The chemistry of peroxynitrite: implications for biological activity. Methods Enzymol 436:49–61PubMedCrossRefGoogle Scholar
  521. Goldstein S, Meyerstein D, Czapski G (1993) The Fenton reagents. Free Radic Biol Med 15(4):435–445PubMedCrossRefGoogle Scholar
  522. Goltsov A, Maryashkin A, Swat M, Kosinsky Y, Humphery-Smith I, Demin O et al (2009) Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations. Eur J Pharm Sci 36(1):122–136PubMedCrossRefGoogle Scholar
  523. Gómez-Pinilla F (2008) The influences of diet and exercise on mental health through hormesis. Ageing Res Rev 7(1):49–62PubMedCrossRefGoogle Scholar
  524. Gómez Ravetti M, Rosso OA, Berretta R, Moscato P (2010) Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus’ gene expression profiles in Alzheimer’s disease. PLoSOne 5(4):e10153Google Scholar
  525. Goncalves S, Paupe V, Dassa EP, Rustin P (2008) Deferiprone targets aconitase: implication for Friedreich’s ataxia treatment. BMC Neurol 8:20PubMedCrossRefGoogle Scholar
  526. González-Cabo P, Llorens JV, Palau F, Moltó MD (2009) Friedreich ataxia: an update on animal models, frataxin function and therapies. Adv Exp Med Biol 652:247–261PubMedCrossRefGoogle Scholar
  527. González-Cabo P, Vázquez-Manrique RP, García-Gimeno MA, Sanz P, Palau F (2005) Frataxin interacts functionally with mitochondrial electron transport chain proteins. Hum Mol Genet 14(15):2091–2098PubMedCrossRefGoogle Scholar
  528. Good PF, Hsu A, Werner P, Perl DP, Olanow CW (1998) Protein nitration in Parkinson’s disease. J Neuropathol Exp Neurol 57(4):338–342PubMedCrossRefGoogle Scholar
  529. Good PF, Perl DP, Bierer LM, Schmeidler J (1992) Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer’s disease: a laser microprobe (LAMMA) study. Ann Neurol 31(3):286–292PubMedCrossRefGoogle Scholar
  530. Good PF, Werner P, Hsu A, Olanow CW, Perl DP (1996) Evidence of neuronal oxidative damage in Alzheimer’s disease. Am J Pathol 149(1):21–28PubMedGoogle Scholar
  531. Goodall EF, Haque MS, Morrison KE (2008) Increased serum ferritin levels in amyotrophic lateral sclerosis (ALS) patients. J Neurol 255(11):1652–1656PubMedCrossRefGoogle Scholar
  532. Goode HF, Webster NR (1993) Free radicals and antioxidants in sepsis. Crit Care Med 21(11):1770–1776PubMedCrossRefGoogle Scholar
  533. Goralska M, Ferrell J, Harned J, Lall M, Nagar S, Fleisher LN et al (2009a) Iron metabolism in the eye: a review. Exp Eye Res 88(2):204–215PubMedCrossRefGoogle Scholar
  534. Goralska M, Nagar S, Colitz CM, Fleisher LN, McGahan MC (2009b) Changes in ferritin H- and L-chains in canine lenses with age-related nuclear cataract. Invest Ophthalmol Vis Sci 50(1):305–310PubMedCrossRefGoogle Scholar
  535. Goralska M, Nagar S, Fleisher LN, McGahan MC (2009c) Distribution of ferritin chains in canine lenses with and without age-related nuclear cataracts. Mol Vis 15:2404–2410PubMedGoogle Scholar
  536. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR (2001) Iron status and the outcome of HIV infection: an overview. J Clin Virol 20(3):111–115PubMedCrossRefGoogle Scholar
  537. Gordeuk VR, Onojobi G, Schneider MF, Dawkins FW, Delapenha R, Voloshin Y et al (2006) The association of serum ferritin and transferrin receptor concentrations with mortality in women with human immunodeficiency virus infection. Haematologica 91(6):739–743PubMedGoogle Scholar
  538. Goris RJ (1990) Mediators of multiple organ failure. Intensive Care Med 16(Suppl 3):S192–196PubMedCrossRefGoogle Scholar
  539. Gorria M, Tekpli X, Rissel M, Sergent O, Huc L, Landvik N et al (2008) A new lactoferrin- and iron-dependent lysosomal death pathway is induced by benzo[a]pyrene in hepatic epithelial cells. Toxicol Appl Pharmacol 228(2):212–224PubMedCrossRefGoogle Scholar
  540. Götz M, Huttner WB (2005) The cell biology of neurogenesis. Nat Rev Mol Cell Biol 6(10):777–788PubMedCrossRefGoogle Scholar
  541. Gotz ME, Double K, Gerlach M, Youdim MBH, Riederer P (2004) The relevance of iron in the pathogenesis of Parkinson’s disease. Redox-Active Metals Neurol Disord 1012:193–208Google Scholar
  542. Gould E (2007) How widespread is adult neurogenesis in mammals? Nat Rev Neurosci 8(6):481–488PubMedCrossRefGoogle Scholar
  543. Governa M, Amati M, Fontana S, Visona I, Botta GC, Mollo F et al (1999) Role of iron in asbestos-body-induced oxidant radical generation. J Toxicol Environ Health A 58(5):279–287PubMedCrossRefGoogle Scholar
  544. Gozzelino R, Jeney V, Soares MP (2010) Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50:323–354PubMedCrossRefGoogle Scholar
  545. Graf E, Eaton JW (1990) Antioxidant functions of phytic acid. Free Radic Biol Med 8(1):61–69PubMedCrossRefGoogle Scholar
  546. Graf E, Eaton JW (1993) Suppression of colonic cancer by dietary phytic acid. Nutr Cancer 19(1):11–19PubMedCrossRefGoogle Scholar
  547. Graf E, Empson KL, Eaton JW (1987) Phytic acid. A natural antioxidant. J Biol Chem 262(24):11647–11650PubMedGoogle Scholar
  548. Graf E, Mahoney JR, Bryant RG, Eaton JW (1984) Iron-catalyzed hydroxyl radical formation. Stringent requirement for free iron coordination site. J Biol Chem 259(6):3620–3624PubMedGoogle Scholar
  549. Grainger DJ (2007) TGF-beta and atherosclerosis in man. Cardiovasc Res 74(2):213–222PubMedCrossRefGoogle Scholar
  550. Granic I, Dolga AM, Nijholt IM, van Dijk G, Eisel ULM (2009) Inflammation and NF-kappaB in Alzheimer’s disease and diabetes. J Alzheimers Dis 16(4):809–821PubMedGoogle Scholar
  551. Grases F, Simonet BM, Prieto RM, March JG (2001) Dietary phytate and mineral bioavailability. J Trace Elem Med Biol 15(4):221–228PubMedCrossRefGoogle Scholar
  552. Grasshoff C, Drexler B, Rudolph U, Antkowiak B (2006) Anaesthetic drugs: linking molecular actions to clinical effects. Curr Pharm Des 12(28):3665–3679PubMedCrossRefGoogle Scholar
  553. Greenberg PL (2006) Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J Natl Compr Canc Netw 4(1):91–96PubMedGoogle Scholar
  554. Greenberg PL, Attar E, Battiwalla M, Bennett JM, Bloomfield CD, DeCastro CM et al (2008) Myelodysplastic syndromes. J Natl Compr Canc Netw 6(9):902–926PubMedGoogle Scholar
  555. Greene BT, Thorburn J, Willingham MC, Thorburn A, Planalp RP, Brechbiel MW et al (2002) Activation of caspase pathways during iron chelator-mediated apoptosis. J Biol Chem 277(28):25568–25575PubMedCrossRefGoogle Scholar
  556. Greene LS (1995) Asthma and oxidant stress—nutritional, environmental, and genetic risk factors. J Am Coll Nutr 14(4):317–324PubMedGoogle Scholar
  557. Grimaud J, Millar J, Thorpe JW, Moseley IF, McDonald WI, Miller DH (1995) Signal intensity on MRI of basal ganglia in multiple sclerosis. J Neurol Neurosurg Psychiatry 59(3):306–308PubMedCrossRefGoogle Scholar
  558. Grootveld M, Halliwell B (1986) Aromatic hydroxylation as a potential measure of hydroxyl-radical formation in vivo. Identification of hydroxylated derivatives of salicylate in human body fluids. Biochem J 237(2):499–504PubMedGoogle Scholar
  559. Grossi C, Francese S, Casini A, Rosi MC, Luccarini I, Fiorentini A et al (2009) Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer’s disease. J Alzheimers Dis 96(3):423–440Google Scholar
  560. Gu Y, Hua Y, Keep RF, Morgenstern LB, Xi G (2009) Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets. Stroke 40(6):2241–2243PubMedCrossRefGoogle Scholar
  561. Gudmundsdóttir KB, Sigurdarson S, Kristinsson J, Eiríksson T, Jóhannesson T (2006) Iron and iron/manganese ratio in forage from Icelandic sheep farms: relation to scrapie. Acta Vet Scand 48:16PubMedCrossRefGoogle Scholar
  562. Gulumian M, van Wyk JA (1987) Hydroxyl radical production in the presence of fibres by a Fenton-type reaction. Chem Biol Interact 62(1):89–97PubMedCrossRefGoogle Scholar
  563. Guo L, Morris DG, Liu XY, Vaslet C, Hurt RH, Kane AB (2007) Iron bioavailability and redox activity in diverse carbon nanotube samples. Chem Mater 19(14):3472–3478CrossRefGoogle Scholar
  564. Gupta RC, Milatovic D (2009) Toxicants and neurodegenerative diseases special issue. Toxicol Appl Pharmacol 240(2):123PubMedCrossRefGoogle Scholar
  565. Gürkan E, Ergun Y, Zorludemir S, Başlamişli F, Koçak R (2005) Liver involvement in sickle cell disease. Turk J Gastroenterol 16(4):194–198PubMedGoogle Scholar
  566. Gusarov I, Shatalin K, Starodubtseva M, Nudler E (2009) Endogenous nitric oxide protects bacteria against a wide spectrum of antibiotics. Science 325(5946):1380–1384PubMedCrossRefGoogle Scholar
  567. Gusella JF, MacDonald ME (2000) Unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci 1(2):109–115PubMedCrossRefGoogle Scholar
  568. Gutierrez JM, Rucavado A, Escalante T, Lomonte B, Angulo Y, Fox JW (2010) Tissue pathology induced by snake venoms: how to understand a complex pattern of alterations from a systems biology perspective. Toxicon 55(1):166–170Google Scholar
  569. Gutteridge JMC, Mitchell J (1999) Redox imbalance in the critically ill. Br Med Bull 55(1):49–75PubMedCrossRefGoogle Scholar
  570. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H et al (2007) Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 46(4):587–595PubMedCrossRefGoogle Scholar
  571. Ha YM, Chung SW, Kim JM, Kim DH, Kim JY, Lee EK et al (2010) Molecular activation of NF-kappaB, pro-inflammatory mediators, and signal pathways in gamma-irradiated mice. Biotechnol Lett 32(3):373–378PubMedCrossRefGoogle Scholar
  572. Haacke EM, Cheng NY, House MJ, Liu Q, Neelavalli J, Ogg RJ et al (2005) Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 23(1):1–25PubMedCrossRefGoogle Scholar
  573. Haacke EM, Garbern J, Miao Y, Habib C, Liu M (2010) Iron stores and cerebral veins in MS studied by susceptibility weighted imaging. Int Angiol 29(2):149–157PubMedGoogle Scholar
  574. Haacke EM, Makki M, Ge Y, Maheshwari M, Sehgal V, Hu J et al (2009) Characterizing iron deposition in multiple sclerosis lesions using susceptibility weighted imaging. J Magn Reson Imaging 29(3):537–544PubMedCrossRefGoogle Scholar
  575. Haas H, Eisendle M, Turgeon BG (2008) Siderophores in fungal physiology and virulence. Annu Rev Phytopathol 46:149–187PubMedCrossRefGoogle Scholar
  576. Hadacek F, Bachmann G, Engelmeier D, Chobot V (2010) Hormesis and a chemical raison d’être for secondary plant metabolites. Dose-response (in press)Google Scholar
  577. Haddad JJ, Olver RE, Land SC (2000) Antioxidant/pro-oxidant equilibrium regulates HIF-1alpha and NF-kappa B redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J Biol Chem 275(28):21130–21139PubMedCrossRefGoogle Scholar
  578. Hadley D, Orlin A, Brown G, Brucker AJ, Ho AC, Regillo CD et al (2010) Analysis of six genetic risk factors highly associated with AMD in the region surrounding ARMS2 and HTRA1 on chromosome 10, region q26. Invest Ophthalmol Vis Sci 51(4):2191–2196PubMedCrossRefGoogle Scholar
  579. Hagen J (2006) Industrial Catalysis: A Practical Approach. Wiley VCH Chemie, WeinheimGoogle Scholar
  580. Haggarty SJ, Clemons PA, Schreiber SL (2003) Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. J Am Chem Soc 125(35):10543–10545PubMedCrossRefGoogle Scholar
  581. Hague T, Andrews PLR, Barker J, Naughton DP (2006) Dietary chelators as antioxidant enzyme mimetics: implications for dietary intervention in neurodegenerative diseases. Behav Pharmacol 17(5–6):425–430PubMedCrossRefGoogle Scholar
  582. Hahn P, Milam AH, Dunaief JL (2003) Maculas affected by age-related macular degeneration contain increased chelatable iron in the retinal pigment epithelium and Bruch’s membrane. Arch Ophthalmol 121(8):1099–1105PubMedCrossRefGoogle Scholar
  583. Hahn P, Qian Y, Dentchev T, Chen L, Beard J, Harris ZL et al (2004) Disruption of ceruloplasmin and hephaestin in mice causes retinal iron overload and retinal degeneration with features of age-related macular degeneration. Proc Natl Acad Sci U S A 101(38):13850–13855PubMedCrossRefGoogle Scholar
  584. Hallberg L, Brune M, Rossander L (1989) Iron absorption in man: ascorbic acid and dose-dependent inhibition by phytate. Am J Clin Nutr 49(1):140–144PubMedGoogle Scholar
  585. Halliwell B (2007) Dietary polyphenols: good, bad, or indifferent for your health? Cardiovasc Res 73(2):341–347PubMedCrossRefGoogle Scholar
  586. Halliwell B (2009) The wanderings of a free radical. Free Radic Biol Med 46(5):531–542PubMedCrossRefGoogle Scholar
  587. Halliwell B, Gutteridge JMC (2006) Free radicals in biology and medicine, 4th edn. Oxford University Press, OxfordGoogle Scholar
  588. Halliwell B, Rafter J, Jenner A (2005) Health promotion by flavonoids, tocopherols, tocotrienols, and other phenols: direct or indirect effects? Antioxidant or not? Am J Clin Nutr 81(1 Suppl):268S–276SPubMedGoogle Scholar
  589. Hammond KE, Metcalf M, Carvajal L, Okuda DT, Srinivasan R, Vigneron D et al (2008) Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 64(6):707–713PubMedCrossRefGoogle Scholar
  590. Han JY, Takeshita K, Utsumi H (2001) Noninvasive detection of hydroxyl radical generation in lung by diesel exhaust particles. Free Radic Biol Med 30(5):516–525PubMedCrossRefGoogle Scholar
  591. Han O, Failla ML, Hill AD, Morris ER, Smith J C Jr (1994) Inositol phosphates inhibit uptake and transport of iron and zinc by a human intestinal cell line. J Nutr 124(4):580–587PubMedGoogle Scholar
  592. Handl J, Kell DB, Knowles J (2007) Multiobjective optimization in bioinformatics and computational biology. IEEE Trans Comput Biol Bioinform 4(2):279–292CrossRefGoogle Scholar
  593. Hanson L, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ et al (2009) Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther 330:679–686Google Scholar
  594. Hanson LN, Engelman HM, Alekel DL, Schalinske KL, Kohut ML, Reddy MB (2006) Effects of soy isoflavones and phytate on homocysteine, C-reactive protein, and iron status in postmenopausal women. Am J Clin Nutr 84(4):774–780PubMedGoogle Scholar
  595. Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21(12):1876–1890PubMedCrossRefGoogle Scholar
  596. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685–1695PubMedCrossRefGoogle Scholar
  597. Haq RU, Wereley JP, Chitambar CR (1995) Induction of apoptosis by iron deprivation in human leukemic CCRF-CEM cells. Exp Hematol 23(5):428–432PubMedGoogle Scholar
  598. Hardy JA, Aust AE (1995a) The effect of iron binding on the ability of crocidolite asbestos to catalyze DNA single-strand breaks. Carcinogenesis 16(2):319–325PubMedCrossRefGoogle Scholar
  599. Hardy JA, Aust AE (1995b) Iron in asbestos chemistry and carcinogenicity. Chem Rev 95(1):97–118CrossRefGoogle Scholar
  600. Harvey PT (2003) Common eye diseases of elderly people: identifying and treating causes of vision loss. Gerontology 49(1):1–11PubMedCrossRefGoogle Scholar
  601. Hasinoff BB, Rahimtula AD, Omar RF (1990) NADPH-cytochrome-P-450 reductase promoted hydroxyl radical production by the iron(III)-ochratoxin A complex. Biochim Biophys Acta 1036(1):78–81PubMedGoogle Scholar
  602. Hassoun EA, Wang X (1999) Time- and concentration-dependent production of superoxide anion, nitric oxide, DNA damage and cellular death by ricin in the J774A.1 macrophage cells. J Biochem Mol Toxicol 13(3–4):179–185PubMedCrossRefGoogle Scholar
  603. Hastie T, Tibshirani R, Friedman J (2001) The elements of statistical learning: data mining, inference and prediction. Springer, BerlinGoogle Scholar
  604. Hattori N, Oda S, Sadahiro T, Nakamura M, Abe R, Shinozaki K et al (2009) YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock 32(4):393–400PubMedCrossRefGoogle Scholar
  605. Haugen AC, Di Prospero NA, Parker JS, Fannin RD, Chou J, Meyer JN et al (2010) Altered gene expression and DNA damage in peripheral blood cells from Friedreich’s ataxia patients: cellular model of pathology. PLoS Genet 6(1):e1000812PubMedCrossRefGoogle Scholar
  606. Hawkins PT, Poyner DR, Jackson TR, Letcher AJ, Lander DA, Irvine RF (1993) Inhibition of iron-catalysed hydroxyl radical formation by inositol polyphosphates: a possible physiological function for myo-inositol hexakisphosphate. Biochem J 294(Pt 3):929–934PubMedGoogle Scholar
  607. Hayashi H, Wakusawa S, Yano M (2006) Iron removal by phlebotomy for the prophylaxis of fulminant hepatitis in a Wilson disease model of Long-Evans Cinnamon Rats. Hepatol Res 35(4):276–280PubMedCrossRefGoogle Scholar
  608. Hayashi H, Yano M (2002) Iron cytotoxicity in chronic hepatitis C. J Health Sci 48(3):227–231CrossRefGoogle Scholar
  609. Hayashi T, Ueno Y, Okamoto T (1993) Oxidoreductive regulation of nuclear factor kappa B. Involvement of a cellular reducing catalyst thioredoxin. J Biol Chem 268(15):11380–11388PubMedGoogle Scholar
  610. Hayes DP (2009) Nutritional hormesis and aging. Dose Response 8(1):10–15PubMedCrossRefGoogle Scholar
  611. He X, Hahn P, Iacovelli J, Wong R, King C, Bhisitkul R et al (2007) Iron homeostasis and toxicity in retinal degeneration. Prog Retin Eye Res 26(6):649–673PubMedCrossRefGoogle Scholar
  612. He X, Yablonskiy DA (2009) Biophysical mechanisms of phase contrast in gradient echo MRI. Proc Natl Acad Sci USA 106(32):13558–13563PubMedCrossRefGoogle Scholar
  613. Heathcote EJ (2004) Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 127(5 Suppl 1):S294–S302Google Scholar
  614. Heckl S (2007) Future contrast agents for molecular imaging in stroke. Curr Med Chem 14(16):1713–1728PubMedCrossRefGoogle Scholar
  615. Hegde ML, Bharathi P, Suram A, Venugopal C, Jagannathan R, Poddar P et al (2009) Challenges associated with metal chelation therapy in Alzheimer’s disease. J Alzheimers Dis 17(3):457–468PubMedGoogle Scholar
  616. Hegreness M, Shoresh N, Damian D, Hartl D, Kishony R (2008) Accelerated evolution of resistance in multidrug environments. Proc Natl Acad Sci USA 105(37):13977–13981PubMedCrossRefGoogle Scholar
  617. Heinrich R, Schuster S (1996) The regulation of cellular systems. Chapman & Hall, New YorkGoogle Scholar
  618. Heintz NH, Janssen-Heininger YM, Mossman BT (2010) Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol 42(2):133–139PubMedCrossRefGoogle Scholar
  619. Helal GK (2008) Systemic administration of Zn2+ during the reperfusion phase of transient cerebral ischaemia protects rat hippocampus against iron-catalysed postischaemic injury. Clin Exp Pharmacol Physiol 35(7):775–781PubMedCrossRefGoogle Scholar
  620. Henshall TL, Tucker B, Lumsden AL, Nornes S, Lardelli MT, Richards RI (2009) Selective neuronal requirement for huntingtin in the developing zebrafish. Hum Mol Genet 18(24):4830–4842PubMedCrossRefGoogle Scholar
  621. Herce-Pagliai C, Kotecha S, Shuker DEG (1998) Analytical methods for 3-nitrotyrosine as a marker of exposure to reactive nitrogen species: a review. Nitric Oxide-Biol Chem 2(5):324–336CrossRefGoogle Scholar
  622. Herrgård MJ, Swainston N, Dobson P, Dunn WB, Arga KY, Arvas M et al (2008) A consensus yeast metabolic network obtained from a community approach to systems biology. Nat Biotechnol 26(10):1155–1160PubMedCrossRefGoogle Scholar
  623. Hershko C, Weatherall DJ (1988) Iron-chelating therapy. Crit Rev Clin Lab Sci 26(4):303–345PubMedCrossRefGoogle Scholar
  624. Hider RC, Liu ZD, Khodr HH (2001) Metal chelation of polyphenols. Flavonoids Other Polyphenols 335:190–203CrossRefGoogle Scholar
  625. Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S (2008) Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans 36(Pt 6):1304–1308PubMedCrossRefGoogle Scholar